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Preliminary observations suggest that aberrations in maternal central hemodynamics and 
uterine artery Doppler velocimetry reflect the severity of hypertensive disorders of 
pregnancy. In addition, the precise changes of cardiac output in normal pregnancy, 
particularly in the third trimester, have remained controversial. 
Aims and Objective: 
To measure concomitantly Doppler echocardiographic maternal central hemodynamics and 
uterine artery Doppler velocimetry and evaluate their association with adverse feto-neonatal 
outcome in hypertensive pregnant women. To evaluate cardiac output longitudinally in the 
latter half of pregnancy in normal healthy women. 
Design and Setting: 
Prospective study conducted at the Obstetric Unit, King Edward VIII Hospital, Durban, 
South Africa. Study sample: forty (40) pregnant hypertensives without any prior therapy and 
a further group of pre-eclamptic women (n=22) treated with stat dose sodium gardinal and 
alpha-methyldopa were studied. 
Results: 
i) A trend to a higher cardiac output was seen in the hypertensives compared to the 
normotensives. Hypertensive women were of larger stature; there was no difference in 
cardiac index. Fetal birthweight correlated poorly with cardiac index in pre-eclamptic 
women (r =0.21). A better correlation was seen with uterine artery resistance index (r = -
0.65) and systemic vascular resistance index (r = -0.49). Critical values for cardiac index 
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and systemic vascular resistance index to predict poor adverse feto-neonatal outcome 
with good predictive values were not identified. 
ii) Pre-eclamptics treated with stat dose of sodium gardinal and/or methyldopa prior to 
echocardiography had a significantly lower systemic vascular resistance index and uterine 
artery resistance index compared to the untreated group. The lower systemic vascular 
resistance index in this treated cohort occurred from a combination of non-significant 
lower blood pressure and higher cardiac index. 
iii) Compared to normotensive women, untreated pre-eclamptics had a significantly lower 
heart rate (p< 0.001), a higher stroke index (p=0.018) and no difference in resultant 
cardiac index (p=0.452). 
iv) In gestational apoteinuric hypertensives presenting after 34 weeks gestation, maternal 
hemodynamics and uterine artery resistance index did not help define a higher risk group. 
v) In chronic hypertensives pregnancies, left ventricular hypertrophy correlated with severity 
of blood pressure. Higher risk chronic hypertensives were better selected by proteinuria 
than maternal central hemodynamics or uterine artery resistance index. 
vi) In normal pregnancy, maternal cardiac output peaked in early to mid third trimester and 
was maintained till term. Significant correlations were observed among maternal cardiac 
output, maternal body surface area and fetal birth weight. 
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Discussion: 
i) This study shows that cardiac index and systemic vascular resistance index measured in 
the latter part of the second and third trimesters in hypertensive pregnant women were not 
associated with adverse fetal outcome. Large variations in cardiac index values were 
observed that restricted detection of satisfactory critical values for cardiac index and 
systemic vascular resistance index to predict adverse outcome. 
ii) An improved correlation of uterine artery resistance index with maternal hemodynamics 
and fetal birthweight in pre-eclampsia supports the hypothesis that poor placentation does 
not allow for a normal increase in uterine blood flow. 
iii) The poor correlation between uterine artery resistance index and maternal central 
hemodynamics, does not support the hypothesis that elevated cardiac output in 
hypertensive pregnancies (hyperdynamic disease model) occurs as a compensatory 
response to maintain adequate perfusion in a utero-placental bed with high resistance that 
did not decrease. 
IX 
Table of contents 
Title 
Declaration 






List of tables 












Introduction and literature survey 
Aims and methods 
Echocardiographic assessment of maternal cardiovascular 
hemodynamics in normal normotensive pregnancy 
Maternal hemodynamics in hypertensive disorders of 
pregnancy: an overview 
Pre-eclampsia and its variants- an echocardiographic evaluation 
Gestational aproteinuric hypertension 


























Chapter 1: Introduction and literature survey 
1.1 Background 1 
1.2 Current classification of hypertensive disorders of pregnancy 2 
1.2.1 Introduction 2 
1.2.2 Classifications of hypertension outside pregnancy 3 
1.2.3 Current classification of hypertensive disorders of pregnancy 4 
1.2.4 Gestational hypertension/gestational aproteinuric hypertension 5 
1.2.5 Pre-eclampsia (gestational proteinuric hypertension) 6 
1.2.6 Chronic hypertension and chronic hypertension with 
superimposed preeclampsia 7 
1.2.7 Unclassified hypertension 8 
1.2.8 The need for continued refinement in classification of 
hypertensive disorders of pregnancy 8 
1.3 Cardiovascular changes in normal pregnancy 10 
1.3.1 Cardiac output 10 
1.3.2 Heart rate, stroke volume and cardiac output 11 
1.3.3 Blood pressure, cardiac output and systemic vascular resistance 12 
1.3.4 Systemic vascular resistance and vasodilatory neurohormones 13 
1.3.5 Volume homeostasis and red cell mass 15 
1.3.6 Placental implantation 17 
1.4 Cardiovascular changes in hypertensive pregnancy with focus on 
preeclampsia 18 
1.4.1 Introduction 18 
1.4.2 Latent (pre-clinical) phase 20 
1.4.3 Clinical Phase 21 
1.4.4 Heart rate - an important cardiac output variable 22 
1.4.5 Volume homeostasis 23 
1.4.6 Maternal haemodynamics and fetal outcome 24 
1.4.7 Vasoactive neurohormones in preeclampsia 25 
1.4.8 Sympathetic activity and vagal baroreflex function 27 
1.4.9 Electrolyte abnormalities 28 
1.4.10 Summary 28 
1.5 Uteroplacental Doppler velocimetry in hypertensive pregnancy 30 
1.6 Doppler echocardiography for assessment of maternal central hemodynamics 
and aims of this thesis 32 
XI 
Chapter 2: Aims and Methods 
2.1 Aims 34 
2.2 Setting 34 
2.3 Design 35 
2.4 Participants 36 
2.4.1 Inclusion criteria 37 
2.4.2 Exclusion criteria 37 
2.5 Methods 38 
2.5.1 Sample size of study 38 
2.5.2 Obstetric assessment 38 
2.5.3 Echocardiography 39 
2.5.4 Uteroplacental Doppler veloimetry 43 
2.6 Statistical methods 44 
2.7 Analysis of results 44 
2.7.1 Classification of hypertensive groups 45 
2.7.2 Stratification by blood pressure (BP) 45 
2.7.3 Stratification by proteinuria 46 
2.7.4 Stratification by treatment group 47 
2.7.5 Stratification based in maternal haemodynamic variables 47 
2.7.6 Adverse feto-neonatal outcome 47 
Chapter 3: Echocardiographic assessment of maternal cardiovascular 
hemodynamics in normal normotensive pregnancy 
3.1 Introduction and aims 48 
3.2 Methods 49 
3.3 Results 51 
3.3.1 Baseline demographics 51 
3.3.2 Haemodynamic changes in cardiac output, heart rate and 
stroke volume 52 
3.3.3 Comparative analysis with subgroup (n=10) without missing visits 55 
3.3.4 Hemodynamics - cardiac output vs cardiac index 57 
3.3.5 Echocardiographic determinate of stroke volume 60 
3.3.6 Cardiac structural and function changes 61 
3.4 Discussion 64 
Xll 
Chapter 4: Maternal hemodynamics in hypertensive disorders of pregnancy: 
Combined group analysis 
4.1 Introduction, aims and methods 73 
4.2 Results 75 
4.2.1 Demographics 75 
4.2.2 Cardiac structure and function 79 
4.2.3 Maternal central hemodymanics and uterine Doppler velocimetry 82 
4.3 Discussion 87 
Chapter 5: Focus on pre-eclampsia and its variants 
5.1 Introduction, aims and methods 89 
5.2 Results 91 
5.2.1 Demographics 91 
5.2.2 Echocardiography - cardiac structure 95 
5.2.3 Maternal hemodynamics and uterine artery Doppler velocimetry 98 
5.2.4 Evaluation of treated pre-eclamptics and combined preeclamptic 
groups 101 
5.2.5 Evaluation of preeclamptics stratified by adverxe feto-neonatal outcome 102 
5.3 Discussion 107 
Chapter 6: Gestational aproteinuric hypertension 
6.1 Introduction, aims and methods 109 
6.2 Results 110 
6.2.1 Demographics 110 
6.2.2 Cardiac structure and function 112 
6.2.3 Echocardiographic hemodynamics and uterine Doppler flow velocimetry 114 
6.3 Discussion 116 
Chapter 7: Chronic hypertension and superimposed pre-eclampsia on chronic 
hypertension 
7.1 Introduction, aims and methods 119 
7.2 Results 120 
7.2.1 Demographics 120 
7.2.2 Echocardiography - cardiac structure and function 122 
7.2.3 Maternal hemodynamics and uterine artery Doppler flow velocimetry 123 
Xlll 
7.3 Stratification by presence of left ventricular hypertrophy 124 
7.4 Discussion 126 
Chapter 8: Discussion 
8.1 Introduction 127 
8.2 Prognostic value of haemodynamic studies 128 
8.2.1 Maternal central haemodynamics, uterine Doppler velocimetry 
and feto-neonatal outcome 128 
8.2.2 Limitations of maternal haemodynamics studies 131 
8.2.3 Clinical limitations : effects of treatment and maternal body habitus 135 
8.3 Blood pressure, maternal haemodynamics and feto-neonatal outcome 140 
8.4 Proteinuria, maternal hemodynamics and fetal outcome 143 
8.5 Maternal hemodynamics, left ventricular mass and systolic function 144 
8.6 Conclusion: maternal hemodynamics in hypertensive disorders of 
pregnancy 148 
8.7 Classification of hypertensive disorders of pregnancy 150 
8.8 Recommendation for future studies 152 
xiv 
List of tables 
Chapter 2: Aims and methods 
Table 2.1: Staging of hypertensive group according to blood pressure levels 46 
Chapter 3: Echocardiographic assessment of maternal cardiovascular 
Hemodynamics in normal normotensive pregnancy 
Table 3.1: Patients studied at indicated gestational periods (n=3 5) 51 
Table 3.2: Baseline characteristics of all participants (n=35) 52 
Table 3.3: Longitudinal changes in normal pregnancy. 54 
Table 3.4: Comparative longitudinal changes in full study group (n=35) and subgroup 
(n= 10) without missing visits in the latter half of pregancny 56 
Table 3.5: Longitudinal changes in normal pregnancy 58 
Table 3.6: Correlation of indices in normal pregnant women 59 
Table 3.7: Longitudinal changes in normal pregnancy 61 
Table 3.8: Longitudinal echocardiographic changes in normal pregnancy 63 
Chapter 4: Maternal hemodynamics in hypertensive disorders of 
pregnancy: combined group analysis 
Table 4.1: Hypertensive group demographics 75 
Table 4.2: Demographics for combined hypertensive and normotensive groups 77 
Table 4.3: Demographic data of hypertensive participants 78 
Table 4.4: Cardiac structure and function - combined hypertensive and normotensive 
groups 80 
Table 4.5: Cardiac structure and function - hypertensive groups 81 
Table 4.6: Maternal central hemodynamics and uterine Doppler velocimetry in 
combined hypertensive and normotensive groups 84 
Table 4.7: Maternal central hemodynamics and uterine Doppler velocimetry in 
Hypertensive groups 85 
Table 4.8: Combined hypertensive cohort (n=40) stratified by feto-neonatal outcome 86 
Chapter 5: Focus on preeclampsia and its variants 
Table 5.1: Demographic data of preeclampsia, normotensive and gestational 
hypertensive groups 93 
Table 5.2: Demographic data of preeclampsia and superimposed preeclampsia groups 94 
Table 5.3: Cardiac structure and function - preeclampsia, normotensives and 
gestational hypertension groups 96 
Table 5.4: Cardiac structure and function - preeclampsia and superimposed 
preeclampsia and superimposed preeclampsia groups 97 
Table 5.5: Maternal central hemodynamics and uterine Doppler velocimetry in 
Preeclampsia, normotensive and gestational hypertension groups 99 
Table 5.6: Maternal central hemodynamics and uterine Doppler velocimetry in 
hypertensive groups 100 
Table 5.7: Comparative demographics in untreated and combined preeclampsia groups 104 
Table 5.8: Comparative hemodynamics and uterine artery velocimetry in treated and 
combined preeclampsia groups 105 
Table 5.9: Combined preeclamptic group (n=32) stratified by feto-neonatal outcome 106 
Chapter 6: Gestational aproteinuric hypertension 
Table 6.1: Demographic data of gestational hypertensive: normotensive and chronic 
Hypertensive groups 111 
Table 6.2: Cardiac structure and function - gestational hypertensives, normotensvies 
and chronic hypertension groups 113 
Table 6.3: Maternal central hemodynamics and uterine Doppler velocimetry in 
Gestational hypertensive, normotensive and chronic hypertensive groups 115 
Chapter 7: Chronic hypertension and superimposed pre-eclampsia 
on chronic hypertension 
Table 7.1: Demographics 121 
Table 7.2: Echocardiography cardiac structure and function 123 
XVI 
Table 7.3: Comparative hemodynamics 124 
Table 7.4: Comparative evaluation of chronic hypertension with left ventricular 
hypertrophy 125 
XVll 
List of figures 
Figure 1: Echocardiographic planes 
Figure 2: Parasternal long axis view 
Figure 3: Apical 5 chamber view, Doppler at LV outflow tract 
Figure 4: M-Mode echocardiographic study of the left ventricle 
Figure 5: Left ventricle diastolic filling by pulsed Doppler 
Figure 6a: Uterine artery Doppler velocimetry (normal) 
Figure 6b: Uterine artery Doppler velocimetry (pre-eclampsia) 
Figure 7: Umbilical artery Doppler velocimetry (normal) 
XVlll 
CHAPTER 1 
INTRODUCTION AND LITERATURE SURVEY 
1.1 Background 
Hypertension in pregnancy is associated with significant cardiovascular morbidity and 
mortality. It is the most common medical disorder complicating pregnancy with a 
reported incidence of 5-10% (Duley, 1992), and is an important cause of fetal and 
maternal morbidity and mortality. In his review on the subject, Bernheim (1997) 
stated that the practical management of hypertensive disorders of pregnancy and in 
particular pre-eclampsia require prudence, careful follow-up and prompt decision on 
the precise moment for delivery. The National Committee on Confidential Enquires 
into Maternal Deaths in South Africa (1998) reported that complications of 
hypertensive disorders of pregnancy accounted for 23% of maternal deaths. At King 
Edward VIII hospital, a tertiary teaching institution in Durban, South Africa, the 
setting for the current study, 18% of all admissions to the obstetric unit are 
hypertensive (Moodley, 1993). 
Women with established hypertension carry a significant increase in feto-maternal 
risks compared to normotensive pregnant women. Kuzniar (1982) and Yang et al, 
(1996), described poor fetal outcome and fetal growth restriction in hypertensive 
women who had a markedly reduced cardiac index or elevated systemic vascular 
resistance, respectively. Nisell et al (1988) also made similar observations of maternal 
hemodynamics of a low cardiac output and high systemic vascular resistance being 
associated with birth of a small for gestational age infant. More recently, Xiong et al, 
(2002) in a large retrospective cohort study reported a significant association of pre-
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eclampsia and gestational hypertension with both large for gestational age infants and 
low birth weight and small for gestational age infants, observations that highlight the 
heterogenous nature of hypertensive disorders of pregnancy. 
Diagnosis of hypertension in pregnancy rests on detection of a persistently elevated 
blood pressure; levels for diagnosis and assessment of severity however, remain 
controversial, as blood pressure is a continuous variable with unimodal distribution 
The degree of impaired maternal cardiovascular adaptation in hypertensive 
pregnancies could potentially be used to risk stratify and identify hypertensive 
pregnancies at risk for adverse fetal outcome. This determines the need for some 
form of classification of both the type and severity of hypertension occurring during 
pregnancy. 
1.2 Current classification of hypertensive disorders of pregnancy 
1.2.1 Introduction 
The current classification of hypertensive disorders of pregnancy is far from ideal as 
the exact aetiology of hypertensive disorders of pregnancy and in particular pre-
eclampsia, is not known. Consequently there are numerous classifications in the 
literature that have varied from being simple, less specific and user friendly to 
complex, more specific and less user friendly (Brown et al, 1999). 
Whatever classification is used, there is consensus that hypertension in pregnancy is 
defined either as a diastolic blood pressure of greater than or equal to 1 lOmmHg on 
any one occasion or a diastolic blood pressure equal to or greater than 90mmHg on 
two consecutive occasions at least 4 hours apart. Proteinuria is defined either by a 24 
2 
hour urine collection or 2 clean-catch or catheter urine specimens collected 4 hours 
apart. The 24 hour urine collection should have > 300mg protein or a spot urine 
sample should have 1+ protein or more on the reagent strip or the sulfosalicylic acid 
"cold" test. 
1.2.2 Classification of hypertension outside pregnancy 
There are similar problems in classifying hypertension outside pregnancy. Earlier 
staging of essential hypertension focussed primarily on blood pressure and its severity 
to identify at 'risk' groups. The limitations of these earlier classifications became 
evident as clinicians and researchers found that they fell short on prognostic risk 
stratification. The recent staging of hypertension outside pregnancy advised by 
international bodies of the Joint National Committee of Hypertension and World 
Health Organization include clinical variables that have improved risk stratification. 
Apart from severity of blood pressure, the current Joint National Committee (JNC 7) 
classification (Chobanian et al, 2003) includes an assessment of associated 
cardiovascular risks, presence of a cardiovascular event and target organ involvement. 
The cardiovascular risk factors emphasized in the JNC staging include age, 
dyslipidaemia, diabetes mellitus, cigarette smoking, menopause status and family 
history of cardiovascular disease. Target organ involvement includes the presence of 
proteinuria, retinopathy, left ventricular hypertrophy and evidence of significant 
atherosclerosis. Left ventricular hypertrophy is now accepted as an independent risk 
factor for adverse outcome in these hypertensive patients, an observation that has 
stimulated research into detection of abnormalities of cardiac structure and function 
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by echocardiography and Doppler. Thus, the presently used staging of hypertension 
outside pregnancy is user-friendly and useful for the clinician as it carries important 
therapeutic and prognostic implications; it is however, not satisfactory in pregnancy 
where hypertension is often acute in onset, and except for proteinuria, not associated 
with the risk markers as a rule. 
1.2.3 Current classification of hypertensive disorders of pregnancy 
A classification must also find general acceptance so that the incidence and outcome 
of hypertensive disorders of pregnancy and the results of research in different centres 
can be compared and mutual understanding achieved. The classifications 
recommended by Davey and MacGillivray (1988) and that by the Australasian society 
for the study of hypertension in pregnancy (Brown et al, 2000) are acceptable as they 
combine the essential components of hypertension and proteinuria. These 
classifications are based largely on the physical signs of hypertension and proteinuria. 
The classifications recommended by the Australasian society for the study of 
hypertension in pregnancy (Brown et al, 2000) and Davey and MacGillivray (1988) 
have the following corresponding categories: 




Pre-eclampsia on chronic hypertension 
Gestational aproteinuric hypertension 
Gestational proteinuric hypertension 
Chronic hypertension 
Pre-eclampsia on chronic hypertension 
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1.2.4 Gestational hypertension 
This is refers to hypertension that develops during pregnancy in a previously 
normotensive non-pro teinuric woman. The term 'gestational' is intended to mean that 
the hypertension developed during pregnancy and disappears in the post-partum 
period. It is important to note whether the first occurrence of hypertension occurred 
antenatally, in labour or post partum. 
Although useful this somewhat arbitrary definition of gestational hypertension in that 
it excludes women with proteinuric hypertension (pre-eclampsia) and women with 
preexisting hypertension, further more it embraces a heterogenous group of 
hypertensive pregnant women with varying prognosis. Also it is not a final diagnosis 
as it may overlap with pre-eclampsia (proteinuric hypertension). Saudan et al, (1998) 
found that approximately 17% of women (15% in a retrospective study and 26% in a 
prospective study) initially diagnosed with gestational hypertension develop pre-
eclampsia. 
Furthermore, many women diagnosed with gestational hypertension carry a good 
prognosis as borne out in the study of Bosio et al, (1999) that showed women with 
gestational aproteinuric hypertension may be 'closer' to normotensive pregnant 
women in risk and outcome than with women who have pre-eclampsia (gestational 
proteinuric hypertension). In addition, the clinical presentation of pregnant women 
with mild aproteinuric chronic hypertension is often similar to women with 
gestational aproteinuric hypertension as clinical evidence of hypertensive target organ 
involvement is often not present in the former especially when the disease is mild. 
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These observations highlight some of the limitations of an arbitrary category of 
gestational hypertension that make accurate differentiation and precise risk 
stratification difficult. 
1.2.5 Pre-eclampsia (gestational proteinuric hypertension) 
Pre-eclampsia is better called gestational proteinuric hypertension because the latter 
term is intended to mean that the hypertension with proteinuria developed during 
pregnancy and disappears in the postpartum period. Pre-eclampsia may be 
categorised as being either mild to moderate or severe. It is labelled as being severe if 
any one of the following is present: 
i) Blood pressure > 160/1 lOmmHg on 2 occasions 4 hours apart. 
ii) Proteinuria of > 5g per 24 hours OR 3+/4+ on semi-quantitative assay 
iii) Oliguria defined as < 500cc urine output per 24 hours 
iv) Pulmonary oedema or cyanosis 
v) Thrombocytopaenia 
vi) Cerebral or visual disturbances such as an altered consciousness, headache, 
scotoma or blurred vision 
vii) Epigastric or right upper quadrant pain 
viii) Impaired liver function of unclear aetiology 
The absence of any of these features categorises the patient as having mild or mild-
moderate pre-eclampsia. Although these features define a high risk cohort labelled as 
severe pre-eclampsia, it has limited usefulness in early diagnosis of severe pre-
eclampsia as Redman and Roberts (1993) have importantly pointed out that a smooth 
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progression from mild pre-eclampsia to a severe form is often not seen. To add to the 
complexity of having an all encompassing classification, Brown & de Swiet (1999) in 
their review have stated that, while remaining a hallmark of pre-eclampsia, 
proteinuria should no longer be considered a 'sine qua non' for this disorder to be 
diagnosed. 
1.2.6 Chronic hypertension and chronic hypertension with superimposed pre-
eclampsia 
Chronic hypertension in pregnancy is defined as the presence of non-proteinuric 
hypertension in women in whom a diagnosis of chronic hypertension was made 
before, during or after pregnancy. At a practical level a diagnosis of hypertension 
made before the 20th week of gestation or persistent hypertension beyond 6 weeks 
postpartum is presumed to be chronic hypertension. The development of proteinuria 
in such women during pregnancy demands an increased surveillance for the 
development of superimposed pre-eclampsia, a diagnosis that is not secure without 
the other features of the pre-eclampsia syndrome. 
Furthermore, although women labelled as chronic hypertension in pregnancy as a 
group are at increased risk of developing placental abruption, fetal growth restriction, 
prematurity and superimposed pre-eclampsia (Haddad et al, 1999), this risk is not 
uniform. The above risks are particularly increased in women who have severe 
hypertension, pre-existing renal disease and in those with hypertensive target organ 
damage. In addition, chronic hypertension usually implies established hypertension 
that warrants antihypertensive therapy; which itself, particularly with the use of 
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diuretics and beta-adrenergic blockers, is not without potential harm. A recent 
analysis by Ferrer et al, (2000) concluded that no study has as yet provided guidance 
on the benefits, consequences of therapies or monitoring strategies of chronic 
hypertension in pregnancy. 
1.2.7 Unclassified hypertension 
In this category are included all cases where essential clinical information is lacking 
or where the diagnosis is uncertain. This category helps ensure that the above 
categories of gestational aproteinuric hypertension, pre-eclampsia, chronic 
hypertension and superimposed pre-eclampsia on chronic hypertension are not 
confused. Such patients are then correctly classified at postpartum follow-up. 
1.2.8 The need for continued refinement in classification of hypertensive 
disorders of pregnancy 
Hypertension as a trait is also problematic as its classification as a blood pressure 
measure above 140/90 mmHg is arbitrary and its aetiology remains highly 
heterogeneous. In studies of hypertension, both in pregnant and non-pregnant settings, 
Peters et al, (1995) highlighted the limitation of using blood pressure as a 
distinguishing parameter because it exhibits great intra-individual variance. 
The complexity of classifying hypertensive disorders of pregnancy becomes evident 
as Spaanderman et al, (2000) suggested that normotensive women with a history of 
pre-eclampsia should be considered as having latent hypertension. Despite the 
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limitations of M-mode echocardiography study methods to evaluate maternal 
hemodynamics, Clapp et al, (1997) showed that cardiovascular adaptations during 
pregnancy may persist up to one year postpartum and that it may be enhanced by a 
subsequent pregnancy. These observations highlight potential limitation of grouping 
together primiparous and multiparous women and of using the postpartum period as 
baseline when evaluating maternal hemodynamics. 
Higgins et al, (2001) point out that definitions of pre-eclampsia based solely on 
hypertension and proteinuria ignore the wide clinical variability, including the 
presence and severity of proteinuria in this syndrome. For instance, Saudan et al, 
(1998) have shown that women with gestational hypertension may progress to pre-
eclampsia. In their review by Brown & de Swiet (1999) consider that proteinuria, 
while remaining a hallmark of pre-eclampsia, should no longer be considered a 'sine 
qua non' for this disorder to be diagnosed. 
In the light of these drawback it is therefore not surprising that researchers have 
turned some of their focus to the maternal hemodynamic determinants of blood 
pressure (cardiac output and systemic vascular resistance) to risk stratify hypertensive 
pregnancies. Non-invasive evaluation of maternal central hemodynamics, cardiac 
structure and function together with simultaneous uteroplacental Doppler velocimetry 
evaluation offer an attractive option for improved understanding of the 
pathophysiology of hypertension in pregnancy and assist in the care of these patients. 
The literature survey focuses on the cardiovascular changes in normal and 
hypertensive pregnancy followed by an evaluation of echocardiographic-Doppler 
maternal central haemodynamics, uterine artery velocimetry and aims of this study. 
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1.3 Cardiovascular changes in normal pregnancy 
1.3.1 Cardiac output 
The precise changes of cardiac output in normal pregnancy have remained 
controversial. A meta-analysis of cross-sectional studies has revealed large ranges in 
cardiac output across studies (van Oppen et al, (1996). Despite numerous limitations 
of the above meta-analysis, pooled data from each trimester showed a tendency to 
higher cardiac output in the second trimester compared with the first and lower 
cardiac output in the third trimester compared to the second. 
Van Oppen et al, (1996) also performed a meta-analysis of 6 longitudinal studies that 
had 2 or more cardiac output measurements during pregnancy. The authors found 
widely divergent changes in cardiac output between the second and third trimesters, 
with 2 studies showing an increase, 2 with no change, and 2 with a decrease. Both van 
Oppen et al, (1996) and Duvekot eand Peeters (1994) cited patient factors rather than 
technique as being responsible for the apparent divergent trends of cardiac output in 
the third trimester. 
In their review Thornburg et al, (2000) reported that cardiac output peaks in the third 
trimester by approximately 50%. The peak has been reported to occur at gestations 
varying from 24 weeks to term in the review by van Oppen et al, (1996). Most of 
these studies of cardiac output in pregnancy were performed with subjects in the 
lateral position so that the effects of inferior vena caval compression are minimized 
and unlikely to account for the variability. However, most studies of maternal 
hemodynamics in normal pregnancy have reported measurement of cardiac output 
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rather than the stature-corrected measure of cardiac index and this may be a 
significant reason for the variable changes. The rise in cardiac output is generally 
accepted as being approximately 50% above pre-conception values but the relative 
contributions of heart rate and stroke volume remain unsettled. Cardiac output 
decreases in the early postpartum period and pre-conception values are reached 
around 6-12 weeks. 
1.3.2 Heart rate, stroke volume and cardiac output 
Although heart rate and stroke volume are the two major determinants of cardiac 
output, most studies of cardiac output in pregnancy have not paid particular attention 
to the effects of heart rate. The meta-analysis by van Oppen (1996) also did not focus 
on the influence of heart rate on cardiac output during pregnancy. In a study by 
Hennessy et al, (1996) of cardiac output measured by Doppler ultrasound, the authors 
showed a 32% increase in heart rate above baseline values. This maximal heart rate 
occurred at 32 weeks gestation corresponding to the time of peak cardiac output. 
Stroke volume however, continued to increase to a maximum at 36 weeks suggesting 
that the decline in cardiac output from 32 weeks is mediated by a decrease in heart 
rate. 
In another longitudinal study, Mabie et al (1994) demonstrated an increase in cardiac 
output of 53% that occurred late in the third trimester; the peak occurring from an 
increase in stroke volume of 18% and an increase in heart rate of 29%. These varying 
contributions of heart rate and stroke volume to changes in cardiac output are not 
easily explained. Variations in autonomic control mechanisms in pregnant women 
l l 
may explain some of the reported differences of heart rate effect on cardiac output. 
Blake et al, (2000) have reported reduced baroreceptor sensitivity for heart rate during 
normotensive pregnancy. 
1.3.3 Blood pressure, cardiac output and systemic vascular resistance 
Systolic, diastolic and mean blood pressure values begin to decline from the first 
trimester at approximately 8 weeks and continue to decline to reach their lowest 
towards the end of the second trimester after which there is a steady increase with a 
return to pre-pregnant blood pressure values at term or soon thereafter. Measuring 
muscle sympathetic nerve activity, Greenwood et al, (2001) showed that central 
sympathetic output was increased in the latter months of normal pregnancy; these 
findings suggest that a moderate increase in sympathetic hyperactivity in the latter 
months of normal pregnancy may help return of arterial pressure to non-pregnant 
levels. In addition, Greenwood et al, (2001) also noted that sympathetic output 
decreased to non-pregnant values after delivery; a change that occurred without 
significant change in blood pressure. This imprecise relationship between central 
sympathetic output and blood pressure in normotensive pregnant women is also 
supported in an earlier study by Ergman et al, (1999) who found no differences in 
neuropeptide Y, levels, modulator of vascular tone by the sympathetic nervous 
system, between normotensive and preeclamptic women. 
As discussed in 1.3.1 cardiac output probably peaks by mid-third trimester; after this 
there is a steady decline to term. This corresponds to the systemic vascular resistance 
which reaches its lowest value at 28-32 weeks and increases steadily thereafter till 
term (van Oppen, 1996). Also Varga et al, (2000), have shown that the maximal 
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increase in glomerular filtration rate as a result of renal vasodilation precedes the 
maximal increase of cardiac output. They attributed the increase of cardiac output in 
the first trimester to a shunt effect of enhanced renal blood flow and in the second and 
third trimester to the shunt effect of the feto-placental unit and maternal kidneys. 
Noting that these observations support the "underfill hypothesis" in normal 
pregnancy, Carbillon et al, (2000) in their review stated that the adaptation of vascular 
tone in early pregnancy precedes and probably triggers blood volume and cardiac 
output increase. 
1.3.4 Systemic vascular resistance and vasodilatory neurohormones 
Thus the fall in systemic vascular resistance in normal pregnancy commences early in 
the first trimester and is related to changes in renal function and blood volume. The 
blood pressure is also diminished, a change noted especially during the second 
trimester. These changes are also associated with altered receptor responses to 
vasoconstrictor and vasodilatory neurohormones. Among the neuro-hormones 
regulating vascular homeostasis both in normal and hypertensive pregnancies, the 
renin-angiotensin system is important because of the known decrease in pressor 
responsiveness to angiotensin II in normal pregnancy. In a study of 7 normal 
pregnant volunteers Langer et al, (1998) showed that in the first trimester of normal 
pregnancy, active renin concentrations are elevated but angiotensin I, angiotensin II, 
and aldosterone levels remained at comparable postpartum levels. The highest activity 
of the renin angiotensin system, with increased levels of angiotensin I, angiotensin II, 
and aldosterone, was observed in the third trimester. 
August et al, (1995) evaluated converting enzyme inhibition with captopril in normal 
pregnancy and concluded that activation of the renin-angiotensin system was 
responsible for maintained blood pressure. Merrill et al, (2002) showed that this is 
associated with a rise in plasma angiotensin II as well as a 51% increase in 
angiotensin 1-7), a bioactive component that has depressor, vasodilatory and 
antihypertensive actions. Angiotensin 1 - 7 is a novel counterregulator lacks the 
vasoconstrictor actions of angiotensin II; it has no central pressor effects, does not 
stimulate aldosterone and results in release of nitric oxide, bradykinin and 
prostacycline. In preeclamptics the level of angiotensin (1-7) is significantly reduced 
despite an increase in plasma angiotensin II levels. 
Magness et al, (1994) have shown that the decreased pressor response to angiotensin 
II in normal pregnancy is not due to an increase in prostaglandin E2, nor is it related to 
alterations in the balance ratio of prostacycline to thromboxane. In contrast there is 
evidence that angiotensin II evokes both a pressor and depressor effect and the latter 
effect could be mediated by angiotensin II - induced stimulation of prostacycline 
synthesis. 
Endothelium-derived nitric oxide, a vasodilator, has also been reported to suppress 
vasoconstrictor reactivity and contributes to the fall in peripheral resistance in normal 
pregnancy. Using forearm blood flow responses Anumba et al, (1999) concluded 
however, that changes in vascular nitric oxide activity are unlikely to account for the 
increased vascular tone seen in pre-eclampsia. These observations are supported by 
Rajagopal et al, (2003) who found no differences in nitric oxide synthases by 
immunostaining in both normotensive and hypertensive pregnancies. Higher 
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concentrations of reproductive hormones such as progesterone and relaxin in early 
pregnancy have been described to be associated with lower systolic blood pressures in 
the second and third trimesters (Kristiansson et al, 2001). The vasodilator effect of 
endogenous calcitonin gene-related vasodilator on fetoplacental vascular tone could 
be mediated by a nitric oxide pathway (Dong et al, 2004). 
Whatever the precise role of vasodilatory neurohormones in contributing to the 
reduced systemic vascular resistance in normal pregnancy it is clear that the renin 
angiotensin system has a principal role not only in regulating the vasodilation in 
normal pregnancy, but it also indicates the pathological vasoconstriction observed in 
pre-eclampsia. 
1.3.5 Volume homeostasis and red cell mass 
Plasma volume and total extracellular fluid volume are increased in normal 
pregnancy. The increase in plasma volume increase occurs from about the seventh 
week of gestation and increases gradually to a maximum at approximately 30 weeks 
and is maintained at this level till term. Brown et al, (1992) have reported that 
maximal increases 1200-1600ml corresponded to a 50% rise above pre-pregnancy 
levels. In addition, the authors also noted that both the maximum increment and the 
maximum plasma volume reached correlated positively with birth weight. These 
observations are consistent with the hypothesis that normal maternal cardiovascular 
adaptive responses are accompanied by increases in maternal cardiac output 
associated with an adequate plasma volume expansion and constitute a state of 
chronic volume overload (Katz et al, 1978). 
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One would expect that atrial distension or an increase in atrial pressure is the stimulus 
for atrial natriuretic secretion. However, atrial natriuretic peptide levels during 
pregnancy are essentially unchanged from pre-pregnant levels (Laragh, 1985). In a 
study of acute volume loading Nisell et al, (1992) did not demonstrate any increase in 
atrial natriuretic peptide concentration during late pregnancy as compared to the non-
pregnant state. More recently, Maggioni et al, (2001) stated that in normal pregnancy, 
the relationship between atrial natriuretic peptide and arterial pressure and the renin-
angiotensin system remains debatable. The authors also described elevated levels of 
atrial natriuretic peptide levels in normotensive pregnancy complicated by intrauterine 
growth restriction compared to normal normotensive pregnancy. It appears that 
during pregnancy atrial natriuretic peptide has negligible effects on plasma volume 
regulation and that volume homeostasis is the result of changes in various inter-
dependent systems. The initial reduction in vascular tone leads to changes in plasma 
osmolality that probably results in resetting of volume and osmoreceptors. Thereafter, 
other volume regulating mechanisms such as the renin-angiotensin-aldosterone 
system, pregnancy hormones and atrial natriuretic peptides adapt to the increase in 
blood volume (Duvekot et al, 1994). 
Plasma volume and red cell mass are closely related in pregnancy. The increase in 
total red cell mass varies from 17-40% (mean 24%) with a pattern that is similar to the 
increase in plasma volume (Brown et al, 1992). Whittaker et al, (1996) reported that 
both haemoglobin concentration and haematocrit show a steady decrease until late in 
the third trimester. These authors found no correlation between red cell indices and 
fetal outcome and suggested that the low haemoglobin noted in late pregnancy reflect 
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plasma volume changes rather than poor maternal nutrition or cardiovascular 
adaptation. Recently McMullin et al, (2003) showed that erythropoietin levels 
increased throughout normal pregnancy and they observed a significant relationship 
between erythropoietin levels and haemoglobin, ferritin, total iron binding capacity 
and folate. These observations support the hypothesis described by Donnelly (2003) 
that hematocrit regulation is mediated by the kidney acting as a "critmeter" that 
regulates the plasma volume and red cell mass. 
1.3.6 Placental Implantation 
In normal pregnancies the cytotrophoblast invades the endothelium and muscular 
tunica media of the maternal spiral arteries, resulting in transformation of these small 
muscular arterioles to large capacitance vessels of low resistance (Zhou et al, 1997). 
This process is dependent on the invasion of the interstitium and spiral arteries of the 
uterine wall by invasive extravillous trophoblast thereby creating a high flow-low 
resistance vessel (Naicker et al, 2003). This normal placental implantation is usually 
associated with the normal maternal cardiovascular adaptive changes characterised by 
an increase in cardiac output, stroke volume, heart rate, blood volume, renal blood 
flow and glomerular filtration and a reduction in systemic vascular resistance (Sibai et 
al, 1995). Defective placentation, that is so characteristic of hypertensive 
pregnancies, is associated with an attenuation or failure of this normal maternal 
cardiovascular adaptation (de Groot et al, 1996). 
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1.4 Cardiovascular changes in hypertensive pregnancy with focus on pre-
eclampsia 
1.4.1 Introduction 
The aetiology of hypertensive disorders of pregnancy, in particular, pre-eclampsia, 
remains elusive despite significant knowledge gained about many of its biological 
characteristics and predictors. In his review of pre-eclampsia, Roberts (2000) 
attributed the primary pathophysiology in pre-eclampsia to reduced placental 
perfusion probably consequent upon abnormal implantation. Other major aetiological 
factors relate to maternal disorders that serve as predisposing factors and include 
conditions such as chronic hypertension, renal disease, diabetes and obesity. 
In pre-eclampsia, trophoblastic implantation is abnormal or is limited to the decidual 
part of the vessels. Trophoblastic function is impaired and may include restricted 
invasive behaviour (Pijnenborg et al, 2000). The decidual portion of the spiral 
arteries does not undergo the normal pregnancy-induced remodelling that converts 
these vessels to high volume-low resistance conduits (de Groot et al, 1993). 
Histopathology of the placental bed in pre-eclamptic women shows the spiral and 
basal arteries to be more tortuous and have smaller calibre lumens and thicker walls 
(Starzyk et al, 1999). This failure of proper placentation in pre-eclamptic women 
may result in abnormal spatial anatomy of the placental bed. It is postulated that 
reduced placental perfusion interacts with maternal constitutional factors to generate 
the systemic pathophysiological milieu of pre-eclampsia (Roberts 2000). 
In contrast to normal pregnancy, widespread injury to vascular endothelial cells is 
believed to result in an increased sensitivity to pressor agents causing vasospasm. 
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This endothelial injury and dysfunction has been described as the secondary 
pathophysiology in pre-eclampsia that results in disturbance in organ function of liver, 
heart, kidneys and brain. Recently, Anim-Nyame et al, (2003) measured circulating 
levels of vascular cell adhesion molecule-1, intercellular cell adhesion molecule-1, E-
selectin and neutrophil elastase in pre-eclamptic women and showed impaired 
microvascular function related to alterations in endothelial cell and neutrophil 
activation. 
Since hypertensive pregnancies comprise a highly heterogeneous group several other 
factors contribute to the pathogenetics. Furthermore the genetic component in such 
groups may elude detection in studies grouped by current criteria (Peters, 1995). As 
yet, the relative contributions of maternal and fetal genotypes are still unclear 
(Roberts, 2001). Other factors that play a pathogenetic role include immune 
mechanisms, genetic susceptibility, parity (either first order or high parities) and 
maternal age (teenagers and women of 35 years or greater), all of which may 
contribute to abnormal implantation of trophoblast. 
The deficient placental implantation process is probably complete many weeks before 
hypertension becomes clinically apparent (Khong et al, 1986). Clinical disease in 
pre-eclampsia usually manifests much later, in the third trimester. However, less 
frequently, clinical disease occurs in the latter half of the second trimester, often 
referred to as early onset pre-eclampsia. These observations allude to the importance 
of evaluating subclinical changes in this latent or pre-clincal phase. A study of the 
time-course pattern of cardiovascular changes in normal pregnancy will allow for a 
more critical evaluation of cardiovascular hemodynamics in hypertensive disorders of 
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pregnancy. The hypothesis is that these adaptive changes may serve as a non-invasive 
'window' to the presence and severity of the defective placentation that occurs in 
hypertensive pregnancies. 
1.4.2 Latent (pre-clinical) phase 
Symptomatic disease in pre-eclampsia is often preceded by a variable and often long 
pre-clinical period (latent phase). There are few studies of maternal cardiovascular 
hemodynamics in the latent phase of hypertensive disorders of pregnancy with most 
reports being limited to retrospective descriptions of changes in blood pressure. 
Although a study by Moutquin et al, (1985) found that a rise in blood pressure or 
elevated mean blood pressure in the second trimester was an early sign of pre-
eclampsia, the value of such mid-trimester blood pressure screening remains limited 
by its low predictive value. 
The work of Easterling et al, (1990) and Bosio et al, (1999) are the only reported 
studies of maternal hemodynamics in the latent phase of pre-eclampsia. In the 
Easterling et al (1990) study, cardiac output was studied prospectively in 98 
nulliparous women using Doppler ultrasound. The authors noted that cardiac output 
was elevated throughout pregnancy in the 9 women who became pre-eclamptic. This 
study suggested that pre-eclampsia is characterised by a hyperdynamic circulation 
with a high cardiac output and challenged the generally accepted belief that pre-
eclampsia is a disease of reduced cardiac output with high systemic vascular 
resistance. A limitation of this important study was that a large number of study 
patients had deficient observations in early and mid pregnancy. Furthermore baseline 
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demographics differed in that pre-eclamptic women were more obese and had higher 
body surface areas. In the second study in primigravida, Bosio et al, (1999) showed a 
similar hyperdynamic state in the latent phase but a change to low cardiac output and 
high vascular resistance in women who developed clinical pre-eclampsia. 
1.4.3 Clinical phase 
Almost 20 years ago, Phelan et al, (1982) studied women with pre-eclampsia and 
showed that all subjects had an elevated cardiac output and normal systemic vascular 
resistance. Subsequently in another invasive hemodynamic study of 49 women with 
severe pre-eclampsia, Mabie and Sibai (1989) also found most women had a high 
cardiac output and a normal to moderately elevated systemic vascular resistance. 
Recent studies however are at variance with these findings. Visser and Wallenburg 
(1991) studied 87 women with early onset severe hypertension (gestational and 
chronic) and demonstrated a uniform pattern of low cardiac output and high systemic 
vascular resistance. The differences in observations were attributed to several factors 
that included small study numbers; variability in disease duration and severity; 
underlying medical problems; therapeutic intervention before hemodynamic 
monitoring and the absence of suitable control groups. 
In a review on the subject Duvekot and Peeters (1994), pointed out that as yet there is 
no clear-cut central hemodynamic profile in hypertensive pregnancies, and that except 
in the setting of clinical cardiovascular decompensation, invasive hemodynamic 
monitoring is not recommended as such techniques are not simple, quite inconvenient 
with unproven risk/benefit advantages in milder disease. 
1.4.4 Heart rate -an important cardiac output variable 
Heart rate is an important parameter directly affecting cardiac output. Yet, most 
studies of maternal cardiovascular hemodynamics in hypertensive disorders of 
pregnancy have given little attention to effects of heart rate on cardiac output. An 
early study by Kuzniar et al, (1982) demonstrated that the average heart rate during 
the third trimester in pre-eclampsia was lower than in the control group. This study 
has been criticised for averaging the heart rate of all visits in the third trimester with 
consequent loss in the power of study observations. 
In a longitudinal study Easterling et al, (1990) demonstrated an elevated cardiac 
output in a predominantly obese pre-eclamptic group, which he attributed to an 
elevated heart rate, there being no differences in stroke volume between study and 
control groups. This study did not account for differences in body mass index at 
baseline. Scardo et al, (1996) corrected for effects of heart rate and showed an 
increased heart rate prevents the expected fall in cardiac output in severe pre-
eclampsia. Using the stroke-systemic vascular resistance index, (heart rate x systemic 
vascular resistance index), they concluded that women with severe pre-eclampsia had 
a greater vasoconstricted state than milder cases of pre-eclampsia. 
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1.4.5 Volume homeostasis 
An increase in capillary permeability leads to a redistribution of intravascular volume 
to interstitial fluid space in hypertensive pregnancies (Brown et al, 1992). As a result 
volume homeostasis is disturbed in hypertensive disorders of pregnancy, particularly 
in severe pre-eclampsia. As a result of the fluid shift plasma volume is reduced in 
pre-eclampsia but this fluid redistribution is not always clinically apparent as 
peripheral oedema. Recently Moran et al, (2003) demonstrated a reduced glomerular 
filtration rate and renal plasma flow in preeclamptics and showed that the glomerular 
dysfunction resolved postpartum. To what extent these changes in volume are 
compensated for by venoconstriction to maintain cardiac output is not clear Roberts 
(2000). 
The onset and severity of plasma volume changes has received scant attention. Silver 
et al, (1998) showed that plasma volume is reduced in pre-eclampsia but is normal in 
women with non-proteinuric gestational hypertension, indicating that disease severity 
is an important factor in determining the magnitude of these changes. Furthermore, 
suboptimal plasma volume expansion (also referred to as contracted/reduced plasma 
volume) has been noted to occur early in the second trimester and changes in plasma 
volume have been reported to correlate with birth weight. Duvekot et al, (1995) noted 
that the reduction in plasma volume expansion occurred early in pregnancy in their 
study of women who developed fetal growth restriction. It therefore appears that the 
abnormal cardiovascular responses in plasma volume and cardiac output precede the 
fetal growth restriction that is detected in the latter half of pregnancy. 
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1.4.6 Maternal haemodynamics and fetal outcome 
Pre-eclampsia increases the risk of intrauterine growth restriction and low birth 
weight Xiong et al, (1999). The relationship between foetal outcome and maternal 
cardiovascular hemodynamics has been studied non-invasively by echocardiography. 
Using M-Mode echocardiography alone Kuzniar et al, (1982), estimated 
hemodynamics in nineteen pre-eclamptic women and found a positive correlation 
between maternal cardiac output and infant birth weight. The three women in the 
study with the lowest cardiac index (cardiac output /body surface area) experienced 
stillbirth or neonatal death. This study is however, limited by its small sample size, a 
heterogeneous pre-eclamptic group (not stratified by severity of disease or gestation) 
and the use of M-mode echocardiography measurements. 
Easterling et al, (1991) also assessed maternal hemodynamics in 76 women with 
hypertensive pregnancies presenting before 28 weeks of gestation. They concluded 
that hypertensive pregnancies characterised by a high systemic vascular resistance 
were associated with a poorer fetal outcome. This study was limited by its 
retrospective design; a heterogeneous hypertensive study group not stratified by 
disease severity and parity, and the sole inclusion of hypertensive pregnancies 
presenting before 28 weeks gestation. 
A third study (Yang et al, (1996)) showed that maternal cardiac output was quite 
variable in pre-eclampsia but elevated systemic vascular resistance was associated 
with a higher incidence of small gestational age infants. Despite their limitations these 
studies do reflect the association between impaired maternal hemodynamics and 
adverse fetal outcome. 
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1.4.7 Vasoactive neurohormones and endothelial dysfunction in pre-eclampsia 
The exact pathogenetic underlying activation of the renin-angiotensin system in pre-
eclampsia remains incompletely understood. Whereas normal pregnancy is 
characterised by a reduced pressor sensitivity to infused angiotensin II, in pre-
eclampsia an enhanced pressor activity to infused angiotensin II has been 
demonstrated to occur even before clinically manifest hypertension. 
Langer et al, (1998), has confirmed earlier observations of a decrease in activity of the 
renin-angiotensin-aldosterone system in pre-eclampsia. The authors postulated that 
this decreased activation of the renin-angiotensin system could contribute to the 
diminished hemodynamic regulation seen in pre-eclampsia. Similar conclusions were 
drawn by Kalenga et al, 1996 and Brown et al, 1994 who showed that concentrations 
of angiotensin II, renin and aldosterone are reduced in pre-eclampsia compared to 
normal pregnancy. Furthermore, in a recent study Merrill et al, (2002) showed that 
levels of angiotensin^ 1-7), a bioactive component of the renin-angiotensin system 
that has depressor and vasodilatory actions, were reduced in women with pre-
eclampsia compared to normal pregnant women. Some of these apparent divergent 
observations of the circulatory renin-angiotensin system in hypertensive disorders of 
pregnancy may be explained in part by impaired functioning of a local renin-
angiotensin system in the uteroplacental unit in pre-eclampsia patients (Baylis et al, 
1998). 
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It has been postulated that reduced nitric oxide and an increase in peroxynitrite levels 
may account for many effects, including reduced prostacyclin production and 
alteration in the balance of thromboxane and prostacyclin favouring vasoconstriction 
and platelet aggregation (Lowe, 2000). 
In a study of endothelial derived relaxing factor in normal and hypertensive 
pregnancy, Ashworth et al, (1999) showed that nitric oxide synthesis appears to 
mediate a greater proportion of the relaxation in pre-eclampsia than in normal 
pregnant women. Early studies (Seligman et al, (1994)) have demonstrated reduced 
levels of nitrate in pre-eclampsia although a recent study by Anumba et al, (1999) 
does not support a role for nitric oxide in the pathogenesis. 
Also Slowinski et al, (2002) have reported that the endothelin system is activated in 
pre-eclampsia. However, the authors did not find a correlation between the elevated 
plasma levels of endothelin-1 and maternal blood pressure or urine protein excretion. 
Khedun et al, (2002) has also shown similar elevation in plasma endothelin-1 levels in 
black pre-eclamptic women compared to aproteinuric hypertensives and 
normotensives controls. 
In contrast to normal pregnancy, atrial natriuretic peptide levels in pre-eclampsia are 
elevated. This appears paradoxical as this increase in atrial natriuretic peptide in pre-
eclampsia subgroups was noted to occur in the setting of a contracted plasma volume 
(Spaanderman et al, 2001). These findings may be explained by the left ventricular 
structural adaptive changes to increased systolic blood pressure which has been 
shown to correlate positively with plasma levels of both atrial natriuretic peptide and 
brain natriuretic peptide Borghi et al, (2000). 
Although endothelial dysfunction is considered to underlie many of the clinical 
manifestation in preeclampsia, the precise biochemical pathways involved remain 
unclear. In a recent review, Shah (2005) suggested that angiotensin II mediated 
mechanisms can explain the vascular maladaptation with increased vasomotor tone 
and endothelial dysfunction seen in pre-eclampsia. A current hypothesis suggested in 
the review by Rodrigo et al (2005) indicates that oxidative stress is involved in the 
pathogenesis as placental and lipid peroxidation products of F2-isoprostanes and 
malondialdehyde are increased with activation of endothelial cells. Finally, Savvidou 
et al (2003) found that maternal endothelial function was impaired in women who 
eventually develop pre-eclampsia and that the maternal endothelial dysfunction 
occurs before the development of the clinical syndrome. Savvidou et al (2003) also 
showed that women with a high resistance placental circulation (at risk of pre-
eclampsia) had raised levels of asymmetric dimethylarginine, an endogenous inhibitor 
of endothelial nitric oxide synthase. 
1.4.8 Sympathetic activity and vagal baroreflex function 
It appears that the increase in peripheral vascular resistance and blood pressure that 
characterise pre-eclampsia is mediated, at least in part, by an increase in sympathetic 
vasoconstrictor activity. There is evidence that sympathetic activity is augmented in 
pre-eclampsia and reverts to normal after delivery (Schobel et al, 1996). More 
recently, Greenwood et al, (2001) also showed that central sympathetic output was 
increased in normal pregnancy and increased to a greater extent in hypertensive 
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pregnant women. A similar pattern of changes in vagal baroreflex gain was reported 
by Silver et al, (2001) who found the normal reduction in baroreflex gain in 
pregnancy is further depressed in women with gestational hypertension and pre-
eclampsia. 
1.4.9 Electrolyte abnormalities 
Various electrolyte abnormalities have been studied to explain regional and racial 
differences in the prevalence of hypertensive disorders of pregnancy. Dietary salt 
restriction and diuretic therapy have not reduced the incidence of pre-eclampsia 
(Steegers et al, 1991). In a meta-analysis by Bucher et al, (1996), calcium 
supplementation in pregnancy was noted to be effective in lowering blood pressure 
with a trend towards reducing the incidence of pre-eclampsia. Despite these 
observations, the authors state that the beneficial effects of calcium supplementation 
remain unproven. 
1.4.10 Summary 
The primary abnormality in hypertensive disorders of pregnancy and in particular pre-
eclampsia, is defective placentation that is seen histologically as inadequate 
remodelling of the spiral arterioles. This results in reduced placental blood flow with 
resultant ischaemia to the fetus that probably commences at some point in the second 
trimester or later depending on the severity of the disease. Maternal cardiovascular 
diseases such as chronic hypertension, diabetes and renal disease are now recognised 
28 
as predisposing factors. Other factors such as age, parity, obesity and genetic 
susceptibility are helpful in defining risk groups. 
The precise biochemical mediators responsible for the inadequate/abnormal maternal 
cardiovascular adaptation in hypertensive pregnancies still remain to be elucidated. 
The biochemical mediators include the renin-angiotensin system hormones, the 
sympathetic nervous system, atrial natriuretic peptides, prostaglandins, endothelins, 
nitric oxide and electrolyte abnormalities. In severe pre-eclampsia widespread 
maternal vascular endothelial dysfunction ensues, often with organ dysfunction and 
organ failure. 
In normal pregnancy, the utero-placental circulation becomes maximally dilated with 
a fall in resistance, a change that seems necessary for fetal growth. Ramsay et al, 
(1994) in their study of the effects of glyceryl nitrate on the uterine artery suggested 
that endogenous nitric acid production is probably responsible for the adaptation of 
the maternal cardiovascular system to pregnancy. 
The development of low resistance blood flow in the placental circulation occurs 
largely from anatomical transformation of trophoblastic invasion and loss of muscle 
layer in the spiral arterioles that may be influenced or directed by biochemically 
mediated vasomotor mechanisms. This anatomical transformation is striking at the 
level of the spiral arteries where a metamorphosis of small calibre spiral vessels into 
flaccid, distended uteroplacental arteries occurs (Pijnenborg et al, 1981). 
The placental circulation is also unique in that the uterus loses its efferent innervation 
during pregnancy and both the placenta including the spiral arterioles and cord are not 
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innervated (Morizaki et al, 1989). Inappropriate changes in the efferent innervation 
of spiral arteries may be associated with impaired development of a low resistance 
placental bed in pre-eclamptic pregnancies. Non-invasive measurement of resistance 
in the uteroplacental circulation permits an evaluation of the placental circulation. 
1.5 Uteroplacental Doppler velocimetry in hypertensive pregnancy 
In recent times utero-placental blood flow using Doppler ultrasound (velocimetry) is 
being increasingly used to assist in predicting at risk hypertensive pregnancies. 
Serum urate, non-stress fetal cardiotocography and ultrasonic amniotic fluid volume 
estimation are still the classical measures that are used to predict fetal outcome and 
assist in therapeutic decisions. Although these tests have good negative predictive 
value, they are limited by a low sensitivity and low positive predictive value. 
The uterine artery resistance index computed from flow velocity waveforms recorded 
at the level of the main uterine arteries reflects the downstream flow impedance in the 
whole uterine circulation (Maulik, 1995). Uterine artery Doppler studies have shown 
that in pregnancies complicated by pre-eclampsia and fetal growth restriction, there is 
a failure of uteroplacental resistance to decrease and accommodate the increased 
utero-placental blood flow, as is observed in normal healthy pregnancy (Harrington et 
al, 1991). The pathophysiology of the uterine Doppler velocimetry abnormalities are 
supported in part by histopathological placental studies by Pijnenborg et al, (1991 & 
2001) who also stated that the placental changes seen in pre-eclampsia may also be 
associated or caused by the other forms of hypertension disorders of pregnancy. In 
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addition, it was noted that extent of failure of spiral artery remodelling did not carry a 
clear-cut correlation to clinical disease. 
Studies evaluating the uteroplacental circulation using Doppler velocimetry have 
produced varying results regarding its predictive value (Bower et al, 1998). Yang et 
al, (1995) showed abnormal umbilical artery Doppler correlated with acute fetal 
distress whereas uterine artery Doppler was not beneficial in this respect. Aquilina et 
al (2001) used uterine artery Doppler at 20 weeks gestation as a screening test to 
predict pre-eclampsia found that uterine Doppler flow velocity alone was not a 
satisfactory predictor. An improved predictive potential was obtained when notching 
on uterine artery Doppler profile and serum inhibin A levels were included in the 
model. 
In their study of uterine artery Doppler velocimetry and placental histopathology in 
preeclamptics with growth restriction, Sargol et al, (1999) showed that an elevated 
uterine artery resistance index (> 0.58) was associated with a higher prevalence of 
impaired trophoblast migration. Subsequently, Coleman et al, (2000) found that 
uterine artery resistance index of > 0.70 at 24 weeks gestation was of value in 
predicting serious adverse outcome in women at high risk. Although lower uterine 
artery Doppler velocimetry cut-off values (resistance index > 0.58) improved 
sensitivity, they were however associated with a reduced specificity and reduced 
positive predictive value. 
All these studies did not combine uterine artery Doppler velocimetry with a measure 
of maternal central haemodynamics. Since uterine artery Doppler has the potential to 
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predict at risk hypertensive pregnancies, a combined evaluation of maternal central 
hemodynamics and concomitant uterine artery Doppler may define and predict at risk 
hypertensive pregnancies more accurately. 
1.6 Doppler echocardiography for assessment of maternal central hemodynamics 
and aims of this thesis 
The development of pre-eclampsia is thought to occur very early in pregnancy. The 
process probably starts with defective implantation and placentation followed by 
reduced placental perfusion and subsequent maternal endothelial dysfunction and 
organ dysfunction (Roberts, 2000). It is thus logical to anticipate that the more severe 
the impairment in trophoblast implantation and placental perfusion, the greater will be 
the extent to which a failure of the normal cardiovascular adaptation manifests. 
Abnormal maternal cardiovascular hemodynamics can thus be a good reflection of 
abnormalities in the fetus and/or placenta. 
Many of the controversies of maternal hemodynamic profile in hypertensive pregnant 
women have arisen because of the limitation of invasive methods used to measure 
central hemodynamics. Furthermore, invasive Swan-Ganz catheter-measured 
hemodynamics requires considerable skill, is inconvenient, and is associated with 
potential hazard and a risk-benefit advantage that is as yet not proven. 
Echocardiography on the other hand, is an excellent non-invasive method of assessing 
cardiac structure and function. Recent refinements in Doppler velocimetry techniques 
have enabled measurement of cardiac output with good accuracy. Doppler 
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echocardiography-derived cardiac output has been validated in pregnant subjects 
against the direct and "gold standard" invasive thermodilution technique (Easterling et 
al, 1987). It is presently accepted as an accurate, safe and repeatable non-invasive 
technique to measure maternal hemodynamics in hypertensive pregnancies, allowing 
correlation with changes in uterine artery Doppler velocimetry. 
An accurate measure of maternal hemodynamics in hypertensive pregnancies will 
provide an improved understanding of the pathophysiology. Doppler 
echocardiography, a non-invasive modality, offers a safe measure of cardiovascular 
hemodynamics with good accuracy and also lends itself to serial measurement of 
hemodynamics without harm to mother or fetus. The altered maternal cardiovascular 
hemodynamics and uteroplacental Doppler velocimetry evaluation will contribute 
towards achieving a more precise definition of hypertensive disorders of pregnancy, 
help to better define high-risk pregnancies and thus allow for more appropriate use of 
available medical therapies. 
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CHAPTER 2 
AIMS AND METHODS 
2.1 Aims 
This principal aim of this study was to document maternal central hemodynamics 
using Doppler echocardiography in women with hypertensive disorders of pregnancy. 
The second aim was to measure concomitantly, cardiac structure, function and uterine 
artery Doppler velocimetry and thereby evaluate associations between maternal 
central hemodynamics, uterine artery Doppler velocimetry, cardiac structural changes 
and feto-neonatal outcome in hypertensive disorders of pregnancy. The third aim was 
to evaluate longitudinally maternal central hemodynamics, cardiac structure and 
function by Doppler-echocardiography in normal normotensive pregnancy. 
2.2 Setting 
The study was conducted at the Obstetric Unit, King Edward VIII Hospital, Durban, 
South Africa. The unit is a tertiary referral centre for the greater Durban region and 
forms part of the academic teaching complex attached to the Faculty of Medicine, 
University of Natal. The maternity unit acts as a referral centre for at risk 
pregnancies. Patients are referred from the southern border of Kwa-Zulu Natal near 
the Port Shepstone area to an area extending far north as Empangeni. The hinterland 
extends about 50kms. 
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Women with hypertensive pregnancies were enrolled in the obstetric admission unit. 
Normal normotensive pregnant women were enrolled at the antenatal clinic attached 
to the obstetric unit; the study details of this normotensive control groups are 
discussed in Chapter 3. 
2.3 Design 
The study design was a prospective analytic study. Eligible hypertensive pregnant 
women presented either to satellite antenatal clinics or directly to the obstetric 
admission unit. Their blood pressure was recorded in the seated position, using a 
mercury sphygmomanometer. At the presenting antenatal unit, the attending 
obstetrician evaluated all pregnant women whose blood pressure was >140/90mmHg 
and verified the elevated blood pressure. 
Women presenting to the obstetric admission unit with a blood pressure < 
160/1 lOmmHg but meeting all inclusion and exclusion criteria were evaluated 
urgently at admission and had Doppler echocardiographic study prior to 
administration of antihypertensive therapy and are analysed as the untreated group of 
women with hypertension in pregnancy. Women presenting to satellite antenatal 
clinics and whose blood pressure was > 160/1 lOmmHg were immediately referred to 
the obstetric admission unit. Prior to referral, and at the discretion of the attending 
obstetrician, eighteen women were prescribed single dose of 1 OOOmg methyl-dopa 
orally and sodium gardinal 200mg by the intramuscular route. A further four women 
35 
were given 1 OOOmg methyl-dopa alone as a single oral dose. This treated group were 
analysed separately as a pre-eclampsia treatment group (n=22). 
Hypertensive women whose blood pressure was >140/90mmHg but below 
160/1 lOmmHg, were asked to rest in a quieter area of the antenatal unit. The resident 
obstetrician reviewed women whose blood pressure remained elevated 
(>140/90mmHg) 4 hours later and were eligible for the study. Women with sustained 
elevation in blood pressure were referred to the obstetric admission unit. 
Upon arrival to the obstetric admission unit, the attending obstetrician assessed 
eligible participants. Maternal cardiovascular examination was performed in the 
ultrasound department attached to the obstetric admission unit. After informed 
consent was obtained, a comprehensive maternal echocardiographic examination was 
performed followed immediately by a Doppler velocimetry of the uterine and 
umbilical arteries. Blood pressure and heart rate were recorded during the echo study 
by an automated blood pressure measuring device (Critikon). The candidate (DK 
Desai) performed both the maternal echocardiographic-Doppler and utero-placental 
Doppler velocimetry studies. 
2.4 Participants 
All hypertensive pregnant women referred to the King Edward VIII Obstetric Unit 
during 1997-1998 were screened for participation in this study. 
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2.4.1 Inclusion criteria 
All pregnant women who fulfilled criteria for the diagnosis of hypertension based on 
the classification of Davey and MacGillivray (1988) were eligible to enter the study. 
This classification required a diastolic blood pressure of > 1 lOmmHg on any one 
occasion or > 90mmHg on two occasions at least 4 hours apart. 
Women were eligible for enrolment and evaluation into a pre-eclampsia treatment 
group sub-study if echocardiography was performed within 6 hours of administration 
of sodium gardinal (200mg) by the intramuscular route and/or methyl-dopa 1 OOOmg 
by the oral route. Institutional ethical approval was obtained and all participating 
women gave informed consent. In 10 normotensive participants, echocardiographic 
and Doppler study was repeated 2 hours apart. A single operator, the candidate (DK 
Desai) performed measurements on screen; this showed an intraobserver variability of 
1.8% for echocardiographic-Doppler derived cardiac output. 
2.4.2 Exclusion criteria 
Women with the following medical and obstetric conditions were excluded from 
participating in this study. 
General and medical conditions -
i) anaemia (haemoglobin < 1 Omg %) 
ii) valvular heart disease 
iii) myo-pericardial heart disease 
iv) pulmonary parenchymal lung disease 
v) renal insufficiency 
vi) significant medical disorder 
vii) unsatisfactory echocardiographic recording 
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Obstetric conditions -
i) complicated hypertensive crises e.g. cardiac failure 
ii) imminent eclampsia 
iii) antepartum haemorrhage 
iv) in labour 
v) prior parenteral dihydrallazine or magnesium sulfate therapy 
vi) obvious fetal abnormality 
vii) multiple pregnancy 
viii) prior vasodilator therapy with hydralazine or nifedipine. 
2.5 Methods 
2.5.1 Sample size of study 
It was planned to recruit 60 hypertensive pregnant women with an aim of enrolling at 
least 20 women with pre-eclampsia and gestational hypertension and at least 20 
women with chronic hypertension and chronic hypertension with superimposed pre-
eclampsia. In addition, it was planned to study 30 normal normotensive women in a 
longitudinal study that would serve also as a control group. Normotensive women 
were enrolled in the second trimester (14-24 weeks gestation) and had serial 
echocardiographic studies at approximately 4 week intervals until delivery (Chapter 
3). 
2.5.2 Obstetric assessment 
At enrolment, all women had an obstetric assessment by the admitting obstetric 
registrar whose assessment was verified by the duty consultant. All relevant clinical 
data were recorded to ensure inclusion and exclusion criteria were met. Gestational 
age was assessed clinically. All women had an obstetric ultrasound examination at 
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entry into the study to ensure accurate fetal gestation, exclude fetal abnormalities and 
to confirm a singleton pregnancy. A senior obstetric consultant determined the 
precise gestational age of the fetus at presentation utilizing clinical assessment, 
gestational age by dates assisted by ultrasound. The gestational age was thereafter 
followed by dates in the longitudinal study evaluating maternal central hemodynamics 
in normal normtensive pregnant women. 
2.5.3 Echocardiography 
All participants had a clinical assessment and examination by the author to rule out 
pre-existing heart disease. Enrolled women rested in the left lateral position with the 
assistance of a wedge for 10 minutes. The echocardiographic study was then 
performed over a period of 12-18 minutes on the Ultramark 9-HDI imaging system 
with a 2.5 MHz transducer (Scientific Medical System). Two-dimensional 
echocardiography facilitated accurate M-Mode recordings and colour flow mapping 
facilitated Doppler measurements according to standard criteria (Devereux, 1997). 
The procedure was carried out as follows: 
An initial two-dimensional study in the standard parasternal long axis and short axis 
planes followed by the apical 4 chamber plane view was performed to evaluate 
cardiac structure and obtain a visual assessment of left ventricle contractile function 
(Fig 1). Two-dimensional imaging directed M-Mode studies at the level of aorta, left 
atrium, left ventricle and mid-position between the tips of the mitral valve leaflets and 
papillary muscle. Frozen M-Mode images on screen were used to measure chamber 
size and ventricular wall thickness (Fig 4). Pulsed Doppler flow across the mitral 
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valve was recorded just beyond tips of the mitral valve leaflets to obtain LV diastolic 
filling pattern. 
For the cardiac output study, 3 estimates of the aortic annulus diameter were made in 
the parasternal long axis plane (Fig 2). The Doppler study was then performed using 
the apical 4 and 5 chamber views (Fig 3). Doppler measurements were then 
performed at the aortic annulus to obtain the best velocity-time profile from which 
screen measurements of velocity time integral were made. 
The formulae for calculating maternal cardiac structural and functional and 
hemodynamic variables are listed in appendix 1. The following echo parameters were 
measured: 
i) Structure and function of the left heart was studied in standard accepted 
views. Two-dimensional directed M-Mode views were used to measure 
left atrial and aortic root diameters and the ratio calculated, 
ii) Two-dimensional directed M-Mode recordings of the left ventricle were 
made in the short axis view at a level just beyond the tips of the mitral 
valve leaflets. On screen measurements of the M-mode tracing was used to 
measure left ventricular (LV) cavity dimensions in systole and diastole, 
from which indices of LV contractile function (fractional shortening; 
ejection fraction; velocity of circumferential fibre shortening and LV end 
systolic wall stress) was computed. At least 2 M-mode tracings of the left 
ventricle was performed to ensure that cavity dimensions were within 
2mm and of ventricular wall thickness was within 1mm of each other. A 
third trace was performed if the first two M-mode traces did not provide 
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satisfactory recordings and representative values of the left ventricle M-
mode trace was obtained by consensus with a cardiology colleague, 
iii) The LV wall thickness of the septum and posterior wall together with LV 
cavity size in diastole was used to calculate LV mass (grams) according to 
the formula of Devereux (1997). Left ventricular mass (g) was corrected 
for maternal size by dividing LV mass by body surface area (m ) to obtain 
LV mass index (g/m2). The LV mass was also corrected for height to 
obtain LV mass/height (g/m). The relative wall thickness ratio, a 
measurement to describe LV geometry and LV hypertrophy was derived 
from measurements of LV posterior wall thickness and LV internal 
diameter. 
iv) LV diastolic filling velocities across the mitral valve were obtained by 
pulsed Doppler in the apical four chamber view; recordings were made at a 
position just distal to the mitral valve leaflets (fig 5). The results were 
recorded as early filling (E) velocity (m/sec), late filling velocity (A) and 
the E/A diastolic filling ratio was calculated. 
v) LV Doppler cardiac output was obtained by standard accepted method as 
described by Ihlen et al, (1984) as follows: The cross sectional area was 
measured from the maximum systolic diameter at the level of the aortic 
annulus using 2-Dimensional echocardiography. Three (3) measurements 
were made and the average was accepted as representative cross sectional 
area at the aortic annulus. The velocity time integral measurement was 
performed in the apical - 5- chamber view at the level of the aortic valve 
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using pulsed Doppler. The best of 3 velocity time integral profile 
measurements were selected and measured; these were measured in the 
resting state with quiet breathing and after visualisation of at least 8-10 
profiles on the screen to obtain a steady state. 
LV Doppler-derived cardiac output was determined from the product of 
stroke volume (aortic cross sectional area X velocity time integral) and the 
average heart rate during the echo study. Systemic vascular resistance was 
derived from the cardiac output and mean BP and the systemic vascular 
resistance index obtained by correcting for body surface area. The LV 
ejection time, measured from the aortic velocity time integral profile was 
used to calculate velocity of circumferential fibre shortening, an index of 
LV contractile function. 
vi) Heart rate and blood pressure (5-7 recordings) were measured by an 
automated blood pressure measuring device (Critikon) at intervals of 3 
minutes during the echo study. Blood pressure was measured in the 
dependent arm and the average of 5-7 measurements of heart rate and 
blood pressure made during the Doppler echocardiographic study at 3 
minute intervals was accepted as the representative measurements. These 
were used with echocardiographic Doppler determined stroke volume to 
derive cardiac output and systemic vascular resistance. 
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2.5.4 Uteroplacental Doppler velocimetry 
Uteroplacental Doppler velocimetry was performed immediately after the maternal 
echocardiographic study with participants remaining comfortable in a slight left 
lateral position. The same imaging system (Ultramark 9-HDI) was used with a 3.5 
MHz transducer. Colour flow mapping assisted in obtaining good uterine artery 
Doppler waveforms. 
The examinations were performed by a single operator (DK Desai). Studies were 
performed whilst ensuring there were no gross fetal or breathing movements. Five 
consecutive waveforms with a clear outline were obtained. The peak systolic velocity 
and end diastolic velocity were measured on screen with a cursor. The resistance 
index for the right and left uterine arteries was calculated using mean values of peak 
systolic and end-diastolic velocities of 5 consecutive waveforms. The average of the 
computed right and left uterine artery resistance index was accepted as representative 
uterine artery resistance index (fig. 6). Ten normotensive women had repeat uterine 
Doppler velocimetry study measurement by the author and the senior obstetric 
ultrasonographer to validate technique and accuracy, this gave an interobserver 
variability of 3.8% 
Umbilical artery Doppler velocimetry was performed using the same transducer as for 
uterine Doppler velocimetry studies. Colour flow mapping identification of the cord 
facilitated pulsed Doppler velocimetry of umbilical artery. At least 10 consecutive 
waveforms with a clear outline were obtained. The peak systolic velocity and end 
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diastolic velocity were measured on screen with a cursor. The umbilical artery 
pulsatility index was calculated using mean values of peak systolic and diastolic 
velocities of at least 5 consecutive waveforms (fig. 7). 
2.6 Statistical Methods 
All statistical comparisons were perfonned using the SPSS statistical Package version 
11.0 and Sysstat software was used for regression analyses. The mean and standard 
deviation of measured cardiovascular parameters in the various hypertensive groups 
and categories were compared by independent samples non-parametric tests (Mann-
Whitney U test or Kruskal-Wallis test). Cross tabulation (chi-squared test) was used 
for evaluation of non-continuous variables. Bivariate correlation and linear and 
multiple regression analyses were used to determine associations between measured 
maternal size, maternal cardiovascular variables, uterine artery resistance index and 
the various parameters reflecting adverse feto-neonatal outcome. 
2.7 Analysis of results 
All echocardiographic and Doppler velocimetry data were analysed where indicated 
according to hypertensive groups as listed below in section 2.7.1. Subgroup analyses 
were performed on data stratified by severity of proteinuria quantified as nil, mild to 
moderate (1+ and 2+ by dipstix testing) or severe proteinuria (3+ and 4+ by dipstix 
testing). Critical cut off values were sought for hemodynamic variables for cardiac 
index, systemic vascular resistance index; uterine artery resistance index and maternal 
size after detecting significant associations of measured parameter with adverse feto-
neonatal outcome. 
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Neonatal outcome was determined as being adverse or non-adverse using criteria of 
fetal birth weight below the 10th centile; intrauterine death, fresh still birth, 
requirement of neonatal intensive support and neonatal death. Feto-neonatal outcome 
was classified as either adverse or non-adverse. The absolute fetal birth weight, 
gestational age at delivery and fetal birth weight centile (using charts of Airman & 
Chitty), were evaluated to determine if adverse feto-neonatal outcome could be 
represented a continuous variable of gestational age at delivery and/or fetal birth 
weight. 
2.7.1 Classification of hypertensive groups 
The hypertensive groups for comparative analysis are as listed below: 
1) Gestational non-proteinuric hypertension (also referred to as gestational 
hypertension) 
2) Gestational proteinuric hypertension (pre-eclampsia) 
3) Chronic hypertension 
4) Superimposed pre-eclampsia on chronic hypertension 
2.7.2 Stratification by blood pressure 
Patients were included in the study if they had a diastolic BP recording of 
> 90mmHg on 2 occasions at least 4 hours apart or a single BP > 160/1 lOmmHg. 
This blood pressure at admission to the study was compared to blood pressure 
measured at echocardiography. 
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The blood pressure immediately prior to the echo study was measured in the left 
lateral position after a 10 minutes rest. Blood pressure and pulse rates were measured 
with automated blood pressure measuring device (Critikon) at 3 minutes intervals. 
The average of these recordings (5-7measurements) was used as representative blood 
pressure at echocardiography and used to stratify women into mild; moderate and 
severe hypertensive cateogories (Table 2.1). 
Table 2.1 Staging of hypertensive group according to blood pressure levels 
Stage severity 
Stage 1 (mild) 
Stage II (moderate) 
Stage III (severe) 




2.7.3 Stratification by proteinuria 
Proteinuria status was assessed by repeated reagent strip (dipstix) testing of at least 2 
specimens 4 hours apart or by a 24 hour urine protein where feasible. A negative or 
trace dipstix reading or a 24 hour urine protein of < 300mg was accepted as nil 
proteinuria. Dipstix testing of 1+/2+ protein or 300-1 OOOmg protein in a 24 hour 
urine collection was accepted as mild or mild -moderate proteinuria. Dipstix testing 
of persistent 3+/4+ or > 1 OOOmg protein in a 24 hour urine collection was classified as 
severe proteinuria. 
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2.7.4 Stratification by treatment group 
Preeclamptic women who were eligible to enter the study but who were prescribed 
treatment (n=22), in the form of single dose of sodium gardinal 200mg by the 
intramuscular route and lOOOmg methyl-dopa by the oral route (n=18) and those who 
received lOOOmg methyl-dopa orally alone (n=4), formed the treatment group and are 
evaluated separately to assess effects of initial stat therapy. 
2.7.5 Stratification based on maternal haemodynamic variables 
Maternal cardiovascular parameters of heart rate; stroke index; cardiac index and 
systemic vascular resistance index together with uterine artery resistance index were 
compared in the various hypertensive categories to establish if any association with 
adverse feto-neonatal outcome. 
2.7.6 Adverse feto-neonatal outcome 
Obstetric outcome was determined utilizing all information on feto-neonatal outcome 
that included occurrence of preterm delivery, intrauterine death and stillbirth, low 
fetal birth weight defined as birth weight below the 10th centile, requiring neonatal 
ventilatory and intensive care and a complicated neonatal course and neonatal death. 
This allowed classifying feto-neonatal outcome into 2 categories of adverse or non-
adverse feto-neonatal outcome. 
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CHAPTER 3 
ECHOCARDIOGRAPHIC ASSESSMENT OF MATERNAL 
CARDIOVASCULAR HEMODYNAMICS IN NORMAL 
NORMOTENSIVE PREGNANCY 
3.1 Introduction and aims 
Normal pregnancy is accompanied by maternal cardiovascular adaptations that 
include an increase in cardiac output with a decline in blood pressure and systemic 
vascular resistance. However, the precise changes of cardiac output in normal 
pregnancy have remained controversial. In a meta-analysis of cross sectional studies 
by van Oppen et al, (1996) to evaluate a trend, the authors showed large ranges in 
cardiac output between studies. Despite numerous limitations of the above meta-
analysis, pooling data from each trimester showed a tendency to a higher cardiac 
output in the second trimester compared to the first and a lower cardiac output in the 
third trimester compared to the second. This observation is supported by the Doppler 
echocardiographic study of Hennessy et al, (1996) which demonstrated a peak cardiac 
output at 32 weeks gestation of 49% that declined to a value of 21% at term. 
Van Oppen et al, (1996) also performed a meta-analysis of 6 longitudinal studies that 
had 2 or more cardiac output measurements during pregnancy. The authors found 
widely divergent changes in cardiac output between the second and third trimesters 
with 2 studies showing an increase; 2 with no change and 2 with a decrease. Both van 
Oppen et al, (1996) and Duvekot and Peeters (1994) cited patient factors rather than 
technique as being responsible for the apparent divergent trends of cardiac output in 
the third trimester. 
Although Thornburg et al, (2000) in their review report that cardiac output peaks in 
the mid-third trimester by approximately 50%, the peaking of cardiac output has been 
reported to occur at gestations varying from 24 weeks to term. In addition, the relative 
contributions to cardiac output made by increases in heart rate and stroke volume 
have not been well addressed. Furthermore, most studies of maternal hemodynamics 
in normal pregnancy have reported measurement of cardiac output rather than a 
stature corrected measure of cardiac index. This study evaluates echocardiographic 
maternal central hemodynamics, cardiac structure and function and maternal stature in 
healthy pregnant women. 
3.2 Methods 
The study was conducted at the Obstetric Unit, King Edward VIII Hospital, Durban, 
South Africa. Healthy normotensive women with a singleton pregnancy who gave 
informed consent to participate in the study were selected and enrolled at the antenatal 
clinic. Women with a history of any medical disorder were excluded from the study. 
The University of Natal Ethics Committee granted ethical approval for the study and 
all participants gave informed consent. 
At enrollment, the attending obstetrician performed an obstetric assessment together 
with clinical assessment of gestational age. Obstetric ultrasound examination was 
performed to obtain accurate fetal gestation; exclude fetal abnormalities and to 
confirm a singleton pregnancy. All participants had a clinical examination to rule out 
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pre-existing heart disease. Enrolled women rested in the left lateral position with 
assistance of a foam wedge for 10 minutes. Echocardiography studies were performed 
thereafter using the Ultramark 9-HDI imaging system with a 2.5 MZ transducer 
(Scientific Medical System). Two-dimensional echocardiography facilitated accurate 
M-Mode recordings and color flow mapping facilitated Doppler measurements 
according to standard criteria (Devereux, 1997). Ten normotensive participants at 
gestation 32-36 weeks had repeat echocardiography study 2 hours apart to evaluate 
reproducibility; the mean percentage error for cardiac output was measured at 1.8 %. 
The procedure was carried out as described in Chapter 2 (section 2.5.3). 
All statistical comparisons were performed using the SPSS version 11 statistical 
package. The primary comparative analyses of cardiovascular hemodynamic and 
structural variables in longitudinal study of normotensive healthy pregnant women 
were made using paired sample t-tests. Noting multiple paired t analyses, discussion is 
focused on highly significant differences (p <0.01) as dictated by Bonferroni 
correction factor. Where appropriate, comparisons of average values between time 
periods were made either by independent samples t test or one-way analysis of 
variance and significance was set at p< 0.05. Cross tabulation (chi-squared test) was 
used for evaluation of non-continuous variables. Bivariate correlation and linear 
regression analyses were used to estimate relationships between measured 
cardiovascular variables. The hypertensive groups, given the smaller size, were 




3.3.1 Baseline Demographics 
The group consisted of 35 women in whom a total of 160 echocardiographic studies 
were performed; 58 in 2nd trimester, 75 in 3ld trimester, and 27 postpartum as listed in 
Table 3.1. The baseline characteristics expressed as mean ±1SD at entry into the study 
are listed in table 3.2. Cardiac output in a subgroup of ten (10) women without 
missing visits are compared with the full cohort in Table 3.4. 
Table 3.1 Patients studied at indicated gestational periods (n=35) 
Gestational Period 
Second trimester - early (14-19 weeks) 
- mid (20-23 weeks) 
- late (24-27 weeks) 
Third trimester - early (28-31 weeks) 
- mid (32-36 weeks) 
- late (37-40 weeks) 
Post partum (6-12 weeks) 
Number of patients studied (%) 
n = 6 (17%) 
n = 23 (66%) 
n = 29 (83%) 
n = 33 (94%) 
n = 28 (80%) 
n=14(40%) 
n = 27 (77%) 
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Table 3.2: Baseline characteristics of all participants (n=35) 




body surface area (m ) 
body mass index (kg/m2) 
parity - number (%) 
nulliparous 
multiparous 
gestation at delivery (weeks) 
caesarean section- number (%) 
birth weight (kg) 
23 ±5 
67 + 12 
157 + 5 
1.68 + 0.15 
27 ±4 
n = 22 (63%) 
n=13 (37%) 
38 + 2 
3 (9%) 
2.9 ± 0,6 
3.3.2 Haemodynamic changes in cardiac output, heart rate and stroke volume 
Table 3.3 details the haemodynamic changes in cardiac output and systemic vascular 
resistance with corresponding changes in heart rate, stroke volume and mean blood 
pressure. Cardiac output increased predominantly in the latter half of pregnancy and 
continued to increase and peak at term. However, statistically significant increases 
(p<0.05) were seen at time periods early third, late second and mid second trimester. 
Using postpartum value as baseline, a 46% increase in cardiac output was present. 
This maximal cardiac output occurred as a result of a 15% increase in heart rate and a 
52 
24% increase in stroke volume. This 24% increase in stroke volume was derived at 
Doppler-echocardiography by a 9% increase in velocity time integral at the aortic 
annulus and a 15% increase in aortic annulus cross-sectional area. 
Heart rate showed a statistically non-significant decrease at late third trimester 
compared to mid third trimester. Although stroke volume increased till term, 
statistically significant increases were only noted in the late third and late second 
trimesters. A statistical maximal decrease in systemic vascular resistance was 
observed early in the third trimester; by comparison mean blood pressure showed a 
statistical increase after early third trimester. 
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75 ±8 (10%) 




80 + 8(16%) 
0.489 










74 +11 (6%) 
0.327 













4.96 ±0.5 (4%) 
5.60+0.8(18%) 
0.295 













74 + 9 (-5%) 
71 ± 6 (-9%) 
0.336 
70 + 8 (-10%) 
0.355 
70 ±7 (-10%) 
0.317 
72 + 6 (-8%) 
0.010* 
74 + 7 (-5%) 
0.024* 



















Data are presented as absolute mean ± one standard deviation (percent change from 
baseline). 
Percent change from baseline is calculated by comparing mean value for the measured 
parameter to the postpartum value 
P values (paired t test) indicate statistical change from preceding gestational period. 
* Statistically significant. 
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3.3.3 Comparative analysis with subgroup (n=10) without missing visits 
Table 3.4 shows the stroke volume and cardiac output in a subgroup of women (n=10) 
who had echocardiographic studies at all time periods from mid second trimester and 
are compared with that of the full group. The stroke volume and cardiac output 
between these groups are similar without any statistical differences. Paired t-testing 
shows similar trends and p-values at the various time periods in the subgroup and full 
group and thus validates conclusions drawn from the full study group who had 
missing visits. The p-values for cardiac output increases in the mid and late third 
trimester in the subgroup (p=0.083 and p=0.156 respectively) indicates that cardiac 
output probably peaks between early and mid third trimester and is maintained till 
term. 
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Table 3.4 Comparative longitudinal changes in full study group (n=35) and 

















Stroke volume (in) 
full î roup subgroup 
hh-l 1 HV'„) 










70 +12 (0%) 
<0.001* 
70+13 (-3%) 










Cardiac output (L'min) 
full group 
4.96+0.5 (4%) 
5.60 ±0.8 (18%) 
0.295 
5.94 ±0.9 (25%) 
0.009* 
6.18 ±0.9 (30%) 
O.001* 
6.42 ±0.9 (35%) 
0.156 
6.94 ±1.8 (46%) 
0.267 
4.75 ±0.7 (0%) 
O.001* 
subgroup 
5.64 ±0.8 (12%) 
5.68 ±0.8 (23%) 
0.276 
6.25 ±0.8 (36%) 
0.024* 
6.61 ±1.1 (43%) 
0.083 
6.97 ±1.8 (51%) 
0.156 
4.61 ±0.9 (0%) 
O.001* 
Data are presented as absolute mean ± one standard deviation (percent change from 
baseline). 
Percent change from baseline is calculated by comparing mean value for the measured 
parameter to the postpartum value. 
P values (paired t test) indicate statistical change from preceding gestational period by 
using paired t tests. 
t-test comparison of means of stroke volume and cardiac output for full group vs 
subgroup at each time period were not significant. 
* Statistically significant. 
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3.3.4 Haemodynamics - cardiac output versus cardiac index 
Tables 3.5 details changes in cardiac output and cardiac index together with weight 
and body surface area. It is noted that both cardiac output and cardiac index show 
similar statistical increases at the indicated time periods. Table 3.6 estimates 
relationships among cardiac output, cardiac index, and maternal stature variables in 
the early and mid third trimester and fetal birth weight. Significant correlations were 
noted between cardiac output with fetal birth weight and maternal stature variables as 
indicated. Linear regression analysis showed that in early and mid third trimesters, 
maternal weight best correlated with maternal cardiac output (r2= 0.56 and 0.50 
respectively). 
57 
Table 3.5: Longitudinal changes in normal pregnancy 















62 ±12 (2%) 
64 ± 11 (5%) 
0.069 
65 + 11 (7%) 
<0.001* 
67 ±12 (10%) 
O.001* 
69 ±12 (13%) 
0.003* 
72 ±14 (18%) 
O.001* 




















4.% ±0.5 (4%) 
5.60 ±0.8 (18%) 
0.295 
5.94 ±0.9 (25%) 
0.009* 
6.18 ±0.9 (30%) 
O.001* 
6.42 + 0.9 (35%) 
0.156 
6.94 ±1.8 (46%) 
0.267 




3.09 ±0.39 (4%) 
3.40 ±0.46 (15%) 
0.395 
3.63 ±0.50 (22%) 
0.011* 
3.67 ±0.35 (24%) 
0.023* 
3.77 ±0,41 (27%) 
0.247 
4.00 ±0.76 (35%) 
0.388 
2.97 ± 0.46 (0%) 
O.001* 
Data are presented as absolute mean ± one standard deviation (percent change from 
baseline). 
Percent change from baseline is calculated by comparing mean value for the measured 
parameter to the postpartum value 
P values (paired t test) indicate statistical change from preceding gestational period. 
* Statistically significant. 
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data are presented as r values 
early 3rd = early third trimester (28-31 weeks gestation) 
mid 3r = mid third trimester (32-36 weeks gestation) 
* statistically significant 
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3.3.5 Echocardiographic determinants of stroke volume 
Table 3.7 details the changes in echocardiographic components of aortic velocity time 
integral and aortic cross sectional area that are used to compute stroke volume. A 
maximal increase in stroke volume of 24% at term was derived from a 9% increase in 
aortic velocity time integral and a 15% increase in aortic annulus cross sectional area. 
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Table 3.7: Longitudinal changes in normal pregnancy 














21 ±3 (-4%) 
23 ±3 (5%) 
0.430 
23 ±3 (5%) 
0.500 
23 ±3 (5%) 
0.480 
23 ±3 (5%) 
0.156 
24 ±3 (9%) 
0.056 
22 ±3 (0%) 
0.011* 
320 ± 30 (0%) 
323 ±39 (1%) 
0.362 
323 ±40 (1%) 
0.085 
331 ±47 (3%) 
0.094 
347 ± 37 (8%) 
0.001* 
367 ±63 (15%) 
0.475 
320 ± 37 (0%) 
0.001* 
66 ±11 (-6%) 
74 ± 11 (6%) 
0.327 
75 ±11 (7%) 
0.133 
77 ±11 (10%) 
< 0.001* 
80 ±13 (14%) 
0.202 
87 ±17 (24%) 
0.048* 
70 ±12 (0%) 
< 0.001* 
Data are presented as absolute mean ± one standard deviation (percent change from 
baseline). 
Percent change from baseline is calculated by comparing mean value for the measured 
parameter to the postpartum value 
P values (paired t test) indicate statistical change from preceding gestational period. 
* Statistically significant. 
3.3.6 Cardiac structural and function changes 
Table 3.8 shows changes in cardiac structure and function variables of left atrial size 
together with left atrial to aorta size ratio; LV early to late diastolic filling ratio; LV 
mass and LV mass index and LV systolic function reflected by fractional shortening 
percentage. Both the absolute left atrial size and left atrial size reflected by left atrial 
to aorta size ratio show a significant increase at term followed by a significant 
reduction postpartum. The LV diastolic filling of early to atrial filling ratio showed a 
decrease in the third trimester compared to postpartum. 
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Table 3.8 also shows significant increases in LV mass and LV mass index that are 
maximal at term. The mean LV mass index remained well below the arbitrary cut off 
level of 110g/m2 to diagnose LV hypertrophy. Although not reflected in the tables, 
LV mass/height and LV mass/height showed similar changes to LV mass index at 
the indicated gestational periods. A lower LV mass index at 14-19 weeks gestation 
compared to postpartum value (6-12 weeks) is noted and probably reflects that LV 
mass measured 6-12 weeks postpartum had not returned to normal pre-pregnant 
values; this limits an accurate assessment of extent of LV mass increase in our study. 
The increased LV mass was due both to an increased LV cavity size and wall 
thickness; both the LV cavity size and septal thickness at term were significantly 
larger than at postpartum. (4.8 ±0.3 versus 4.6 ±0.4cm; p=0.040 and 1.09 ±0.10cm 
versus 0.96 ±0.09cm; p=0.001 respectively). 
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LV mass (e) j LV mass 
index (g/m2) 
102:1 KM 15"-) 
127 ±18 (6%) 
0.038* 
124 ±23 (3%) 
0.096 






120 ±31 (0%) 
0.001* 
63 ±10(-5%) 
77 ±11 (4%) 
0.099 
75 ±12 (1%) 
0.089 
78 ±11 (5%) 
0.376 























Data are presented as absolute mean ± one standard deviation (percent change from 
baseline). 
Percent change from baseline is calculated by comparing mean value for the measured 
parameter to the postpartum value 
P values (paired t test) indicate statistical change from preceding gestational period. 
* Statistically significant. 
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3.4 Discussion 
Using 6-12 weeks postpartum as baseline, our study shows the expected increase in 
cardiac output in normal pregnancy of 46-51 %. Approximately half of this increase 
occurred by 28 weeks gestation. Although we show a significantly higher cardiac 
output in the third trimester compared to the second, the increases of cardiac output 
between early, mid and late third trimesters were not statistically significant. A large 
variability in measured cardiac output at late third trimester, probably occurring from 
patient factors, did not allow for confident conclusions to be made of the precise 
changes in late third trimester. However, the data do show that cardiac output 
certainly peaks in early to mid third trimester and thereafter is maintained till term. 
The literature has conflicting data on cardiac output changes during pregnancy, 
particularly in the third trimester. Although the meta-analysis of cross-sectional 
studies by van Oppen et al, (1996) showed a trend to a lower cardiac output in the 
third trimester compared to the second, the authors observed large ranges in cardiac 
output between the different studies that did not allow for any firm conclusions. In 
evaluating 6 longitudinal studies, van Oppen et al, (1996) found that cardiac output 
between the second and third trimesters plateaued, decreased or increased. Of these, 
the 4 studies with comparable techniques still showed striking differences in the 
course of cardiac output in the third trimester with Duvekot et al, (1993) showing a 
decrease of 11.5%; no change by Robson et al, (1989) and increases of 9.3% by 
Mabie et al, (1994) and 16.4% by Thomsen et al, (1993). 
Although design differences and measurement techniques between studies can explain 
some of the reported differences in maternal hemodynamics in normal pregnancy, 
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most researchers concur that patient factors rather than measurement error are largely 
responsible for discrepancies in reported studies. The longitudinal study by Robson et 
al, (1989) of 13 patients, cited as the only true longitudinal study in the van Oppen 
meta-analysis (1996), surprisingly showed a significant increase in cardiac output of 
75% of peak value by 12weeks gestation that was followed by a very gradual rise to 
peak cardiac output occurring at 24-36 weeks and cardiac output being maintained 
thereafter till term. It is to be noted that after 16weeks gestation, the Robson study 
data did not show any statistically significant increase in cardiac output at any of the 
defined 4week time periods. It is also noted in an earlier M-mode echocardiographic 
study by Capeless et al (1989) that cardiac output increased greater than 50% by 8 
weeks gestation using preconception values as baseline. 
Our study shows a similar increase in mean cardiac output till term as described by 
Mabie et al, (1994) in their longitudinal study of 18 normotensive women. However, 
although the Mabie study showed a peak cardiac output at term, none of the increases 
in the comparative time periods (4weeks) were significant. In addition a similar wide 
variation in measured cardiac output at mid and late third trimester was also noted. In 
contrast, our study shows a statistically significant increase in cardiac output in early 
third trimester over late second trimester, data that clearly indicate that cardiac output 
at the very least peaks in early to mid third trimester. The increase in cardiac output in 
mid and late third trimester in our study, although not statistically significant, does 
indicate that at the very least, cardiac output in the mid and late third trimester is 
maintained. 
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The ability of our study to show a statistically significant increase in cardiac output at 
early to mid third trimester compared to the Robson and Mabie studies described 
above probably reflect differences in observed cardiac output increase in the first half 
of pregnancy. We did not directly measure cardiac output in early pregnancy but 
using postpartum values as baseline, our data show that 40% of peak cardiac output 
occurred at 24 weeks compared to the Robson and Mabie studies described above 
where >75% of peak cardiac output occurred by 24 weeks. These differences of a 
"predominantly early" versus a "predominantly late" increase in cardiac output in 
normal pregnancy are not easily explained. Although maternal body surface area and 
cardiac output increase expressed as a percentage in our study are similar to the study 
by Mabie et al, (1994), the peak cardiac index of 4.8 ± 0.8 l/min/m" in the Mabie 
study is higher than 4.0±0.8 1/min/m in our study. In addition, the mean birth weight 
in our study was 2.9 ± 0.6kg compared to 3.4 ± 0.6kg in the Mabie study. The above 
observations provide supportive evidence for a positive association between maternal 
cardiac output and fetal birth weight. In addition, they are hypothesis generating 
especially for comparative studies in different population groups where apparent 
normal maternal health and accepted normal fetal birth weights may not be so and 
simultaneous utero-placental evaluation may provide a more precise research 
definition of normal healthy pregnancy. 
Most of the heart rate increase in our study (60%) probably occurred in the first 
trimester and that of stroke volume in the third trimester, since changes in heart rate in 
the second and third trimester were not significant. It therefore appears that the mild 
increase in cardiac output in early pregnancy is largely accounted for by an increase in 
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heart rate and the progressive increase in cardiac output thereafter in the latter half of 
pregnancy is due to an increase in stroke volume. The apparent bimodal peaking of 
stroke volume occurring initially in the second trimester probably occurs as a result of 
changes in heart rate described above. These observations are supported by the 
hypothesis of Carbillon et al, (2000) that adaptive changes in vascular tone in early 
pregnancy precedes and probably triggers blood volume and cardiac output increase. 
The satisfactory association between maternal cardiac output and maternal body size 
in our study suggest that variations in cardiac output in normotensive pregnant women 
can be explained by differences in maternal stature and/or fetal birth weight. Van 
Oppen et al, (1995) showed a poor correlation between maternal cardiac output and 
body surface area whereas studies in children and obese adult participants indicate 
that variables such as cardiac output need correction for body stature to allow 
appropriate comparison between groups (de Simone et al, (1997)). The need for 
correction of cardiovascular variables for maternal size is highlighted in some early 
studies. Rosso et al, (1992) found that underweight mothers had lower birth weight 
babies compared to normal weight mothers and this corresponded with lower 
maternal plasma volume and cardiac output. Similarly, Carpenter et al, (1990) found 
that differences in maximal oxygen uptake during exercise in pregnant women were 
eliminated when measurements were corrected for maternal weight. 
The poor correlation between cardiac output and body surface area in the van Oppen 
et al, (1995) study is not easily explained; possible reasons include the increased 
number of women (n=78) who had cardiac output measured by thoracic electrical 
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bioimpedence technique compared to only 10 women by the Doppler technique. Both 
groups in the van Oppen study had cardiac output increases of 88% and 92% of peak 
values by fifth and eight week gestation respectively; observations that do not make 
physiologic sense and Duvekot et al, (1993) suggested that this increase of cardiac 
output in early and mid first trimesters is probably mediated by an endocrine stimulus 
and hence not surprisingly, poorly related to maternal body surface area at this stage. 
It is also to be noted that the correlation of maternal cardiac output with maternal 
stature variables reported in our study were made, albeit more appropriately, only in 
the third trimester. Finally, the use of body surface area (DuBois and Dubois (1916)) 
to standardize maternal cardiovascular variables seems justified. Wang et al, (1992) 
in their study evaluating predictors of body surface area that included 60 women at 
gestation between 34-40 weeks, concluded that several body surface area formulas, 
including the Dubois formulas adequately predict measured body surface area over a 
wide range of patient population. 
Differences in LV systolic function between studies may also explain some of the 
observed variation in measured cardiac output and hence heart rate and stroke 
volume. Normal pregnancy is associated with a significant drop in blood pressure and 
systemic vascular resistance index, a reflection of the reduced cardiovascular 
afterload and fall in uterine vascular resistance. Physiologically, an increase in 
preload and/or reduced afterload is often accompanied by an increase in left 
ventricular systolic function. Our study demonstrates that LV fractional shortening 
during pregnancy is preserved; findings that are similar to data of Robson et al, 
(1989) and Mabie et al, (1994). However, these observations are at variance to 
studies by Mone et al, (1996) who showed a transient fall in LV fractional shortening 
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during the third trimester and that of Schannwell et al, (2000) who also showed a 
reduction in left ventricular systolic function parameters of fractional shortening and 
velocity of circumferential fibre shortening that had a nadir at the first postpartum 
visit. Mone et al, (1996) and Schannwell et al, (2000) postulated that the reduced pre-
load in the latter part of the third trimester probably contribute to a reversible fall in 
LV systolic function. 
The study by Poppas et al, (1997) is of particular interest, in that they report a steady 
increase in cardiac output till term but without any change in LV contractility, 
measured both by load dependent parameter of fractional shortening and also by load 
independent indices of LV velocity of circumferential fibre shortening and LV 
systolic wall stress. As indicated, a limitation of LV fractional shortening and 
echocardiography derived ejection fraction are that they are sensitive to loading 
conditions, particularly preload and to a lesser extent, afterload. Group ethnic profile 
as a factor associated with LV contractility is also noted, as all participants in our 
study were Black-African. Desai et al, (1995) had previously reported a very high 
prevalence of peripartum cardiomyopathy in the same population group. Such 
differences in LV systolic function, although clinically small and transient, may 
explain some of the divergent trends in cardiac output in the third trimester. 
In addressing a possible effect of parity on cardiac output changes in pregnancy, 
Clapp et al, (1997) in their M-mode echocardiography c study suggested that 
cardiovascular adaptation is enhanced by a subsequent pregnancy. In the study by van 
Oppen et al, (1996) that evaluated cardiac output in the third trimester by thoracic 
electric bioimpedence, the authors found a significant difference in mean cardiac 
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output between nulliparous and multiparous women. The number of participants in 
our study did not allow for any comparison in the hemodynamics between 
primiparous and multiparous normotensive pregnant women. It is possible that some 
of the differences in cardiac output between studies may be related to parity 
differences of study participants. 
The variability of echocardiographic-doppler determined stroke volume and hence 
cardiac output depends largely on measurement of aortic annulus diameter and the 
computed aortic annulus cross sectional area. Data on appropriate and accurate 
measure of aortic annulus measurements are conflicting. In our study using a single 
operator and obtaining three measurements and using the average as representative 
measurement, the aortic annular measurement accounted for only 1.8% of the 
variation in measured cardiac output. Robson et al, (1987) have reported within 
subject (intraobserver) and temporal variation for Doppler derived cardiac output in 
pregnancy at <5%. A limitation however in our study is that reproducibility was 
tested only at 32-26 weeks gestation; this could potentially be different at other 
gestational periods. Furthermore a smaller number of subjects had echocardiographic 
evaluation in late third trimester, which probably limited a more precise and confident 
measure of changes between mid and latter portions of the third trimester where 
expected absolute changes are smaller. 
Our study shows a significant increase in LV mass and LV mass index of 26% and 
18% respectively using 6-12 weeks postpartum as baseline; observations that are 
similar to data of Mabie et al, (1994). However, reported increases in LV mass in 
pregnancy have been variable: it was 10% in a study of 14 normal pregnant women 
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by Poppas et al, (1997), 16% in a study of 33 normotensive women by Mone et al, 
(1996) and a 34% increase in left ventricular mass index by Schannwell et al, (2000). 
These variations in percentage increase in LV mass probably reflect differences in the 
precise timing of postpartum measurements. Robson et al (1987) have showed that 
although most of the haemodynamic parameters and to a lesser extent the structural 
cardiac changes return to pre-pregnant levels early in the pueperium, full return may 
take up to 24 weeks after delivery. Furthrmore, Mone et al, (1996) have indicated that 
it takes up to four weeks to develop a compensatory increase in LV mass to offset the 
increase in LV wall stress that accompanies elevation in ventricular pressures. 
This study also shows that in normal pregnant women, there is an excellent 
correlation between LV mass and its stature corrected variables of LV mass index; 
LV mass/height or LV mass/height17. An echocardiographic diagnosis of LV 
hypertrophy (LV mass index > 1 lOg/m ) was noted in only 1 of 35 normotensive 
women at term. The data of this study thus supports the fact that although LV mass 
increases significantly in normotensive pregnancy, levels that define the presence of 
LV hypertrophy do not occur in most women. 
Our study shows significant increases in LV mass in mid and late third trimester that 
correspond with small but statistically significant increases in mean blood pressure; a 
significant increase in left atrial size at term and non-significant decrease in LV 
diastolic filling parameter reflected by reduced LV early to atrial filling ratio. These 
observations may be of relevance as we have reported abnormalities in LV diastolic 
filling in pregnant women who presented with hypertensive crises complicated by 
pulmonary oedema (Desai et al, 1996). As it is also accepted that LV diastolic 
dysfunction often precedes systolic dysfunction, differences in the degree of LV 
hypertrophy and diastolic filling could explain some of the reported small differences 
in LV contractility and cardiac output in the third trimester in normotensive pregnant 
women. 
In conclusion, our study shows a significant increase in cardiac output at early third 
trimester that is maintained till term. Cardiac output increased predominantly in the 
latter half of pregnancy. We also show a significant correlation between cardiac 
output and maternal stature and birth weight. Comparative analyses of our data with 
that of Mabie et al, (1994) further support this association of maternal cardiac output, 
stature and fetal birth weight. 
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CHAPTER 4 
MATERNAL HEMODYNAMICS IN HYPERTENSIVE 
DISORDERS OF PREGNANCY: COMBINED GROUP ANALYSIS 
4.1 Introduction, aims and methods 
Hypertensive disorders of pregnancy are not only an important cause of fetal and 
maternal morbidity and mortality, but are also the most common medical disorders 
complicating pregnancy (Duley, 1992). At King Edward VIII hospital (KEH), a 
tertiary teaching institution in Durban, South Africa, the setting for the current study, 
18% of all admissions to the obstetric unit are hypertensive (Moodley, 1993). The 
National Committee on confidential enquires into maternal deaths in South Africa 
(2000) reported that complications of hypertensive disorders of pregnancy accounted 
for 23% of maternal deaths. This burden is highlighted in a comparative report by 
Mantel et al, (2002) which showed that maternal mortality ratios in South Africa was 
12.3 times higher than that of the United Kingdom. In order to avoid adverse 
outcomes Bernheim (1997) stated that the practical management of hypertensive 
disorders of pregnancy requires prudence, careful follow-up and prompt decisions on 
the precise moment for delivery. 
In studies by Kuzniar (1982) and Yang et al, (1996), the authors describe poor fetal 
outcome and fetal growth restriction in hypertensive women who had a markedly 
reduced cardiac index or elevated systemic vascular resistance respectively. In 
another study of invasive central hemodynamic in pre-eclampsia, Visser and 
Wallenburg (1991) emphasized that altered hemodynamics (elevated systemic 
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vascular resistance index) rather than the type of severity of hypertension was 
important in detecting at risk hypertensive pregnancies. A meta-analysis by Dadelszen 
et al, (2000) indicated that in addition to the hypertensive disease, treatment-induced 
falls in blood pressure may also be responsible for fetal growth restriction. It is 
possible that the cardiovascular haemodynamic maladaptation occurring in 
hypertensive pregnancies may serve as a measure of at risk pregnancies. . 
Therefore all hypertensive patients were examined first as a combined group and later 
subdivided into individual groups. This section details the echocardiographic and 
uterine artery Doppler velocimetry evaluation of the combined and individual 
untreated hypertensive pregnant study groups compared to normotensive patients. 
Forty untreated hypertensive pregnant women (table 4.1) were compared with the 27 
normotensive pregnant women who formed part of the longitudinally normotensive 
hemodynamic study as detailed in chapter 3. The enrolment, inclusion - exclusion 
criteria and echocardiographic and uterine Doppler flow velocimetry methods and 
statistical analysis are as described in chapter 2. 
It is noted that during recruitment period of this study, guidelines for the initial care of 
hypertensive pregnant women prior to referral to the Obstetric Unit at King Edward 
VIII Hospital from satellite clinics were developed and enforced. The commencement 
of medical therapies such as alpha-methyldopa and /or sodium gardinal at satellite 
clinics as part of their initial care resulted in ineligibility for the study and resultant 
difficulty in recruitment and failure to reach the target study number of hypertensive 
pregnant women without prior medical therapies. 
4.2 RESULTS 
4.2.1 Demographics 
The numbers in the individual groups are shown below. 
Table 4.1 Hypertensive group demographics 
Pre-eclampsia 
Gestational aproteinuric hypertension 
Chronic hypertension 








The demographic comparison of the combined hypertensive group shows that 
hypertensive pregnant women were of higher age, parity and had larger body size 
(body mass index and body surface area) compared to normotensives (Table 4.2). The 
chronic hypertensive and superimposed pre-eclampsia groups show a significantly 
larger maternal size than the pre-eclampsia and gestational hypertension groups 
(Table 4.3). 
The mean blood pressure in the hypertensive cohort was significantly higher at entry 
into the study compared to blood pressure at echocardiography (p < 0.001) for the 
combined group. Blood pressure recordings in normotensive participants prior to 
echocardiography did not follow a similar time frame and are therefore not shown. 
Blood pressure in the full hypertensive cohort, showed that n=14 had severe 
hypertension and with the remaining n==26 having mild to moderate hypertension. 
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The lower birth weight in the hypertensive group is associated with a four week 
difference in gestation at delivery and occurred largely from a lower fetal birth weight 
and earlier gestation at delivery in the pre-eclampsia and superimposed pre-eclampsia 
groups. Feto-neonatal outcome was defined as adverse in 17 and non-adverse in the 
remaining 23 participants. Of the 17 defined as having an adverse outcome, 9 had 
fetal birth weight below the 10 centile. 
Of the twenty preeclamptic patients with proteinuria, eleven had 1+or2+ proteinuria 
and n=9 had 3+ or4+ proteinuria or dipstix; the remaining twenty patients with 
gestational hypertension (n=10) and chronic hypertension (n=10) groups had nil or 
trace proteinuria. 
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Table 4.2 Demographics for combined hypertensive and normotensive groups 
Age (years) 
Parity: number (%) : para 0 
: >para 0 
body mass index (kg/m2) 
body surface area (m2) 
height (cm) 
weight (kg) 
gestation at evaluation (weeks) 
systolic blood pressure at 
echocardiography (mmHg) 
diastolic blood pressure at 
echocardiography (mmHg) 
mean blood pressure at echocardiography 
(mmHg) 
heart rate at echocardiography 
(beats/min) 
gestation at delivery 
(weeks) 
fetal birth weight 
(kg) 
systolic blood pressure at admission to 
study (mmHg) 
diastolic blood pressure at admission to 
study (mmHg) 




n = 4« 
28 + 6 
5 (13%) 
35 (87%) 
34 + 8 
1.81 +0.23 
156 + 5 
80 ±18 
31+6 
158 + 26 
93+15 
114+18 
77 + 15 
34 + 5 
2.32 + 0.97 
165 + 19 
105 + 11 




n = 2"' 
24 + 5 
15 (56%) 
12 (44%) 
27 + 4 
1.70 + 0.14 
158 + 5 
69 + 12 
33 + 1 
102 + 9 
56 + 6 
71+7 
82 + 8 

















Data are presented as absolute mean ± one standard deviation 
* Statistically significant, P values derived by Mann-Whitney U test. 
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Parity: para 0 
: para >0 
body surface area 
(m2) 










systolic BP (mmHg) 
at echocardiography 
diastolic BP (mmHg) 
at echocardiography 
mean BP (mmHg) 
at echocardiography 








p-value: mean BP at 
admission versus 
echocardiography 
systolic blood pressure 
at admission (mmHg) 
diastolic blood pressure 
at admission (mmHg) 





n = 3 
n = 7 
1.63 ±0.14 







119 ± 12 
0.36 ± 0.07 












n = 2 
n = 8 
1.78 ±0.18 







































112 ± 14 





n = 0 
n = 1 0 
1.96 ±0.29 






101 ± 6 
121 ±8 
0.29 ± 0.07 






111 + 14 


















Data are presented as absolute mean ± one standard deviation 
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* Statistically significant, p values by Kruskal-Wallis one-way analysis of variance 
4.2.2 Cardiac structure and function 
Table 4.4 compares the echocardiographic data in the full hypertensive group with 
normotensives. The analysis of the individual hypertensive groups are shown in 
Table 4.5. 
Compared to normotensive pregnant patients, hypertensive patients had a larger left 
atrial size but this difference existed only when left atrium to aorta size ratio was 
compared. There were no differences in atrial size between the hypertensive groups. 
The increased left ventricular mass index in the hypertensive cohort was associated 
with an increased septal thickness, higher relative wall thickness ratio and increased 
peak atrial filling veolocity. All hypertensive groups had a significantly higher left 
ventricle mass index compared to normotensives. 
Higher left ventricular end systolic stress in the combined group was associated with 
preserved left ventricular contractile function indices, fractional shortening, ejection 
fraction, and velocity of circumferential fibre shortening with no differences in these 
indices between the hypertensive groups (table 4.5). The elevated left ventricular end 
systolic stress in the combined hypertensive group thus reflects the vasoconstricted 
state but without any impairment of left ventricle contractile function. Blood pressure 
(systolic, diastolic and mean) measured at echocardiography in the combined 
hypertensive cohort showed a good correlation with left ventricular hypertrophy as 
reflected by left ventricular mass index (r = 0.45). 
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Table 4.4 Cardiac structure and function- combined hypertensive and 
normotensive groups 
LV internal diameter-diastole (cm) 
LV internal diameter-systole (cm) 
left atrium (cm) 
left atrial to aorta size ratio 
LVseptal thickness (cm) 
LV relative wall thickness ratio 
LV mass (g) 
LV mass index (g/m2) 
LV mass/height (g/m) 
LV E/A (early to atrial) filling ratio 
LV peak E (early) filling(m/sec) 
LV peak A (atrial) filling (m/sec) 
LV fractional shortening (%) 
LV ejection fraction (%) 
LV velocity of circumferential fibre 
shortening (circum/sec) 




5.00 + 0.46 
3.23 + 0.41 
3.7 ±0.4 
1.38 + 0.17 
1.27 + 0.26 







35 + 5 
65 + 6 
















0.48 ± 0.09 





















Data are presented as absolute mean + one standard deviation 
* Statistically significant, p values derived by Mann-Whitney U test. 
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LV mass index 
(g/m2) 
% with LV-mass 
index > 11 Og/m2 
% with LV-mass 
index > 100 g/m2 
LV mass/height 
(g/m) 



























36 + 5 
64 ± 6 
1.16 ±0.16 

















37 + 5 
67 + 6 
1.34 + 0.21 


















34 ± 5 
6 3 + 7 
1.24 + 0.34 
















3 5 + 4 
62 ± 6 
1.23+0.23 
90 + 22 















Data are presented as absolute mean ± one standard deviation 
* Statistically significant, P values by Kruskal-Wallis one-way analysis of variance 
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4.2.3 Maternal central hemodynamics and uterine Doppler velocimetry (Tables 
4.6 and 4.7) 
There were no differences in cardiac index between the individual hypertensive 
groups and normotensives. The elevated systemic vascular resistance index in the 
hypertensive group was thus largely a reflection of the elevated blood pressure. The 
higher stroke volume in the hypertensive group was associated with a trend to a lower 
heart rate and a larger maternal size as reflected by body surface area. The trend to a 
lower heart rate in preeclamptic cohort was associated with a higher stroke index but 
did not reach statistical significance. 
The severity of hypertension and the severity of proteinuria were related to feto-
neonatal outcome using chi-square analyses. Both the severity of blood pressure 
(classified as mild to moderate versus severe) (p=0.041) and the absence/presence of 
dipstix proteinuria showed good association with adverse/non-adverse feto-neonatal 
outcome (p<0.001). 
Although both uterine artery resistance index and systemic vascular resistance index 
are elevated in the combined hypertensive group, the correlation between these 
variables was modest at r = 0.44. Uterine artery resistance index showed a better 
correlation with fetal birth weight and gestation at delivery (r = -0.69 and -0.67 
respectively) compared to systemic vascular resistance index that gave correlation 
values with fetal birth weight and gestation at delivery of r = -0.49 and -0.55 
respectively. 
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The hypertensive group (n = 40) was stratified by feto-neonatal outcome into two 
groups (Table 4.8). As expected, the adverse outcome group shows a significant 
lower fetal birth weight and earlier gestational age at delivery. The principal 
observations that characterised adverse feto-neonatal outcome cohort were the 
presence and severity of proteinuria, severity of hypertension, an elevated uterine 
artery resistance index and also of an elevated umbilical artery pulsatility index. 
There was no difference in the cardiac index between the adverse/non-adverse 
outcome groups but the systemic vascular resistance index was elevated in the adverse 
outcome group. The significantly lower heart rate in adverse outcome group was 
associated with a corresponding higher stroke index. 
Stepwise multiple regression analysis using a model to evaluate predictors of adverse 
feto-neonatal outcome reflected that uterine artery resistance index indexed to 
maternal body surface area best predicted delivery gestational age (r2 =0.634). The 
model used quadratic analysis of variance co-variance where the square of the uterine 
artery resistance index is the co-variate and the study group is the factor. Maternal 
central hemodynamics showed only modest to poor correlations with adverse feto-
neonatal outcome. 
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Table 4.6 Maternal central hemodynamics and uterine Doppler velocimetry in 
combined hypertensive and normotensive groups 
heart rate 
(beats/min) 






systemic vascular resistance 
(dyn.sec/cm5) 






systemic vascular resistance 
index 
(dyn.sec/cm /m ) 
Uterine artery resistance index 




77 + 15 
115 + 18 
89 ±18 
6.76 + 1.56 




2564 ± 680 
0.60 ±0.12 







6.42 + 0.90 



















Data are presented as absolute mean ± one standard deviation 
* Statistically significant, P values derived by Mann-Whitney U test. 
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surface area (/m") 
umbilical artery 
pulsatility index 
fetal birth weight 
(kg) 










119 + 12 
1.63 ±0.14 
53 ± 8 
3.51 ±0.62 
2796 ± 574 
0.67 ± 0.09 















4 5 + 6 
3.75 + 0.62 
2132 ±523 
0.48 ± 0.07 

























































Data are presented as absolute mean ± one standard deviation. 
*Statistically significant, P values by Kruskal-Wallis one-way analysis of variance. 
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Table 4.8 Combined hypertensive cohort (n=40) stratified by feto-neonatal 
outcome 
Age (years) 
parity-number (%):para 0 (n=16) 
:para>0(n= 16) 
body surface area (m ) 
proteinuria dipstix : nil/trace 
:l+and2+(n=20) 
:3+and4+(n=12) 
gestation at evaluation (weeks) 
serum urate values (mmol/1) 
systolic blood pressure at 
echocardiography (mmHg) 
diastolic blood pressure at 
echocardiography (mmHg) 
LV mass index (g/m ) 
heart rate at echo (beats/min) 
stroke index (ml/m ) 
cardiac index (1/min/m ) 
systemic vascular resistance index 
(dyn.sec/cm5/m2) 
uterine artery resistance index 
umbilical artery pulsatility index 
fetal birth weight (kg) 


































































Data are presented as absolute mean ± one standard deviation. 
* Statistically significant, P values derived by Mann-Whitney U test. 
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4.3 Discussion 
As a group the hypertensive patients in this study had a typical profile as seen in 
clinical practice. They were characterized by higher age, parity and body mass index 
and a higher systemic vascular resistance index. There was no difference in cardiac 
index between this combined hypertensive group normotensives patients. 
These patients had a significantly lower fetal birth weight that correlated best with 
uterine artery resistance index (r - -0.65) and showed very modest correlations with 
systemic vascular resistance index (r = -0.49) and systolic and mean blood pressure 
(r = -0.40). The correlation of fetal birth weight with cardiac index was surprisingly 
poor (r = 0.21). Although severe hypertension at echocardiography recognized at risk 
hypertensive pregnancies, blood pressure alone did not correlate well with adverse 
feto-neonatal outcome. 
An interesting observation was the significantly lower levels of blood pressure 
recorded at the time of echocardiography compared to that measured at entry into the 
study. This placebo effect probably reflects the more "pleasant" and quiet 
circumstances of the ultrasound laboratory compared the admission obstetric unit. 
Furthermore blood pressure measurements were taken in the recumbent as opposed to 
the sitting position in the laboratory. The fall in blood pressure could also include the 
presence of milder or possibly more labile hypertension, or even a "white coat" effect. 
The above observations call for a more standardized procedure for measuring blood 
pressure and evaluation of ambulatory blood pressure monitoring as well as 
personnel-free methods such as electronic blood pressure measurement. 
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Hypertensive women had significantly higher LV mass index with preserved 
contractility, characterized by a concentric increase in LV wall thickness and mass. 
Wall stress was still elevated indicating that these changes were still inadequate to 
offset this increased wall tension. 
CHAPTER 5 
FOCUS ON PREECLAMPSIA AND ITS VARIANTS 
5.1 Introduction, aims and methods 
Pre-eclampsia-eclampsia complicates 3-5% of pregnancies and remains a leading 
cause of maternal and neonatal mortality worldwide (Duley, 1992). Pre-eclampsia is 
also termed gestational proteinuric hypertension, the presence of proteinuria being 
associated with an increased risk of fetal and maternal morbidity. This disease is 
progressive and in its advanced form leads to maternal renal failure, disseminated 
intravascular coagulation, liver failure, pulmonary oedema and death (Bolte et al, 
2001). Although delivery cures progressive disease in pre-eclamptic women, it often 
results in delivery of a premature infant. Bernheim (1997) has stated that the 
management of pre-eclampsia requires prudence, careful follow up and prompt 
decisions on the precise moment for delivery. To this end, the clinician requires 
improved antenatal predictors to assist with management. 
Although the aetiology of pre-eclampsia is not known, the primary pathophysiology is 
probably placental. Defective implantation and placentation is thought to result in 
reduced placental perfusion with ischaemia and subsequent maternal endothelial and 
organ dysfunction (Roberts, 2000). In an echocardiographic study of severe pre-
eclamptic women, Yang et al, (1996) found that an elevated systemic vascular 
resistance index was associated with a higher prevalence of small for gestational age 
babies. These observations lend support to the view that the severity of pre-eclampsia 
may be stratified by measurement of maternal central hemodynamics. Doppler 
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echocardiography is safe in pregnancy and Doppler-derived cardiac output has been 
validated as an accurate measure of maternal hemodynamics by Easterling et al, 
(1990). 
The elevated systemic vascular resistance seen in pre-eclamptic pregnancies is 
accompanied by varying degrees of increased resistance to flow in the uterine arteries. 
Sargol et al, (1999) showed that high uterine artery flow resistance was related to a 
reduced trophoblast migration into the myometrium and inadequate physiological 
changes in the spiral arteries not only in pre-eclamptic women but also in 
normotensive women with intrauterine growth restriction. Doppler velocimetry 
studies of the uterine arteries however, have produced varying results regarding its 
predictive value (Bower et al, 1998). Furthermore, most of these studies did not 
relate uterine artery Doppler velocimetry to maternal central hemodynamics. 
In this chapter, participants with pre-eclampsia are compared with the other 
hypertensive groups. Since it has been well documented that pregnant women with 
gestational aproteinuric hypertension may progress to pre-eclampsia (Saudan et al, 
1998) and since pre-eclampsia may complicate chronic hypertension in pregnancy 
these groups were compared with each other to elucidate any trend or gradation in 
haemodynamics and cardiac structural changes. 
The enrolment, inclusion and exclusion criteria, echocardiographic and Doppler 
methods and statistical analysis are as described in Chapter 2. This study compares 
10 women with pre-eclampsia without any prior anti-hypertensive therapy to 10 
women with gestational hypertension and 10 women with superimposed pre-
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eclampsia on chronic hypertension compared with ten normotensive gestation 
matched controls taken from the longitudinal echocardiography study in 
normotensive pregnancy (Chapter 3). 
In addition, a cohort of 22 pre-eclamptic women (referred to as treatment group 
preeclamptics) comprised of 18 women who received a single dose of methyl-dopa 
1 OOOmg orally and sodium gardinal 200mg by the intramuscular route and 4 women 
who received methyl-dopa 1 OOOmg alone. This treatment group were evaluated by 
echocardiography and uterine Doppler velocimetry within 6 hours of having taken 
prescribed methyl-dopa and/or sodium gardinal. It is anticipated that evaluation of 
this larger cohort of preeclamptics (treated and untreated) will further contribute to an 
improved understanding of pre-eclampsia. 
5.2 Results 
5.2.1 Demographics (Tables 5.1 and 5.2) 
Preeclamptic patients had a significantly smaller stature (body surface area and 
height) than the superimposed pre-eclampsia and gestational hypertension groups. 
Both pre-eclampsia and superimposed pre-eclampsia groups were associated with an 
earlier gestation at delivery while the gestational hypertensive participants presented 
closer to term. 
Preeclamptic patients had a significantly lower heart rate and higher blood pressure at 
echocardiography than gestational hypertension groups. There was a trend to a lower 
blood pressure at echocardiography compared to the blood pressure measured at 
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inclusion into the study; this decrease in blood pressure reached statistical 
significance in the chronic hypertension and superimposed pre-eclampsia groups. 




Parity: para 0 
: > para 0 
body surface area 
(m2) 










systolic BP (mmHg) at 
echocardiography 
diastolic BP (mmHg) at 
echocardiography 
mean BP (mmHg) at 
echocardiography 








p-value: mean BP at 
admission versus 
echocardiography 
systolic blood pressure 
at admission (mmHg) 
diastolic blood pressure 
at admission (mmHg) 





n = 3 (30%) 
n - 7 (70%) 
1.63 ±0.14 
29 ±5 






119 + 12 
0.36 ± 0.07 





















0.27 ± 0.06 

















O . 0 0 1 * 
<0.001* 
O . 0 0 1 * 
O . 0 0 1 * 
0.134 
0.705 










n = 2 (20%) 
n = 8 (80%) 
1.78 ±0.18 
33 ±6 














117 + 12 

























Data are presented as absolute mean + one standard deviation 
* Statistically significant, P values derived by Mann-Whitney U test. 
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Parity: para 0 
: > para 0 
body surface area 
(m2) 










systolic BP (mmHg) 
at echocardiography 
diastolic BP (mmHg) 
at echocardiography 
mean BP (mmHg) 
at echocardiography 








p-value: mean BP at 
admission versus 
echocardiography 
systolic blood pressure 
at admission (mmHg) 
diastolic blood pressure 
at admission (mmHg) 




26 ± 7 
n = 3 (30%) 
n = 7 (70%) 
1.63 ±0.14 
29 ± 5 
152 + 5 
67 ± 1 3 
31 ± 4 
67 ± 1 1 
166 ± 1 6 
96 ± 1 2 
119 + 12 
0.36 + 0.07 
207 ± 86 
31 ± 4 
1.69 ±0.91 
0.088 
168 ± 1 5 
107 ± 1 0 






30 ± 6 
n = 3 (30%) 
n = 7 (70%) 
1.86±0.13 
35 ± 6 
157 ± 6 
86 ± 1 3 
29 ± 6 
79 ± 2 0 
179 ± 2 3 
104 ± 1 3 
129 ± 1 6 
0.35 ±0.09 
188 ±82 
31 ± 5 
1.56 ±0.91 
0.046* 
182 ± 1 9 
112 ± 14 
136±15 
























Data are presented as absolute mean + one standard deviation 
* Statistically significant, P values derived by Mann-Whitney U test. 
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5.2.2 Cardiac structure and Function (Tables 5.3 and 5.4) 
There were no differences in left ventricle diameters between the groups. Compared 
to preeclamptics and normotensive groups, patients with gestational hypertension and 
superimposed pre-eclampsia had larger atria but this was not evident when left 
atrial/aorta size ratios are compared. LV mass (and index) in pre-eclamptic 
participants was higher than normotensives but lower than that of superimposed pre-
eclampsia group. This increased left ventricle mass in preeclamptic participants 
occurred from increased left ventricle wall thickness and was associated with a trend 
to a higher relative wall thickness ratio compared to normotensive participants. There 
were no differences in left ventricle diastolic filling rates between preeclamptics and 
normotensive groups but a trend to a lower left ventricle diastolic early to atrial filling 
ratio was noted in superimposed pre-eclampsia group. Left ventricle contractility 
indices reflected by load dependent indices (fractional shortening and ejection 
fraction) and less load dependent measure of velocity of circumferential fibre 
shortening were similar in preeclamptics and normotensive and superimposed pre-
eclampsia groups. The elevated left ventricle systolic stress in the pre-eclampsia 
groups reflects the vasoconstricted state but with preserved left ventricle systolic 
function. 
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Table 5.3 Cardiac structure and function- pre-eclampsia, normotensives and 
gestational hypertension groups. 
I pre-eclampsia \ normotensive j p - value ; gestational 
' pre-eclampsia ' ^proteinuric 
i | i versus j hvpi-rtension 
; | normotensive ] 

















LV mass index 
(g/m2) 
% with LV-mass 
index > 110g/m2 
% with LV-mass 
index >100 g/m2 
LV mass/height 
(g/m) 











LV end systolic 
stress (dyn/cm5) 
4.84 ±0.32 
3.13 + 0.38 
3.4 + 0.4 
1.4 + 0.2 
1.2 + 0.3 
0.25 ± 0.07 
179 + 59 
110 + 35 
40 
60 
118 + 39 
1.67 + 0.43 
36 ±5 
64 ±6 
1.16 + 0.16 
98 + 24 
4.83 + 0.34 
3.23+0.36 
3.3 + 0.4 
1.4 + 0.3 
1.0+0.1 
0.22 + 0.04 
136 + 26 
79 + 11 
0 
0 
86 + 15 
1.76 + 0.37 
33+4 
62 + 6 
















5.00 + 0.29 
3.12 + 0.30 
3.8 + 0.4 
1.4 + 0.2 
1.1+0.2 
0.25 + 0.03 
177 + 36 
99 + 16 
20 
50 
114 + 22 
1.53 + 0.40 
37 + 5 
67 + 6 
1.34 + 0.21 
77 + 16 



















Data are presented as absolute mean ± one standard deviation; LV=left ventricle. 
* Statistically significant, P values derived by Mann-Whitney U test. 
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LV mass index 
(g/m2) 
% with LV-mass 
index > 11 Og/m2 
% with LV-mass 
index > 100 g/m2 
LV mass/height 
(g/m) 















4.84 + 0.32 
3.13 + 0.38 
3.4 + 0.4 
1.4 + 0.2 
1.2 + 0.3 
0.25 + 0.07 
179 + 59 
110 + 35 
40 
60 
118 + 39 
1.67 + 0.43 
36 + 5 
64 + 6 
1.16 + 0.16 






5.04 + 0.47 
3.33 + 0.46 
3.8 + 0.5 
1.4 + 0.2 
1.5 + 0.3 
0.32 + 0.09 




167 + 38 
1.28 + 0.54 
34 + 5 
63 + 7 
1.24 + 0.34 
105+28 





















Data are presented as absolute mean ± one standard deviation. 
* Statistically significant, P values derived by Mann-Whitney U test. 
5.2.3 Maternal hemodynamics and uterine artery Doppler velocimetry (Table 
5.5) 
Evaluation of cardiac output and cardiac index between preeclamptic participants and 
the superimposed preeclampsia group show a significant lower cardiac output in 
preeclamptic women (p=0.049) but no differences in cardiac index. The larger body 
surface area in superimposed preeclampsia group (p= 0.005) compared to 
preeclamptic women is noted. The hypertensive participants as a group showed a fair 
positive correlation between cardiac output and body surface area (r =0.71), an 
association that remains but is less strong for the preeclampsia group alone at r = 0.58. 
In pre-eclamptic women, fetal birth weight and gestation at delivery correlated best 
with uterine artery resistance index (r =: -0.59). There is a significantly elevated 
uterine artery resistance index in the preeclampsia cohort compared to both 
normotensive and gestational hypertensive groups. Maternal body surface area also 
showed a modest correlation with fetal birth weight (r =0.50) and the uterine artery 
resistance index standardized to maternal body surface area showed an improved 
correlation with fetal birth weight (r = -0.70) in the preeclamptic groups an 
association that was also valid for the other hypertensive groups in this study. 
In preeclamptic women, the correlation between fetal birthweight and maternal 
cardiac output, cardiac index and systemic vascular resistance were poor. In addition, 
it is noted that maternal haemodynamics reflected by systemic vascular resistance and 
its indexed value correlated poorly uterine artery resistance index. 
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Table 5.5 Maternal central hemodynamics and uterine Doppler velocimetry in 
pre-eclampsia, normotensive and gestational hypertension groups 


































surface area (/m") 
umbilical artery 
pulsatility index 
fetal birth weight 
(kg) 






67 ± 11 
86 + 16 
5.73 ±1.21 
166 ± 1 6 
96 ± 1 2 
119 ± 12 
1.63 ±0.14 
53 ± 8 
3.51 ±0.62 
2796 ± 574 
0.67 ± 0.09 






82 ± 8 
79 ±12 
6.42 ± 0.90 
102 ± 9 
56 ± 6 
71 ± 7 
1.70 ±0.14 
46 ± 5 
3.78 ±0.45 
1528 ±236 

































82 ± 1 0 
100 ± 1 6 
1.78 ±0.18 
45 ± 6 
3.75 ±0.62 
2132 ±523 
0.48 ± 0.07 

























Data are presented as absolute mean ± one standard deviation. 
* Statistically significant, P values derived by Mann-Whitney U test. 
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surface area (/m2) 
umbilical artery 
pulsatility index 
fetal birth weight 
(kg) 






86 ± 1 6 
5.73 ±1.21 
166 ± 1 6 
96 ± 1 2 
119 + 12 
1.63 ±0.14 
5 3 + 8 
3.51 ±0.62 
2796 ±574 
0.67 ± 0.09 
0.42 ± 0.07 









79 ± 20 
92 ±16 
7.11 ±1.58 
179 ± 2 3 
104 ± 1 3 
129+ 16 
1.86 + 0.13 
























Data are presented as absolute mean ± one standard deviation. 
* Statistically significant, P values derived by Mann-Whitney U test. 
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5.2.4 Evaluation of treated preeclamptics and combined preeclamptic groups 
(Tables 5.7 and 5.8) 
Because of the possible effects of prior treatment on haemodynamic measurements 
these patients who received treatment were analysed separately. The treated pre-
eclampsia group consisted of 22 participants who had been given a combination of 
sodium gardinal (200mg) by the intramuscular route and single dose of oral methyl-
dopa lOOOmg (n=18) or a single dose of oral methlydopa lOOOmg alone (n=4) prior to 
echocardiography. The above therapy was prescribed at admission at the discretion of 
the attending obstetrician and the haemodynamic evaluation was performed within six 
hours of the administered medication. 
Table 5.7 and 5.8 list the relevant demographic and echocardiographic data of treated, 
untreated and combined (untreated and treated) pre-eclampsia groups. 
Table 5.7 lists and compares demographics data of untreated (n=T0) and treated 
(n=22) preeclamptics and also that of the combined pre-eclampsia group (n=32) with 
normotensives (n=27). Body surface area and multiparity was higher in the treated 
group. There were no statistical differences in blood pressure and severity of 
proteinuria between the groups. 
Cardiac output (Table 5.8) was higher in the treated pre-eclampsia group, but there 
were no differences in cardiac index (p = 0.143). A trend to a lower heart rate is noted 
in the untreated preeclamptic cohort but stroke index was similar for both groups. As 
expected, the systemic vascular resistance index was significantly lower in the treated 
pre-eclamptic group and this was associated with a significantly lower uterine 
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resistance index in treated patients probably due to the single dose of methyl-dopa and 
sodium gardinal at admission. 
Maternal central hemodynamics showed poor correlation with both fetal birth weight 
and uterine artery resistance index. This poor correlation between maternal central 
hemodynamics and fetal birth weight remain when treated and untreated 
preeclamptics groups are evaluated separately. Systemic vascular resistance index 
showed the best correlation with uterine artery resistance index, (r =0.43). 
Examined together, treated and untreated patients (combined preeclamptic group 
(n=32)) showed good correlation of uterine artery resistance and its indexed value 
with fetal birth weight (r = -0.71). This correlation remains unchanged when treated 
and untreated preeclamptics are evaluated separately. 
The level of blood pressure, presence of severe proteinuria (3+ and 4+ on dipstix 
testing) and multiparity showed no significant association with adverse feto-neonatal 
outcome, (p = 0.683 for severe hypertension, p= 0.273 for severe proteinuria and p -
0.724 for multiparity) The associations remained similar when evaluated against low 
birth weight group defined by fetal birth weight below the 10th centile. 
5.2.5 Evaluation of preeclamptics stratified by adverse feto-neonatal outcome 
(Table 5.9) 
Significant differences emerged when the combined (treated and untreated) group 
(n = 32) was stratified by feto-neonatal outcome into adverse and non-adverse 
outcome groups. Fetal birth weight and gestation of delivery were lower in the 
adverse outcome group. There was a difference in maternal central hemodynamics 
between groups but the uterine artery resistance index was higher in the adverse 
outcome group. Both the uterine artery resistance and its standardized value corrected 
and correlated equally well with fetal birth weight (r = 0.51). Adding variables of 
proteinuria, severity of hypertension, parity and systemic vascular resistance index to 
the regression model brought the predictive value of the model to r = 0.62. 
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Table 5.7 Comparative demographics in untreated and combined pre-eclampsia 
groups ,„____„__ 







: para 0 



























fetal birth weight 
(kg) 







1.63 + 0.14 
152±5 





168 + 15 
107 + 10 
126 + 11 
31 ± 4 
166 ±16 
96 + 12 
119 + 12 
31+4 






1.75 + 0.14 
156±5 





168 + 13 
114 + 10 
132 + 10 
33+4 
155 + 16 
90 + 9 
112 + 11 
34 ±4 






























154 + 5 





168 + 14 
112+11 
130 + 10 
33+4 
158 + 16 
92 + 10 
114 + 12 
33+4 





1.70 + 0.14 
158 + 5 







. . . 
33 + 1 
102 ±9 
56 + 6 
71+6 




















Data are presented as absolute mean ± one standard deviation 
* Statistically significant, P values derived by Mann-Whitney U test. 
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Table 5.8 Comparative hemodynamics and uterine artery velocimetry in treated 












LV end systolic 



















53 ± 8 
5.73 ±1.21 
3.51+0.62 











52 ± 7 
6.91 ±1.29 































1.22 + 0.46 
normotensivc 
n=27 
82 ± 8 





















Data are presented as absolute mean ± one standard deviation. 
* Statistically significant, P values derived by Mann-Whitney U test. 
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Table 5.9 Combined pre-eclamptic group (n=32) stratified by feto-neonatal 
outcome 
Age 
Parity-number (%):para 0 (n=16) 
:para>0(n= 16) 
body surface area (m ) 
Proteinuria dipstix: 1+and 2+ (n=20) 
:3+and4+(n=12) 
gestation at evaluation (weeks) 
serum urate values (mmol/1) 
systolic blood pressure at 
echocardiography (mmHg) 
diastolic blood pressure at 
echocardiography (mmHg) 
mean blood pressure at 
echocardiography (mmHg) 
LV mass index (g/m ) 
heart rate at echo (beats/min) 
stroke index (ml/m2) 
cardiac index (1/min/m2) 
systemic vascular resistance index 
(dyn.sec/cm /m ) 
uterine artery resistance index 
umbilical artery pulsatility index 
fetal birth weight (kg) 













116 + 12 





















90 ± 9 
113 + 12 






























Data are presented as absolute mean ± one standard deviation. 
* Statistically significant, P values derived by Mann-Whitney U test. 
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5.3 Discussion 
The pre-eclamptic women in this study were of smaller stature compared to women 
with gestational hypertension and superimposed pre-eclampsia. There were no 
differences in cardiac index between groups. Similar to most studies on maternal 
hemodynamics, our study demonstrates a wide variation in cardiac index and systemic 
vascular resistance index values both in normotensive and hypertensive pregnancy 
groups that occurred largely from patient factors. This limited identification of a 
critical cardiac index or systemic vascular resistance index value with good 
discriminatory power to predict adverse fetal outcome. 
The higher systolic and diastolic blood pressure in preeclamptic women compared to 
women with gestational hypertension was not accompanied by a similar statistical 
increase left ventricular mass index (Table 4.3). This suggests that the higher blood 
pressure in these groups allowed for a corresponding increase in left ventricular mass 
to occur. However there was a modest correlation between left ventricular mass index 
and systemic vascular resistance index (r =0.43), and a better correlation with uterine 
artery resistance index (r =0.56). This suggests that in addition to loading conditions 
non-haemodynamic factors such as activation of sympathetic and changes in renin-
angiotensin systems may contribute to the development of left ventricular 
hypertrophy. The short duration of hypertension in pre-eclamptic women will also 
explain the modest correlation of maternal hemodynamics and development of LV 
hypertrophy. The increased left ventricular mass index in preeclamptic women was 
associated with an elevated left ventricular systolic wall stress but with preserved left 
ventricular systolic function. 
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Our data illustrate the limited benefit of maternal hemodynamics in defining at risk 
preeclamptic pregnancies as use of any arbitrary cut off value is only achieved at a 
cost of significant reduction in specificity and vise versa. The best predictor of an 
adverse feto-neonatal outcome in preeclamptic pregnancy was the uterine artery 
resistance index. The comparative review of our study with previously published 
research is discussed in Chapter 8, section 8.2. 
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CHAPTER 6 
GESTATIONAL APROTEINURIC HYPERTENSION 
6.1 Introduction, aims and methods 
Gestational aproteinuric hypertension appears to carry a low risk of fetal and maternal 
morbidity. Bosio et al, (1999) showed that women with gestational aproteinuric 
hypertension may be 'closer' to normotensive pregnant women in risk and outcome 
than to women who have pre-eclampsia (gestational proteinuric hypertension). 
It appears that the clinical presentation of pregnant women with gestational 
aproteinuric hypertension may be similar to women with mild aproteinuric chronic 
hypertension. Although evidence of hypertensive target organ involvement is often 
not present in the former, gestational hypertension does carry a significant risk. A 
recent study by Galanti et al, 2000 described significant adverse feto-neonatal 
outcome in women with gestational hypertension. Saudan et al, (1998) found that 
approximately 17% of women (15% in a retrospective study and 26% in a prospective 
study) initially diagnosed with gestational hypertension develop pre-eclampsia. The 
authors identified early gestation at presentation and history of prior miscarriage as 
variables that development to pre-eclampsia. These factors make accurate 
differentiation and risk stratification of women with gestational hypertension difficult. 
Antenatal predictors which help define risk in women with gestational hypertension 
more precisely may facilitate management pf these patients. 
Therefore women with untreated gestational hypertension were compared with the 
normotensive control and mild chronic hypertensive groups, focussing on maternal 
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hemodynamics and uterine Doppler velocimetry. The rational, methods of enrolment, 
inclusion and exclusion criteria, echocardiographic and Doppler methods and analysis 
are as described in chapters 1 and 2. The study group comprised 10 women with 
untreated gestational hypertension and 10 with aproteinuric chronic hypertension 
compared with the control group normotensive pregnant women (n=27). 
6.2 Results 
6.2.1 Demographics 
The women with gestational aproteinuric hypertension were similar in age and parity 
to the normotensive group (table 6.1) but with a significantly elevated body mass 
index compared to normotensives (p=0.003). In gestational hypertension women, the 
blood pressure at admission was elevated similar to chronic hypertensive participants. 
At echocardiography (performed within 6 hours of inclusion into the study) their 
blood pressure (systolic, diastolic and mean) was significantly lower than chronic 
hypertensive participants (p=0.008). Uterine artery resistance index measurements in 
gestational hypertensive women were similar to that of normotensive women but 
significantly lower than chronic hypertensive patients. 
The later presentation of gestational hypertensive women is noted, the majority 
presenting after 34 weeks gestation. Two participants, who presented at gestational 
ages of 30 and 32 weeks had higher body mass index of 38 and 36 and were also of 
higher parity than the mean for the group. One of these women had an adverse feto-
neonatal outcome. This participant had a body mass index of 38, parity of 6 and 
delivered at 35weeks with a fetal birth weight between 50th to 90th centiles. She 
required neonatal ventilatory support for 2 weeks. 
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Table 6.1 Demographic data of gestational hypertensive; normotensive and 







Parity: para 0 
: > para 0 
body surface area 
(m2) 










systolic BP (mmHg) 
at echocardiography 
diastolic BP (mmHg) 
at echocardiography 
mean BP (mmHg) 
at echocardiography 








p-value: mean BP at 
admission versus 
echocardiography 
systolic blood pressure 
at admission (mmHg) 
diastolic blood pressure 
at admission (mmHg) 
mean blood pressure at 
admission (mmHg) 
27 ± 5 
n = 2 (20%) 
n = 8 (80%) 
1.78 ±0.18 
3 3 + 6 
155 + 5 
80 + 16 
37 ± 3 
84 ± 9 
134+19 
82 + 10 
98 ± 1 6 
0.30 + 0.08 
245 ± 52 
37 + 2 
3.02 + 0.38 
0.008* 
150+15 
101 + 10 
117 + 12 
normotensive 
n=27 
24 + 5 
n=15 (30%) 
n=12 (70%) 
1.70 + 0.14 
27 + 4 
158 + 5 
69 + 12 
33 + 1 
82 + 8 
102 ± 9 
56 ± 6 
82 ± 8 
0.27 + 0.06 
259 + 90 


























31 ± 5 
n = 0 
n = 1 0 
1.96 + 0.29 
38 + 11 
160 + 7 
97 + 30 
29 + 8 
79 + 15 
154 + 22 
1 0 1 + 6 
1 2 1 + 8 
0.29 + 0.07 
263 ± 73 
35 + 6 
2.77 + 1.22 
0.024* 
161+13 
1 0 1 + 6 

























Data are presented as absolute mean ± one standard deviation 
* Statistically significant, P values derived by Mann-Whitney U test. 
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6.2.2 Cardiac structure and function 
There were no differences in left ventricle cavity dimensions between the groups 
(table 6.2). The left atrium and left ventricular mass index was significantly greater 
than that in normotensive patients but showed no differences from hypertensive 
women (p = 0.09). 
Using 2 standard deviations above the mean LV mass index of normotensive 
(>100g/m2) as cut off value to diagnose LV hypertrophy, half of the gestational 
hypertensive participants and 90% of chronic hypertensive women had left ventricular 
hypertrophy. These observations persisted when LV mass was corrected for LV 
mass/height. The correlation of LV mass index with LV diastolic filling abnormalities 
reflected by E/A filling ratio was modest at r = -0.30. Indices of LV contractility were 
significantly higher in gestational hypertensive women compared to normotensive 
patients. 
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Table 6.2 Cardiac structure and function- gestational hypertensives, 

















LV mass index 
(g/m2) 
% with LV-mass 
index > 110g/m2 
% with LV-mass 
index >100 g/m2 
LV mass/height 
(g/m) 











LV end systolic 
stress (dyn/cm5) 
gestational I normofensivc i p value: ! chronic 
(aproteinuric) j gestational hypertension 
hypertension hypertension i 
. •'. versus 
n-10 j n=27 | normotensfve ' n=10 
5.00 + 0.29 
3.12 + 0.30 
3.8 + 0.4 
1.4 + 0.2 
1.1+0.2 
0.25 + 0.03 




114 + 22 
1.53 + 0.40 
37 + 5 
67 + 6 
1.34 + 0.21 
77 + 16 
4.83+0.34 
3.23+0.36 
3.3 + 0.4 
1.4 + 0.3 
1.0 + 0.1 
0.22 + 0.04 
136 + 26 
79 + 11 
0 
0 
86 + 15 
1.76 + 0.37 
33 + 4 
62 + 6 
















5.14 + 0.68 
3.36+0.48 
3.8 + 0.5 
1.4 + 0.2 
1.3 + 0.2 
0.30 + 0.06 
233 + 71 




1.35 + 0.55 
35 ± 4 
62 + 6 
1.23 ±0.23 
90 ± 2 2 



















Data are presented as absolute mean ± one standard deviation; LV=left ventricle. 
* Statistically significant, P values derived by Mann-Whitney U test. 
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6.2.3 Echocardiographic hemodynamics and uterine Doppler velocimetry 
There were no differences in cardiac index between the groups and also no significant 
difference in systemic vascular resistance index. As mentioned, the lower systolic 
blood pressure in gestational hypertensives compared to chronic hypertensives just 
fell short of statistical significance (p = 0.053). The uterine artery resistance index 
was normal in both gestational hypertensive and normotensive women (0.46) but 
significantly elevated at 0.58 in chronic hypertensive women (Table 6.3). 
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Table 6.3 Maternal central hemodynamics and uterine Doppler velocimetry in 















































84 ± 9 
79 ± 1 5 
6.69 ±1.46 
134+ 19 
82 ± 1 0 
100 ± 1 6 
1.78 ±0.18 
45 ± 6 
3.75 ±0.62 
2132 ±523 
0.48 ± 0.07 






82 ± 8 
79 ± 1 2 
6.42 ±0.90 
102 ± 9 
56 ± 6 
71 ± 7 
1.70 ±0.14 
46 ± 5 
3.78 ±0.45 
1528 ±236 













O . 0 0 1 * 
O . 0 0 1 * 














79 ± 1 5 
97 ± 2 4 
7.49 ±1.62 
154 ± 2 2 
90 + 13 
111 + 14 
1.96+0.29 
50 ± 1 3 
3.79 ±0.53 


























Data are presented as absolute mean ± one standard deviation. 
* Statistically significant, P values derived by Mann-Whitney U test. 
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6.3 Discussion 
This study shows that women with gestational aproteinuric hypertension who 
presented after 34 weeks gestation have a good feto-neonatal outcome. Hemodynamic 
parameters did not help to further define a higher risk group. In fact the cardiac index 
and fetal outcome in these gestational hypertensive women was similar to 
normotensive participants. These observations are similar to a retrospective review by 
Xiong et al, (1999) who concluded that gestational hypertension did not significantly 
increase the risk of low birth weight. The above observations are also supported by 
findings in a larger multicentre, retrospective cohort study (Magee et al, 2003). These 
authors state that non-proteinuric chronic hypertension or gestational hypertension 
that presented before 34 weeks was associated with substantial adverse feto-neonatal 
outcome. This may explain the good outcome in our patients who presented late, at 
37 weeks. 
However it is apparent that gestational hypertension may include women with the pre-
eclampsia syndrome who have not manifested proteinuria or developed the syndrome 
Saudan et al, (1998). This suggests that early gestational age at presentation itself 
recognizes a potentially higher risk group. Early detection of microalbuminuria or an 
elevated uterine artery resistance index may identify gestational hypertensive women 
at higher risk of disease progression. 
A smaller sample size makes it difficult to adequately stratify gestational hypertensive 
women in this study by gestation at presentation. Analysis of an additional 6 women 
with gestational hypertension to the study (data not shown in results) who were 
prescribed a single dose of lOOOmg methyl-dopa revealed similar conclusions as 
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above. Two women who presented before 34 weeks gestational age had a larger body 
mass index and higher parity. One of these delivered at 35 weeks without any 
evidence of fetal growth restriction but required neonatal ventilatory support and had 
a satisfactory outcome. 
Weak correlations were noted between fetal birth weight and cardiac index (r = 0.23), 
systemic vascular resistance index (r = 0.15), mean blood pressure (r = 0.24) and 
uterine artery resistance index (r = -0.21). The above observations indicate that 
maternal hemodynamics and uterine artery resistance index did not help define a 
higher risk gestational hypertensive group presenting after 34 weeks gestation. 
In our study the elevated blood pressure and systemic vascular resistance in 
gestational hypertensive women was associated with a significantly higher left 
ventricular mass index and suggests that the increased blood pressure in gestational 
hypertensive women is probably sustained. Bosio et al, (1999) described a 
hyperdynamic circulation of an elevated cardiac output and normal to near normal 
systemic vascular resistance index in gestational hypertensive women who had good 
feto-neonatal outcome. In our study cardiac index was unchanged and it was not 
associated with any depression in cardiac contractile function as reflected by ejection 
fraction and velocity of circumferential fibre shortening. This is in contrast to the 
study by Valensise et al, (2001) who reported a mildly depressed systolic function in 
these patients. The same group showed that left ventricular concentric geometry 
detected by echocardiography was independently associated with adverse feto-
neonatal outcome (Novelli et al, (2003)). The important difference in the Novelli 
study is that gestational hypertension participants were diagnosed between 27 to 31 
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weeks. It is therefore not surprising that 54% of participants had echocardiography 
left ventricular hypertrophy or concentric remodelling. This suggests that their 
hypertension was probably present from mid second trimester as it takes six weeks to 
show changes in LV mass. The high good negative predictive value of this (88%) 
supports our observations that absence of left ventricular hypertrophy in women with 
gestational hypertension is associated with a good feto-neonatal outcome. In our 
study the chronic hypertensives had larger left ventricular mass index (p=0.070) in 
keeping with high blood pressure. Haemodynamic parameters were similar in both 
groups. 
In conclusion, this study shows that gestational hypertensive women who present 
close to term have a good perinatal outcome. Maternal hemodynamics and uterine 
artery Doppler velocimetry did not help to define a higher risk group among these 
women with gestational hypertension. The elevated blood pressure that was 
associated with a significant increase in left ventricular mass and a trend to LV 
hypertensive diastolic filling abnormalities suggest that these women with gestational 
hypertension presenting late in pregnancy have a similar clinical profile to mild 
chronic hypertension in pregnancy. This provides some supporting evidence that 




CHRONIC HYPERTENSION AND SUPERIMPOSED PRE-
ECLAMPSIA ON CHRONIC HYPERTENSION 
7.1 Introduction, aims and methods 
Pregnant women with chronic hypertension are at increased risk of developing 
placental abruption, fetal growth restriction, prematurity and superimposed pre-
eclampsia (Haddad et al, 1999). This risk is particularly increased in pregnant women 
who have severe hypertension, in those with hypertensive target organ damage, in 
women who develop superimposed pre-eclampsia and also in women with prior renal 
disease (Livingston et al, 2003). A recent meta-analysis of studies of chronic 
hypertension in pregnancy by Ferrer et al, (2000) concluded that no study has as yet 
provided guidance on the benefits, consequences of therapies or monitoring strategies 
in this condition. 
The diagnosis of superimposed pre-eclampsia on chronic hypertension tests the skills 
of the clinician. The Australasian society of the study of hypertension in pregnancy 
guidelines (2000) advise that in women with chronic hypertension, any sudden 
increases in proteinuria or hypertension should lead to increased surveillance for 
superimposed pre-eclampsia. This diagnosis is not secure without the development of 
other features that are associated with the pre-eclampsia syndrome. Therefore in the 
individual pregnant woman with chronic hypertension, a more precise risk assessment 
is necessary to assist the clinician towards correct decisions on management and 
delivery. This is especially important in the light of potential hazards of blood 
pressure lowering with antihypertensive medications. Recent studies emphasize that 
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the risk benefit of such therapies in chronic hypertensive pregnant women needs 
continued evaluation. 
This study compares the haemodynamics in chronic hypertension and those with 
superimposed pre-eclampsia. The rationale for this study, methods of enrolment, 
inclusion and exclusion criteria, echocardiographic and uterine artery Doppler 
velocimetry methods and analyses are as described in chapters 1 and 2. Twenty 
women formed this group, 10 with chronic hypertension alone (no proteinuria) and 10 
with superimposed pre-eclampsia (persistent proteinuria of > 1+ on dipstix). 
7.2 Results 
7.2.1 Demographics (Table 7.1) 
The patients in both groups had similar age, parity distribution, body habitus and 
gestational age at evaluation. A higher systolic (p = 0,011) and diastolic (p = 0,024) 
blood pressure at echocardiography was present in the superimposed pre-eclampsia 
group. In addition, the blood pressure at admission into the study was significantly 
higher than that measured at echocardiography in both chronic hypertensive groups. A 
lower fetal birth weight in the superimposed pre-eclampsia group was associated with 
a 4 week difference in gestation at delivery (p = 0,052). Also a significant lower 
platelet count was seen in the superimposed pre-eclampsia group (p = 0,039); the 
differences in serum urate level were not significant. 
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Table 7.1 Demographics of chronic hypertensive groups 
age 
(years) 
parity : number (%) : para 0 
: > para 0 
body mass index 
(kg/m2) 






systolic blood pressure at admission 
(mmHg) 
diastolic blood pressure at admission 
(mmHg) 
mean blood pressure at admission 
(mmHg) 
mean gestation at evaluation 
(weeks) 
systolic blood pressure at 
echocardiography (mmHg) 
diastolic blood pressure at 
echocardiography (mmHg) 
mean blood pressure at 
echocardiography (mmHg)+ 
p-value: mean BP at admission 
versus echocardiography 
heart rate at echocardiography 
(beats/min) 




gestation at delivery 
(weeks) 
fetal birth weight 
(kg) 








38 + 11 
1.96 + 0.29 
160 + 7 
97 + 30 
161 + 13 
101+6 
121+8 
29 + 8 
154 + 22 
90 + 13 
113 + 14 
0.024* 
79 + 15 
0.29 ± 0.07 
263 ± 73 
35 + 6 




n = 10 
30 + 6 
0 (0%) 
10(100%) 
35 + 6 
1.86 + 0.13 
157 + 6 
86 + 13 
182 + 19 
112 + 14 
136 + 15 
29 + 6 
179 + 23 
104 + 13 
129 + 16 
0.046* 
79 + 20 
0.35 + 0.09 
188 + 82 
31 ±5 




















Data are presented as absolute mean ± one standard deviation 
* Statistically significant; p values derived by Mann-Whitney U test. 
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7.2.2 Echocardiography - cardiac structure and function (Table 7.2) 
There were no differences in ventricular and atrial dimensions between the groups. A 
larger septal wall thickness was noted in the superimposed pre-eclampsia group (p = 
0,025) but the higher left ventricular (LV) mass index fell short of statistical 
significance. A significant proportion of women in both groups had 
echocardiographic LV hypertrophy (LV mass index > 110g/m2). Indices of LV 
contractility were similarly preserved in both groups. 
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Table 7.2 Echocardiographic cardiac structure and function 
LV internal diameter in 
diastole (cm) 




left atrial to aorta size 
ratio 
LV septal thickness 
(cm) 




LV mass index 
(g/m2) 
LV mass index >110g/m2 
LV early to atrial diastolic 
filling ratio 
LV fractional shortening 
(%) 
LV ejection fraction 
(%) 
LV velocity of 
circumferential fibre 
shortening (circum/sec) 










0.30 ± 0.06 
233 ±71 
119 + 32 















264 ± 63 
141 ±27 
n = 9 
1.28 ±0.54 
34 ± 5 

















Data are presented as absolute mean ± one standard deviation 
* Statistically significant; p values derived by Mann-Whitney U test. 
7.2.3 Maternal hemodynamics and uterine artery Doppler velocimetry 
There were no differences in cardiac output or cardiac index between the groups 
(table 7.3). The higher systemic vascular resistance index in the superimposed pre-
eclampsia group is thus largely a reflection of the higher blood pressure. There was no 
significant difference in measured uterine artery resistance index between the groups. 
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The correlation of systemic vascular resistance index with uterine artery resistance 
index for the combined groups was weak(r = 0.28). Systemic vascular resistance 
index (r = 0.45) correlated better with fetal weight but the best correlation was with 
uterine artery resistance index (r = 0,64). 




mean blood pressure 
(mmHg) 










systemic vascular resistance 
index (dyn. sec/cm5) 
uterine artery resistance 
index 
umbilical artery pulsatility 
index 






























Data are presented as absolute mean ± one standard deviation 
* Statistically significant; p values derived by Mann-Whitney U test. 
7.3 Stratification by presence of left ventricular hypertrophy 
The data in both hypertensive groups (n = 20) were divided into those with and those 
without left ventricular hypertrophy (Table 7.4). The presence of left ventricular 
hypertrophy (LV mass index > 110g/m2) was associated with a higher mean, systolic 
and diastolic blood pressure but with a non-significant higher systemic vascular 
resistance index, lower fetal birth weight and earlier gestation at delivery. Mean 
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blood pressure showed a good correlation with LV mass index (r = 0.53). Regression 
analyses identified gestation at presentation, severity of hypertension and presence of 
proteinuria as best associated with adverse feto-neonatal outcome. 
Table 7.4 Comparative evaluation of chronic hypertension with left ventricular 
hypertrophy 
systolic blood pressure at 
echocardiography (mmHg) 
diastolic blood pressure at 
echocardiography (mmHg) 
mean blood pressure at 
echocardiography (mmHg) 
systemic vascular resistance 
index (dyn.sec/cm /m ) 
cardiac index 
(1/min/m2) 
gestation at delivery 
(weeks) 
fetal birth weight 
(kg) 
LV early to atrial diastolic 
filling ratio 
uterine artery resistance index 
umbilical artery pulsatility 
index 




































Data are presented as absolute mean ± one standard deviation 
* Statistically significant; p values derived by Mann-Whitney U test. 
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7.4 Discussion 
This study demonstrates a poorer feto-neonatal outcome in chronic hypertensive 
women who develop superimposed pre-eclampsia. These differences were not 
associated with any significant differences in maternal cardiovascular haemodynamics 
or uterine artery resistance index. Septal wall thickness was higher in the 
superimposed pre-eclampsia group (p=0.025). 
Pregnant women with chronic hypertension have been described as having elevated 
maternal and fetal risks and greater fetal growth restriction (Haelterman et al, (1997) 
and Ferrer et al (2000). McCowan et al, (1996) however, noted that the risk was 
particularly high in chronic hypertensive women who had severe hypertension before 
20 weeks gestation. Our study shows that at risk chronic hypertensive pregnancies 
were better associated with an early gestation at presentation (second trimester), 
severe hypertension of blood pressure > 160/1 lOmmHg and presence of proteinuria. 
Haddad et al, (1999) described increased complications only in women classified as 
higher risk (pre-existing cardiovascular and renal disease and target organ 
involvement) chronic hypertensives, in keeping with our findings of LV hypertrophy 
and proteinuria in the high risk group. 
In conclusion, our study evaluating chronic hypertensive women show that early 
presentation (before 28 weeks gestation), persistent severe hypertension (BP > 
160/1 lOmmHg) at initial presentation and proteinuria of 1+ or more by reagent strip 





The principal findings of this study are that cardiac index and to a lesser extent 
systemic vascular resistance measured in the latter part of the second and/or third 
trimesters in hypertensive women showed only modest to weak associations with 
adverse feto-neonatal outcome. There was a marginally stronger association between 
systemic vascular resistance index and adverse feto-neonatal outcome which largely 
reflected the severity of hypertension. In contrast, uterine artery resistance index 
measured by Doppler velocimetry showed a satisfactory association with adverse 
feto-neonatal outcome. In a multiple regression analysis as detailed in chapter 4, 
uterine artery resistance index was the best variable that identified an adverse feto-
neonatal outcome. 
The poor correlation between maternal cardiac index and adverse feto-neonatal 
outcome and/or fetal growth restriction (reflected by fetal birth weight below the 10th 
centile), is not surprising. In a recent literature review Young et al, (2001) evaluated 
the clinical usefulness of both invasive and non-invasively measured maternal 
hemodynamics in pre-eclampsia. The authors concluded that the clinical impact of 
measuring maternal hemodynamics has yet to be demonstrated. 
Similar to most studies on maternal hemodynamics, our study demonstrates a wide 
variation in cardiac index and systemic vascular resistance index values both in 
normotensive and hypertensive pregnancy groups that occurred largely from patient 
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factors. This limited the ability of variables of cardiac index or systemic vascular 
resistance index to be better associated with adverse feto-neonatal outcome. 
Using fetal birthweight < 1.8kg as an adverse outcome measure yielded sensitivity 
and specificity values of 39% and 73% for cardiac index < 3.5 1/min/m2; 53% and 
80% for systemic vascular resistance index value > 2500 dyn.sec/cm /m and 53% 
and 87% for uterine artery resistance index > 0.65 respectively. These data illustrate 
the limitations in predictive value of maternal hemodynamics in defining at risk 
hypertensive pregnancies as an improved sensitivity is achieved at a cost of reduced 
specificity and visa versa. 
8.2 Prognostic value of haemodynamic studies 
8.2.1 Maternal central haemodynamics, uterine Doppler velocimetry and feto-
neonatal outcome 
The pre-eclampsia syndrome is associated with a significant increase in maternal and 
perinatal morbidity and mortality. It has been recognized that the hypertension is just 
one manifestation of an underlying multifactorial and multisystem disorder that is 
often initiated early in pregnancy (Bolte et al, 2001). Presently used criteria to predict 
unfavourable outcome are inadequate in that they diagnose disease at a late stage 
(Zhang et al, 2001). An earlier detection of women with at risk hypertensive 
pregnancies is important as they may benefit from therapies aimed at beneficial 
prolongation of the pregnancy (Withagen et al, 2001). In an echocardiographic study 
of severe pre-eclamptic women, Yang et al, (1996) found that an elevated systemic 
vascular resistance index was associated with a higher prevalence of small for 
128 
gestational age babies. However, in a recent review Zhang et al, (2001) showed that 
the blood pressure alone has poor discriminatory value and that improved antenatal 
predictive tests are required to better define at risk pregnancies. 
Defective implantation and placentation in hypertensive pregnancies is thought to 
result in reduced placental perfusion. This results in a failure of the normal maternal 
cardiovascular adaptation with subsequent maternal endothelial and organ dysfunction 
(Roberts, 2000). 
Measurement of uterine artery Doppler velocimetry to predict adverse foetal outcome 
is limited by its low specificity and low positive predictive value (Coleman et al, 
2000, Soregaroli et al, 2001). A refinement in uterine artery Doppler velocimetry is 
the notch index in the uterine artery waveform, which has improved predictive value 
but with a non-consistent benefit (Aquilina et al (2000), Aardema et al (2000). In a 
low risk study group defined as occurrence of pre-eclampsia and pre-eclampsia 
requiring delivery before 37 weeks. Aquilina et al (2001) found that adding the 
notching index and serum inhibin levels to a predictive model improved the predictive 
potential. 
In another study Aardema et al, (2000) evaluated uterine artery velocimetry to predict 
recurrence of hypertensive disorder. The authors noted that although uterine artery 
velocimetry was unsatisfactory at predicting risk of recurrence of gestational 
hypertension and pre-eclampsia, it did show a satisfactory association with fetal 
growth restriction and adverse outcome. It appears that the varying risks of pregnant 
women in the above studies did not allow for confident evaluation of the potential 
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benefit of uterine artery Doppler velocimetry in hypertensive and/or at risk 
pregnancies. 
A further confounding factor is that initial abnormal uterine artery velocimetry indices 
normalise later in pregnancy. Soregaroli et al, (2001), for instance, showed that 
approximately half of the study participants with abnormal uterine artery velocimetry 
at 24 weeks had normalisation of indices at 34 weeks gestation and this corresponded 
to a significant better feto-neonatal outcome than the group with persistently 
abnormal uterine artery waveforms. 
In another study Valensise et al, (2001) described abnormalities in maternal diastolic 
function at 24 weeks gestation in a group of normotensive women who had abnormal 
uterine artery velocimetry with the waveform abnormality of bilateral notching. Fifty-
eight (58) % of this cohort had normal feto-neonatal outcome. In the remaining 
pathological outcome group, 33% developed gestational hypertension and 8% had 
small for gestational age babies. As the abnormalities in maternal diastolic function 
were more prevalent in the pathological outcome group, the authors hypothesize that 
the abnormal placentation process reflected by abnormal uterine artery velocimetry 
results in maladaptation of the entire maternal cardiovascular system. 
These studies provide plausible reasons to explain the modest to poor correlation 
between maternal central hemodynamics and uterine artery resistance index observed 
in our study. They also suggest that uterine artery velocimetry perhaps performed 
serially, remains a good diagnostic option. 
Our study shows that the uterine artery resistance index measured at late second or 
early third trimesters, probably encompasses all the known risk variables such as 
severity and chronicity of hypertension, presence and severity of proteinuria, and 
possibly also bad obstetric history, multiparity, higher age, and maternal size. It 
proved to be the best single variable to correlate with adverse feto-neonatal outcome. 
These findings are supported by recent observations made by Frusca et al, (2003) in 
their retrospective study evaluating uterine artery velocimetry in women with 
gestational hypertension and pre-eclampsia. In a multivariate model that looked at 
presence of proteinuria, severity of hypertension and uterine artery velocimetry, the 
authors found that abnormal uterine velocimetry was the variable that was more 
frequently associated with adverse pregnancy outcome. 
8.2.2. Limitations of maternal haemodynamics studies 
Some of the difficulties of evaluating maternal central hemodynamics in hypertensive 
and/or at risk pregnancies are illustrated in the frequently cited studies of Easterling et 
al, (1999) and Bosio et al, (1999). The Easterling study was actually a retrospective 
review that used an elevated cardiac output of >7.41/min at 24 weeks gestation in 
normotensive and diabetic women to select women who may benefit from 
antihypertensive medication of atenolol. The implied message in the selection criteria 
is that an elevated cardiac output in the pre-clinical stage of hypertensive disorder of 
pregnancy is associated with the development of hypertension and associated risks 
and that the elevated cardiac output has a pathogenic role. The treatment component 
of the study aimed to support the hypothesis that appropriate treatment of the elevated 
cardiac output with anti-hypertensive medications will result in an improved feto-
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neonatal outcome. One of several conclusions made by the authors was that a failure 
to adjust antihypertensive medication in response to an excessive drop in cardiac 
output or a corresponding increase in systemic vascular resistance was associated with 
an increased risk of fetal growth restriction. Apart from being a retrospective 
analysis, the arbitrary cut-off value for cardiac output (without stratifying for maternal 
size) and the inclusion of normotensive patients with a history of fetal growth 
restriction are significant limitations in this study. 
The more conclusive work of Bosio et al, (1999) described an elevated maternal 
cardiac output in the pre-clinical period of normotensive women who developed 
hypertension later in pregnancy. Their data supports the hypothesis of a hyperdynamic 
disease model in women with pre-eclampsia and gestational aproteinuric 
hypertension. However, again this study did not correlate cardiac output to maternal 
body size (normalised BSA). Earlier studies have shown a poor correlation of 
maternal cardiac output with maternal body size, but in our study of normotensive 
pregnant there is women show a significant positive correlation between maternal 
cardiac output and maternal body size. In addition our study together with that of 
Bosio et al, (1999) show a very satifactory feto-neonatal outcome in women who 
present with gestational hypertension late in pregnancy. These patients have normal 
cardiac output with mildly elevated systemic vascular resistance late in pregnancy, 
supporting the concept that the elevated cardiac output in the pre-clinical phase of the 
disease is followed by a reduction in cardiac output in the clinical phase of disease 
(pre-eclampsia). This highlights the limitation of a single measure of cardiac output 
to risk stratify pre-eclamptic women. It can probably be stated that if increased 
cardiac index is indeed a feature of the initial stages of pre-eclampsia, then the results 
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of our study suggest that this does not persist into the clinical stage of the disease 
when cardiac index may be within the normal range but systemic vascular resistance 
index is high. 
Our study evaluated women in the clinical phase of pre-eclampsia with the aim of 
providing more precise risk stratification. We show a trend to a lower cardiac output 
in a smaller sample of preeclamptic women compared to normotensives (p = 0.116) 
that corresponded to significant differences in feto-neonatal outcome. The lower 
cardiac output in our preeclamptic group compared to chronic hypertension with 
superimposed pre-eclampsia was not associated with a more adverse feto-neonatal 
outcome. Standardizing maternal cardiac output for maternal body size (body surface 
area) in our study revealed no differences in cardiac index among the hypertensive 
groups. These data suggest that, if indeed a reduced cardiac output is a marker of 
adverse feto-neonatal outcome, then there must be compensatory mechanisms, 
probably at uteroplacental level, to maintain satifactory fetal health. Our study thus 
provides supporting evidence for this hypothesis since there was poor correlation of 
maternal central hemodynamics compared to uterine artery velocimetry with adverse 
feto-neonatal outcome in hypertensive pregnancies. 
The modest to poor correlation of maternal haemodynamic parameters with uterine 
artery resistance index, and the fact that the echocardiographic Doppler technique is 
labour and skills intensive - shows that risk stratifying hypertensive pregnancies by 
Doppler measurement of uterine artery resistance index is a more rewarding approach. 
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Yang et al, (1996), has shown that women with systemic vascular resistance index in 
the upper textile had a higher incidence of small for gestational age babies. Similar to 
most studies of maternal hemodynamics in hypertensive pregnancies, the authors 
reported the limitations that arise as a result of a large variability in cardiac index. 
They observed that the pre-eclamptic sub-group had an elevated uterine artery 
resistance without a corresponding reduction in cardiac output or significant elevation 
of systemic vascular resistance index. This suggests that the relationship between 
regional uterine hemodynamics and maternal central hemodynamics is not linear in 
hypertensive pregnancies and it is likely that uteroplacental vasospasm occurs before 
systemic vasospasm. These authors hypothesized that an elevated cardiac output in 
these pre-eclamptic women reflected a hyperdynamic circulation that may be 
compensatory to maintain adequate perfusion in a high resistance utero-placental 
circulation. 
Two studies using bioimpedance have evaluated the responses to volume expansion in 
pre-eclampsia. Siekmann et al, (1986) found that hypervolemic hemodilution with 
dextran in pre-eclampsia correlated with a rise in fetal blood flow velocity and flow 
volume and proposed that elevation in uteroplacental perfusion occurred as a result of 
an increase in maternal cardiac output. Subsequently Belfort et al, (1994) evaluated 
maternal hemodynamics by thoracic electrical bioimpedance and simultaneous uterine 
artery Doppler in five preeclamptics who received volume expansion followed by 
verapamil infusion. The authors noted widely varying changes in cardiac index but 
either unchanged or improved measurement in uterine artery velocimetry indices and 
the authors concluded that volume expansion could have limited benefits in such 
patients. 
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8.2.3 Clinical limitations: effects of treatment and maternal body habitus 
Other factors that limit a precise evaluation of hemodynamics in hypertensive 
pregnancies include severity of disease at presentation, maternal body habitus and 
administration of sedative anti-hypertensive medication prior to measurements being 
made. Our study, similar to most others, confirms that hypertensive pregnant women 
are of larger stature than normotensive controls. In a recent review Broughton-Pipkin 
and Roberts (2000) suggest that obesity as a risk factor may in fact represent the 
metabolic syndrome and possibly an underlying genetic predisposition. The larger 
maternal stature and/or obesity in our study were reflected by a bigger weight, body 
surface area and body mass index of study participants with a trend to a smaller height 
than normotensive controls. Interestingly, this lower height in preeclamptics was 
statistically significant when compared to normotensive women. 
Normotensive pregnant women in our study showed satisfactory positive correlations 
of maternal body surface area with maternal cardiac output measured in early and mid 
third trimester (r=0.72) and fetal birth weight (r= 0.60). The variations in cardiac 
output in normotensive pregnant women can thus be explained to a significant extent 
by differences in maternal size. There was a lower cardiac output in severe pre-
eclamptic women compared to other hypertensive groups, but these differences were 
not significant when indexed for body surface area. Should maternal hemodynamic 
variables be standardized by correcting for body surface area? In a recent study there 
was a poor correlation between cardiac output and body surface area Oppen et al, 
(1995). Early invasive studies in hypertensive disorders of pregnancy reported 
standardized hemodynamic measurements of cardiac index rather than cardiac output. 
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We also describe an elevated cardiac output in gestational hypertensive participants 
compared to normotensives pregnant women, but these differences were not evident 
when cardiac output was standardized for body surface area. These findings imply 
that the elevated cardiac output reported early in pregnancy as a marker for 
subsequent development of hypertensive disease (Easterling et al (1999) and Bosio et 
al (1999) may in fact be recognising the risk related to obesity. Despite shortcomings 
when applied to pregnant women, it still remains necessary and logical to standardize 
maternal hemodynamic parameters for differences in body surface area or height; 
otherwise the effects of obesity would be obscured (de Simone et al, (1997). 
Our study is limited by baseline differences in maternal body size and clinical severity 
of the disease as well as the treatment effect medication prior to measurement on 
hemodynamic parameters. Early invasive hemodynamic studies (Cotton et al, 
(1988)) showed that most pre-eclamptic participants had a hyperdynamic circulation 
with an elevated cardiac index. However, in addition to the inclusion of chronic 
hypertensives the pre-eclamptic women in Cotton's study received magnesium 
infusion prior to baseline measurements, introducing significant heterogenicity in the 
study groups. 
The other large invasive hemodynamic study of Mabie et al, (1989) also demonstrated 
a hyperdynamic circulation with an elevated cardiac index in majority of their pre-
eclamptic participants similar to the Cotton study. These findings were also 
complicated by effects of treatment, since approximately a third of the participants 
had received hydralazine and almost half were in early labour, factors that likely 
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affected hemodynamic measurements. In both studies, intravenous fluid was also 
administered. This differed from the invasive study of Visser et al, (1991) in which 
intravenous fluid was not administered. Visser et al, (1991) pointed out that the 
marked disparity in haemodynamic studies in pre-eclamptic women, erroneously 
attributed to a variable hemodynamic expression of the disease, may in fact be related 
to administration of anti-hypertensive medication and/or intravenous fluids. 
Such effects of treatment on maternal hemodynamics were reported in a study by 
Hung et al, (2000) who showed that preeclamptic women given methyl-dopa for five 
days had a significant reduction in retinal artery vascular resistance. In a small study 
assessing treatment effects in preeclamptic women, Scardo et al, (1999) reported a 
significant increase in cardiac index measured by thoracic electric bioimpedence in 
the group given non-dihydropyradine calcium antagonist, nifedipine, but no change in 
the group that was administered combined alpha-beta adrenergic blocking agent, 
labetalol. These differences in cardiac index occurred despite similar reductions in 
blood pressure, and, in part, were due to differences in heart rate; (an increase with 
nifedipine and a decrease with labetalol. 
The contribution of heart rate to cardiac output was reported by Bolte et al, (1998) 
who attributed the increase in cardiac index to an increased heart rate in hypertensive 
pregnant women given dihydrallazine compared to group given the selective serotonin 
receptor blocker, ketanserin. Similarly, in their echocardiographic hemodynamic 
study of predominantly obese hypertensive pregnant women, Easterling et al (1990) 
attributed an elevated cardiac output to an increased heart rate. In another study of 
hemodynamics measured by thoracic electric bioimpedence in severe preeclamptics, 
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Scardo et al, (1996) also observed an increased heart rate but without any change in 
cardiac output. The authors therefore stated that the increased heart rate in their 
preeclamptics cohort prevented the expected fall in cardiac output. 
Our study clearly demonstrates a significant lower heart rate in untreated 
preeclamptics with severe proteinuria compared to untreated gestational aproteinuric 
hypertensives (60 ± 11 versus 84 ± 9; p=0.001). Untreated preeclamptics with mild to 
moderate proteinuria had an intermediate heart rate of 72 ± 8. This lower heart rate 
was associated with a significantly higher stroke index resulting in little change in 
cardiac index. This is an important observation as pre-eclampsia has been described 
as a state of relative hypovolemia or failure of an adequate expansion of plasma 
volume and with some resultant hemoconcentration. However, the compensatory 
increase in stroke volume and preserved cardiac index and left ventricular systolic 
function indicate that there is probably an adequate preload reserve to allow for a 
compensatory increase in stroke volume, thereby maintaining maternal cardiac output. 
This reduced heart rate in untreated pre-eclamptic women in our study supports early 
observations made by Kuzniar et al, (1982) in a M-mode echocardiography study of 
pre-eclamptic women and in the important invasive hemodynamic study of Visser et 
al, (1991). At variance to our study, however Kuzniar et al, (1982) also showed a 
reduced stroke volume that was measured by the less accurate and unvalidated 
technique of M-mode echocardiography. 
Differences of heart rate in pre-eclamptic women observed between studies can also 
be attributable to significant disease heterogenecity and maternal body size. For 
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instance, the Easterling study (1990) included women who were hypertensive prior to 
20 weeks gestation and also included a milder category of hypertensive pregnant 
women defined by an increase in diastolic blood pressure of 15mmHg above baseline. 
It is unlikely variations in levels of aerobic conditioning as described in the non-
pregnant setting could account for differences in heart rate. Wolfe et al, (1999) 
recently reported that aerobic conditioning had minimal effects on cardiovascular 
parameters in normotensive pregnant women. These effects are probably obscured by 
more powerful hemodynamics effects of pregnancy in the resting state. 
Haemodynamic changes secondary to pharmacologic therapy may be an important 
determinant of cardiac index. In the setting of bradycardia, cardiac index is the 
normal pregnant state usually maintained by a compensatory increase in stroke index. 
In severe pre-eclampsia a significantly contracted plasma volume may attenuate this 
compensatory increase in stroke volume with a resultant fall in the cardiac index. It is 
worth nothing that treatment with B-adrenergic blocking agents may significantly 
lower heart rate to an extent whereby the compensatory increase in stroke volume 
may be inadequate to maintain a satisfactory cardiac output. This scenario explains 
the reduced cardiac output and associated fetal growth restriction in hypertensive 
women prescribed atenolol in the study by Easterling et al, (1999). This observation 
was further supported by the recent meta-analysis of Easterling et al, (2001) in which 
atenolol associated with a reduced incidence of pre-eclampsia but with fetal growth 
restriction that was attributed to inappropriate reduction in cardiac output with the 
drug. Similar observations were made by von Dadelszen et al, (2000) in a meta-
analysis of randomised controlled trials evaluating pharmacological lowering of blood 
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pressure during pregnancy and feto-neonatal outcome. They concluded that treatment 
induced falls in maternal blood pressure could adversely affect fetal growth. 
8.3 Blood pressure, maternal hemodynamics and feto-neonatal outcome 
The finding that maternal central hemodynamics in this study showed only a modest 
to poor association with adverse feto-neonatal outcome indicating that these changes 
are secondary to the main pathology in the placenta. As there were no differences in 
cardiac index between the hypertensive and normotensives groups, the more modest 
elevation between elevated systemic vascular resistance index and adverse feto-
neonatal outcome was largely a reflection of the severity of the measured blood 
pressure. While severe hypertension at echocardiography clearly recognized at risk 
hypertensive pregnancies; this higher risk cohort was often associated with the 
presence of proteinuria. Blood pressure alone had poor discriminatory value 
demanding better antenatal predictive tests to define at risk pregnancies Zhang et al, 
(2001). 
An interesting observation in our study was that blood pressure measured at 
echocardiography performed soon after admission into the study was significantly 
lower than that measured at entry into the study. This placebo effect probably reflects 
the more "pleasant" circumstances of the ultrasound laboratory compared to that of 
the admission obstetric unit. Also the blood pressures were taken in the supine as 
opposed to the sitting position. Whatever the precise reason, it does demonstrate the 
variability in blood pressure measurements, and the importance of repeated readings. 
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It appears that participants who have an elevated but labile blood pressure that settles 
with time and/or bed rest probably have a milder disease process. 
Any fall in blood pressure with more frequent blood pressure recordings may restage 
hypertensive pregnant women into lower risk categories and potentially improve risk 
stratification. This also dictates a more precise definition of procedures of 
measurement of blood pressure. In particular, methods that call for more frequent 
automated blood pressure recordings and or ambulatory blood pressure monitoring 
seem suited to provide a more accurate estimate of the hypertensive burden. Frequent 
measurements are more likely to remove the labile component in blood pressure 
measurements and thereby allow for a more accurate classification. For example, 
performing more frequent recordings at clinic, for example of 5-10 recordings over a 
30 minute period and/or using ambulatory blood pressure measurements performed 
over periods varying from 6-24 hours in borderline and mild hypertension may 
identify the white coat hypertensive effect. This may help the clinician to avoid 
prescription of potentially harmful anti-hypertensive therapy to low risk pregnant 
women (Dadelszen et al, 2000). 
Twenty-four hour ambulatory blood pressure study has significant prognostic value. 
There is a significant inverse relationship between mean daytime diastolic blood 
pressure and fetal birth weight; no association exists between day clinic assessment of 
blood pressure and fetal birth weight Waugh et al, (2000). Using ambulatory readings 
Hermida et al, (2002) described an improved stratification of women with gestational 
hypertension. Using hyperbaric index to describe the area of blood pressure excess 
above the upper limit of a time-specified tolerance interval they described 
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hypertensive categories that included detected and undetected gestational 
hypertension and white coat hypertension. A similar incidence of preterm delivery 
and fetal growth restriction was observed for both gestational hypertension categories 
compared to normotensive and white coat hypertensive groups. 
Further support for use of ambulatory blood pressure comes from Penny et al, (1998) 
who found that daytime systolic and diastolic blood pressures predicted progression to 
severe pre-eclampsia (severe hypertension and/or proteinuria) better than obstetric 
clinic blood pressure measurements. In another recent study, Hermida et al, (2001) 
showed that 48 hour ambulatory blood pressure monitoring in normotensive and 
hypertensive pregnancies demonstrated the expected variability in blood pressure and 
defined proper reference limits that could be used in the early diagnosis of 
hypertensive pregnancies. However, Brown et al, (2001) recently reported that 
although 24 hour ambulatory blood pressure monitoring in mid-trimester identifies 
some women who may develop pre-eclampsia, the sensitivity is actually no better 
than other predictive tests even when women at higher risk are chosen. 
The observations in our study, together with reported experience of ambulatory blood 
pressure measurement in hypertensive pregnancies, indicate that frequent blood 
pressure measurements performed in an appropriate setting provide a more accurate 
measure of the hypertensive burden with improved predictive potential. 
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8.4 Proteinuria, maternal hemodynamics and feto-neonatal outcome 
Our study confirms the value of detecting the presence and severity of proteinuria by 
the reagent strip test to risk stratify hypertensive pregnancies. Stratifying hypertensive 
pregnant women by the presence of proteinuria clearly identified a higher risk group 
hypertensive pregnancies compared to hypertensive pregnancies without proteinuria. 
This was independent of the severity of blood pressure, systemic vascular resistance 
index and left ventricular hypertrophy, but was associated with an elevated uterine 
artery resistance index. As indicated in chapter 4 and section 8.1, multiple regression 
analysis for the entire hypertensive cohort showed uterine artery resistance index as 
the single variable that was best associated with adverse feto-neonatal outcome. Our 
data also concur with that of Scardo et al, (1996) who found that preeclamptic 
participants initially risk stratified by proteinuria did not show any differences in 
cardiac index. 
Severe proteinuria was associated with a significantly higher mean uterine artery 
resistance index (0.67) compared to mild proteinuric pre-eclamptic women (0.56) and 
gestational aproteinuric hypertensive women (0.48). Similar findings have been 
reported in other studies (Soregaroli et al, (2001), Coleman et al, (2000) and 
McCowan et al, (2001)). Barton et al, (2001) also reported that the development of 
proteinuria in gestational hypertensive women was associated with earlier gestational 
age at delivery, lower fetal birth weight and higher incidence of small for gestational 
age newborns. He reported that 46% of women with mild gestational (aproteinuric) 
hypertension remote from term ultimately developed pre-eclampsia. These findings 
lend support to the concept that the elevated uterine artery resistance index parallels 
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the inadequate physiological changes in the spiral arteries that occur in women with 
intrauterine growth restriction and or pre-eclampsia. 
Unlike hypertension outside pregnancy, our study showed a poor correlation between 
proteinuria and left ventricular hypertrophy. This again suggests that precise measures 
of proteinuria such as 24 hour urine protein excretion and/or blood pressure 
measurements (24 hour ambulatory blood pressure) are necessary to explore this 
association and to define more precise risk and stratification. For example, 
microalbuminuria (50-300mg/24 hours) in hypertensive pregnant women may identify 
mild disease at an earlier stage and thus allow for selection of hypertensive women 
who may benefit from closer monitoring. This is an area that provides scope for 
future research. 
8.5 Maternal hemodynamics, left ventricular mass and systolic function 
Left ventricular hypertrophy is now accepted as an important independent 
cardiovascular risk factor in hypertensives outside pregnancy, and is the result ov both 
hemodynamic and non-hemodynamic factors (neuro-humoral). 
Our study however shows a modest to poor association of left ventricular mass index 
with maternal central hemodynamic in hypertensive pregnancies. Furthermore, 
women with pre-eclampsia were of smaller stature and had a significantly higher 
blood pressure than gestational aproteinuric hypertensive participants. Despite these 
differences in blood pressure at echocardiography, the left ventricular mass index and 
LV diastolic filling ratios were similar for both these groups. This suggests that the 
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higher blood pressure in pre-eclamptic women at presentation was probably of a 
shorter duration and did not allow for a corresponding increase in left ventricular 
mass or changes in left ventricular diastolic filling parameters. 
This poor correlation of maternal hemodynamics to the severity of left ventricular 
hypertrophy is probably affected by a shorter duration of hypertension in the setting 
of pregnancy. 
Similar to systemic vascular resistance index, uterine artery resistance index also 
showed a poor correlation with left ventricular mass index. The above is not 
unexpected as vasoconstriction is not the basic pathology in the uteroplacental 
circulation in these hypertensive pregnancies. An alternate explanation for the above 
may be the inherent limitations of less frequent clinic blood pressure measurements 
that probably provide a less accurate measure of the hypertensive burden. In addition, 
non-haemodynamic factors such as activation of sympathetic nervous system, 
alterations in angiotesin II vascular sensitivity (Fischer et al, 1999) and other humoral 
factors may contribute to the development of left ventricular hypertrophy with 
resultant poor correlation of maternal central hemodynamics and degree of left 
ventricular hypertrophy, as is described in hypertension outside pregnancy. 
Although women with gestational aproteinuric hypertension in our study were 
identified as a low risk group with good outcome, their elevated blood pressure is 
probably persistent as echocardiographic evaluation of cardiac structure showed a 
significant increase in LV mass index, relative wall thickness ratio and changes in LV 
diastolic filling ratio compared to normotensive pregnant women, findings similar to 
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the cardiac structural changes recently reported by Valensise et al, (2001). The time 
frames in gestational aproteinuric hypertension (in pre-eclampsia) probably do not 
allow for development of significant left ventricular hypertrophy to impact on risk. 
This explains why women with chronic hypertension in pregnancy had a significantly 
greater left ventricular mass index compared to women with gestational hypertension 
and pre-eclampsia in our study. Chronic hypertension is known to increase fetal and 
maternal risk significantly. Our data do show a (albeit non-significant) lower fetal 
birth weight, earlier gestation at delivery and a lower cardiac index in this group. 
The echocardiographic structural changes we have described are similar to that 
reported by Vasquez Blanco et al, (2000) and Valensise et al, (2001) where most 
hypertensive women had a geometric pattern of eccentric left ventricular hypertrophy. 
In addition, all hypertensive groups had a significantly elevated left ventricular mass 
index compared to normotensives participants and this was not associated with any 
impairment of cardiac contractile function. Our data also show a significantly higher 
ejection fraction in chronic hypertensives compared to normotensives but no 
difference when less load dependent index of velocity of circumferential fibre 
shortening is compared suggesting little change in intrinsic myocardial contractility. 
Our study is limited by the absence of parameters of systolic and diastolic function 
that are truly load and pressure independent. Nor did we correlate diastolic filling 
abnormalities with brain natriuretic peptide. Recent studies using tissue Doppler of 
the septal and lateral walls of the left ventricle reveal early changes in diastolic 
function while systolic function is preserved, findings that deserve study in 
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hypertensive pregnancy. Also the observations of preserved left ventricular systolic 
function in our study contrast with other studies by Valensise et al, (2001) and Borghi 
et al, (2000) who reported a reversible depression in systolic function reflected by left 
ventricular fractional shortening and ejection fraction, in such hypertensive pregnant 
groups. We have previously shown cardiac abnormalities on echocardiography in 16 
consecutive women presenting with hypertensive crises in pregnancy complicated by 
pulmonary oedema (Desai et al 1996). The echocardiographic abnormalities included 
impaired systolic function in 4 women (25%) and abnormalities in left ventricular 
diastolic filling in the remainder. 
A likely explanation for these apparent differences in left ventricular systolic function 
lies in the effect of loading conditions (Lang et al, (1991)) on left ventricular 
mechanics in pre-eclampsia. The authors concluded that intrinsic myocardial 
contractility is preserved when load is eliminated as a confounding variable. It is 
possible clinically small and subtle differences in left ventricular function may be 
detected by tissue Doppler studies. 
Normotensive pregnancy is associated with a significant drop in blood pressure and 
systemic vascular resistance index, a reflection of the reduced cardiovascular 
afterload, partly in response to the increased cardiac output. Physiologically, an 
increase in preload and/or reduced afterload is often accompanied by an increase in 
left ventricular systolic function. 
In our study systolic function was preserved through pregnancy. This contrasts with 
studies by Mone et al, (1996) who showed a transient fall in fractional shortening 
147 
during the third trimester. Similarly Schannwell et al, (2000) showed a reduction in 
fractional shortening and velocity of circumferential fibre shortening that had a nadir 
at the first postpartum visit. Differences in loading conditions probably explain these 
apparent differences in ejection fraction and velocity of circumferential fibre 
shortening. 
Similar considerations pertain to pre-eclampsia. In an earlier study by Lang et al, 
(1991) evaluated left ventricular mechanics in preeclamptics during early labour and 4 
weeks after delivery, and demonstrated that intrinsic left ventricular contractility was 
preserved and similar to control normotensive participants. The authors concluded 
that when load is eliminated as a confounding variable, the decrement in overall left 
ventricular performance in pre-eclampsia reflects a mechanically appropriate response 
to increased afterload rather than an abnormality in the ventricular contractile state. 
Again, these issues will also be better resolved when future studies focus on 
measuring load independent measures of left ventricular contractility and tissue 
Doppler studies. 
8.6 Conclusion: maternal hemodynamics in hypertensive disorders of pregnancy 
The principal findings in this study are that cardiac index and systemic vascular 
resistance measured in the latter part of the second and/or third trimesters in 
hypertensive women show only a modest to poor association with adverse feto-
neonatal outcome. 
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In contrast, uterine artery resistance index measured by Doppler velocimetry showed 
a satisfactory association with adverse feto-neonatal outcome. In a multivariate 
model, uterine artery resistance index emerged as a single variable that had the best 
association with adverse feto-neonatal outcome. Addition of severity of hypertension, 
presence and severity of proteinuria did not influence the predicitive model to any 
significant extent. Uterine artery velocimetry and proteinuria status provided better 
risk stratification in hypertensive pregnancy. 
There was a modest correlation of systemic vascular resistance index with uterine 
artery resistance index, the systemic vascular resistance index being largely a 
reflection of the blood pressure as cardiac index was similar between the hypertensive 
groups. Furthermore, less expertise is required in performing uterine artery 
velocimetry compared to maternal central hemodynamics, thus making the former 
more suitable for clinical risk stratification in hypertensive pregnancies. 
Gestational hypertensives presenting after 34 weeks had a feto-neonatal outcome 
similar to normotensives and here knowledge of uterine artery velocimetry did not 
assist with further risk stratification. The cardiac index was not reduced and in fact 
similar to women with normotensive pregnancy. The elevated systemic vascular 
resistance index (largely a reflection of this elevated blood pressure) did not help to 
predict at risk pregnancies. 
Finally, neither the haemodynamic parameters and severity of left ventricular 
hypertrophy nor the uterine artery resistance index helped to define risk in women 
with chronic hypertension. 
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8.7 Classification of hypertensive disorders of pregnancy 
Comprehensive classifications of hypertensive disorders of pregnancy are limited by 
being less user-friendly to the clinician. Further such classifications have little value 
since they often create and recognize hypertensive groups that do not carry any 
adverse risk compared to normal pregnant women. 
As an example, Levine et al, (2000) recently showed that 'normotensive' women 
whose hypertension was defined by a rise in diastolic BP of > 15mmHg, did not have 
an adverse feto-neonatal outcome; an observation that highlights the shortcomings of 
evaluating blood pressure alone to predict at risk pregnancies. Zhang et al, (2001) also 
made observations that mild hypertension occurring for the first time in labour and 
isolated mild systolic hypertension were not associated with adverse feto-neonatal 
outcome. This problem was also observed in Easterling's echocardiographic study 
(1990) which included women whose blood pressure was defined by an elevation in 
diastolic blood pressure of 15mmHg, resulting in inclusion of a lower risk 
hypertensive group. 
In another example, Spaanderman et al, (2000) observed differences in 
hemodynamics and volume homeostasis in women with a history of pre-eclampsia; 
the authors therefore proposed a category of latent hypertension for asymptomatic 
women with a history of pre-eclampsia. These observations are supported by 
Chambers et al, (2001) who showed that women with previous pre-eclampsia had 
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impaired endothelial function outside of pregnancy and this was reversed by folic 
acid. 
The wide variation in hemodynamic measurements and prognosis in hypertensive 
disorders of pregnancy determine the need for a precise classification within the 
generally accepted broader hypertensive groups to allow for meaningful comparison 
between research studies. We therefore support comments of Higgins and de Swiet 
(2001) that research definitions for hypertensive disorders of pregnancy need to be 
more stringent as research studies are weakened if women without the disease are 
included. The caveat is that definitions for clinical purposes should be as safe as they 
are practical even though they are likely to include a considerable number of false 
positives. 
Therefore, as a practical guide to the clinician, the results of this study support the use 
of the present classification of hypertensive disorders of pregnancy as a satisfactory 
initial step for risk stratification (stepl) into gestational (aproteinuric) hypertension; 
pre-eclampsia (gestational proteinuric hypertension); chronic hypertension in 
pregnancy and chronic hypertension in pregnancy with superimposed pre-eclampsia. 
This step immediately utilizes information of proteinuria and hypertension. At step 2, 
this stratification is improved by incorporating gestational age and a measure of 
severity of proteinuria within the above hypertensive groups. 
In the absence of severe hypertension and in the absence of chronic hypertension, an 
elevated level of uterine artery resistance index > 0.65 is very likely to select out the 
higher risk hypertensive pregnancies (step 3). Finally as step 4, following on early 
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research by Kuzniar et al (1982); Yang et al (1996) and Nisell et al (1988), a measure 
of cardiac index of < 3.0 1/min/m and/or systemic vascular resistance index > 2500 
dyn.sec/cm5/m2 in this selected hypertensive pregnancy group may help to select 
hypertensive pregnancies at extremely high risk for adverse outcome in whom 
risk/benefit of allowing continuation or terminating pregnancy need to be made. 
In conclusion, Brown et al, (1999) stated that without an agreed and acceptable 
classification of the hypertensive disorders of pregnancy, critical evaluation of studies 
from different research units would be extremely difficult. Lindheimer et al, 2001 also 
state in a review that a systematic attempt to accurately define and differentiate the 
various categories of hypertensive disorders is necessary so as to arm the clinician to 
better predict, prevent and improve the management of hypertensive disorders of 
pregnancy, in particular pre-eclampsia. The wide variability in measured maternal 
central hemodynamics in this and other studies reaffirm the importance of a precise 
and comprehensive definition of hypertensive participants in future studies that 
evaluate hemodynamics in hypertensive pregnancies. 
8.8 Recommendations for future studies 
Research in hypertensive disorders of pregnancy falls into 2 broad categories; the first 
category includes systematic attempts to accurately define and differentiate the 
various disorders of hypertension in pregnancy. The second include population 
studies to predict, prevent, and improve the management of women with hypertensive 
disorders of pregnancy. Continued research in both these areas is necessary to achieve 
improved maternal and feto-neonatal outcome. Research likely to result in clinical 
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benefit is particularly necessary as hypertensive disorders carry a 20-50% recurrence 
rate in the second pregnancy (Zhang et al, 2001). Our study evaluated 
echocardiography maternal central hemodynamics and uterine artery velocimetry in 
hypertensive and normotensives pregnant women in an attempt to clarify the 
pathogenesis of hypertensive disorders in pregnancy from a haemodynamic with 
standpoint. 
Future studies of maternal central hemodynamics in hypertensive pregnancies, where 
feasible, should incorporate a measure of biochemical markers that reflect volume 
homeostasis and renal function. Abnormal left ventricular geometry (concentric 
hypertrophy and remodelling) is now being increasingly recognised as a marker of 
higher risk hypertensive pregnancy. It is therefore of particular interest that Yasumoto 
et al, (2002) recently reported that in essential hypertention, decreased plasma and 
blood volume was associated with concentric remodelling. 
To what extent genetic predispositions may be responsible for abnormalities in 
volume homeostasis and the maternal haemodynamic responses to therapeutic 
intervention is not clear. Spaanderman et al, (2001) for example explored the 
observation that many women with a history of pre-eclampsia have an underlying 
vascular or thrombophilic disorder. They found that pre-eclamptic women who were 
either hypertensive or without thrombophilia 5 months after delivery exhibited sub-
optimal plasma volume expansion in their subsequent pregnancy. This was detected 
as early as seven weeks in the subsequent pregnancy and correlated inversely with 
circulating levels of alpha-atrial natriuretic peptide. This aspect of research becomes 
particularly important as it is being increasingly recognised that changes in maternal 
153 
renal function precede maternal cardiovascular changes of a decrease in systemic 
vascular resistance and an increase in cardiac output. 
Also research into inflammatory markers and its associated endothelial dysfunction in 
pre-eclamptic women (Roberts et al, 2000) will elucidate the role of oxidant damage, 
endothelial dysfunction and its possible association with aberrations in maternal 
hemodynamics in hypertensive pregnant women. Carr et al, (2001) have demonstrated 
an interesting association of maternal hemodynamics and inflammatory markers in 
women at risk for pre-eclampsia. 
More studies are also needed to explore traditional cardiovascular risk factors such as 
dyslipidaemia, obesity and insulin resistance that reflect the metabolic syndrome in 
normotensive and pre-eclamptic women of different population groups. This becomes 
especially important in the current epidemic of obesity and diabetes mellitus. In a 
recent epidemiological study Orskou et al, (2003) identified maternal overweight and 
obesity as one of the factors for delivering large for gestational age babies with its 
attendant risks. These maternal and fetal risks are likely to increase as Cundy et al, 
(2002) also reported the expected higher prevalence of hypertensive disorders of 
pregnancy in women with diabetes. Similarly, Kvetny et al, (2003) also reported a 
consistent higher body mass index in women with gestational hypertension and a 
higher prevalence of gestational hypertension in women with gestational diabetes 
mellitus. In a recent review Castro et al, (2002) in their review stressed the need for 
counselling of obese pregnant women and the need for specific guidelines for 
managing their pregnancy. 
Research into the echocardiographic techniques used to measure stroke volume and 
diastolic dysfunction will help detect early changes in ventricular function. The 
Doppler echocardiographic technique is accurate and has been validated in pregnancy, 
but this technique requires extensive expertise and is labour intensive. Simplifying the 
above procedure by modifications in ultrasound techniques to perform automated 
cardiac output measurement was disappointing in a pilot study by Basdogan et al, 
(2000). Using thermodilution technique derived cardiac output as gold standard, the 
authors reported that automated Doppler echocardiography (in intensive care patients 
that included 5 pre-eclamptic women) underestimated measurements at higher levels 
of cardiac output. Despite these initial disappointing results, further studies of 
simplified Doppler echocardiographic measured cardiac output are necessary as there 
are subgroups of hypertensive pregnant women who require and benefit from 
intensive monitoring and control of central hemodynamics. 
Ambulatory blood pressure monitoring permits a more accurate measure of the 
hypertensive load. This will allow for a closer evaluation, of systolic versus diastolic 
blood pressure, pulse pressure and its association with age in the hypertensive 
pregnancies. Similar to that described for hypertension outside pregnancy (Slotwiner 
et al, (2001)) ambulatory measurements also allow for a more precise measure of 
blood pressure load in pregnancy, described as the hyperbaric index. Such an 
approach is described by Hermida et al, (2002) and is likely to assist the clinician to 
make a more confident diagnosis of white coat hypertension and avoid potentially 
harmful antihypertensive medication. In addition it will also assist in diagnosing 
undetected hypertension in at risk patients in whom the diagnosis is not made by 
conventional office blood pressure measurements. 
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Studies of maternal central hemodynamics should also combine a measure of uterine 
artery resistance since concomitant maternal hemodynamics can be accompanied by 
parallel changes in uterine artery resistance. Research in this area will contribute to 
exploring the hypothesis of whether changes in maternal hemodynamics occur as a 
hemodynamic compensatory phenomenon to maintain uteroplacental perfusion, an 
avenue of research that will have particular significance in evaluating the risk/benefit 
of anti-hypertensive medications used in pregnancy. This area of research is also 
important as it may shed light on initial observations by Pijnenborg et al, (2000) 
which suggests that uterine hemodynamics may be a driving force for endovascular 
trophoblast migration in the placental bed. 
It would also be interesting to see whether echocardiographic changes can be 
identified by biochemical markers such as brain natriuretic peptide as described by 
Borghi et al, (2000) who suggested that a measure of plasma natriuretic peptide 
helped differentiate pre-eclampsia from volume overload. 
Finally our study also suggests that meaningful comparison of maternal 
hemodynamics is feasible only after standardization of these hemodynamic 
parameters by maternal stature that can be reflected either by body surface area or its 
variations. It is recommended that future studies of maternal hemodynamics and 
cardiac structure report both unstandardized and standardized measurements until 
consensus is reached. Continued research into the hypertensive diseases of pregnancy 
is necessary now more than ever before since hypertensive diseases of pregnancy 
seem to be associated in later life with diseases of hypertension (Wilson et al, (2003)). 
156 
A greater understanding and awareness of this association will lead to earlier 
diagnosis and management of such diseases. 
Appendix-1 
Formulae for calculation of left ventricle (LV) structure, function and 
hemodynamics 
LV-fractional shortening (%) = LVID (d) - LVID (s) .100% 
LVID (d) (1) 
*LVID (d) = left ventricle internal dimension in diastole 
*LVID (s) = left ventricle internal dimension in systole 
LV- Ejection fraction (%) (Teicholz) = LVV(d) - LVV (s) .100% 
LVV(d) (2) 
* LVV(d) = left ventricle volume in diastole 
* LVD (s) = left ventricle volume in systole 
and where LV volume is calculated by the Teichholz formula-
LV Volume = (_7 } . (D)3 
2.4 + D ( 3 ) 
* D = LV minor axis dimension in diastole (cm) 
LV - mean circumferential fibre shortening (circum/sec) 
= LV- fractional shortening 
LV-ejection time (seconds) - (4) 
LV - mass (g) = 
= 1.04 [ (LVID(d) + LV septum(d) + LV pw (d)]3 - [(LVID (d)3] -13.6 (5) 
*LVID (d) = left ventricle internal dimension in diastole in cm 
*LV-septum (d) = left ventricle septal thickness in diastole in cm 
*LV-pw (d) = left ventricle posterior wall thickness in diastole in cm 
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LV mass index (g/m2) = LV mass (g) 
Body surface area (m ) — (6) 
LV-relative wall thickness ratio = 2. LV pw 
LVID (d) (7) 
* LVID (d) = left ventricle internal dimension in diastole in cm 
* LV-pw (d) = left ventricle posterior wall thickness in diastole in cm 
LV - Doppler stroke volume (ml) = 
= VTI aorta (m) x aortic annular area (mm2) (8) 
VTI aorta (m) = velocity time integral at the level of aorta in meters 
LV-end systolic wall stress (dyn./cm5) = 
= 0.334. Systolic blood pressure(mmHg). LVID(s) 
( LVpw (d)). ( 1 + LVpw (d) ) 
LV ID (s) (9) 
*LVID (s) = left ventricle internal dimension in systolic in cm 
*LV-septum (d) = left ventricle septal thickness in diastole in cm 
*LV-pw (d) = left ventricle posterior wall thickness in diastole in cm 
Uterine artery resistance index = peak systolic velocity - diastolic velocity —(10) 
systolic velocity 
Umbilical artery pulsatility index = 2 (systolic velocity - diastolic velocity) --(11) 
(systolic velocity + diastolic velocity) 
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Apical Four-chamber plane —* 
Figure 1 
Echocardiographic planes 
AO = aorta 
PA = pulmonary artery 
LA = left atrium 
LV = left ventricle 
RA = right atrium 
RV = right ventricle 
pericardium - ^ 
Figure 2 - Parasternal long axis view 
AMVL = anterior mitral valve leafle, PMVL = posterior mitral valve leaflet, CS = coronary sinus 
DA = descending aorta, RPA = right pulmonary artery, RVOT = right ventricle outflow tract 
Post. Wall = posterior wall of left ventricle, LA = left atrium, LV = left ventricle 










































































Figure 4 - M - mode echocardiographic study of the left ventricle 
LVID = left ventricular internal dimension in diastole, LVIS = left ventricular internal dimension in systole 






Left ventricle diastolic 
filling by pulsed doppler 
E = peak early filling velocity 
A = late (atrial) filling velocity 
Figure 6(a) - Uterine artery Doppler velocimetry(Normal) 
S = peak systolic velocity 
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Figure 7 - Umbilical artery Doppler velocimetry (Normal) 
